17512723	CHEMICAL	GENE	T1	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ murine Rdh12 @/GENETgt$ ? [SEP] We show that @GENETgt$ murine Rdh12 @/GENETgt$ and human RDH13 do not reveal activity towards the checked steroids , but that human type 12 RDH reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 12 3|12|4 3|12|4 12|4 3|12|4 4 9 4 12 12 2 12 17 17 17 13 12 12 25 22 24 24 25 12 25 28 25 25 25 25 12 35 35 35 12 38 38 35 2	None-BC7
17512723	CHEMICAL	GENE	T2	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ RDHs @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( @GENETgt$ RDHs @/GENETgt$ ) were tested for steroid converting abilities : human and murine RDH 12 and human RDH13 .	4 1|4 4 1|4 10 6 4 4 4 6 10 10 14 14 14 10 14 23 16 16 16 19 16 16 14 10	None-BC7
17512723	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ human type 12 RDH @/GENETgt$ ? [SEP] We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids , but that @GENETgt$ human type 12 RDH @/GENETgt$ reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 11 5 11 5 8 5 11 11 2 11 16 16 16 12 11 11 25 25|19|20 25|19|20 25|19|20 25|19|20 25|20 25|19|20 11 25 28 25|23 25 25|23 25 11 35 35 35 11 38 38 35 2	PRODUCT-OF
17512723	CHEMICAL	GENE	T2	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ human and murine RDH 12 @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( RDHs ) were tested for steroid converting abilities : @GENETgt$ human and murine RDH 12 @/GENETgt$ and human RDH13 .	4 1|4 4 1|4 9 6 4 6 9 9 13 13 13 9 13 15|13|23 15|13|23 15|13|23 15|13|23 15|13|23 15|23 15|13|23 15 15 13 9	None-BC7
17512723	CHEMICAL	GENE	T2	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ human RDH13 @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( RDHs ) were tested for steroid converting abilities : human and murine RDH 12 and @GENETgt$ human RDH13 @/GENETgt$ .	4 1|4 4 1|4 9 6 4 6 9 9 13 13 13 9 13 21 15 15 15 18 15 19|13|15 19|13|15 13|15 19|13|15 9	None-BC7
17512723	CHEMICAL	GENE	T3	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ RDH12 @/GENETgt$ ? [SEP] @GENETgt$ RDH12 @/GENETgt$ , a @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenase causing Leber 's congenital amaurosis , is also involved in steroid metabolism .	0|16 16 0|16 1 7 3|7 7 3|7 1 7 12 9 12 8 1 16 16 16 19 19 16 16	None-BC7
17512723	CHEMICAL	GENE	T1	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ human RDH13 @/GENETgt$ ? [SEP] We show that murine Rdh12 and @GENETgt$ human RDH13 @/GENETgt$ do not reveal activity towards the checked steroids , but that human type 12 RDH reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 12 5 12 5 5|6|7 5|6|7 5|7 5|6|7 12 12 2 12 17 17 17 13 12 12 25 22 24 24 25 12 25 28 25 25 25 25 12 35 35 35 12 38 38 35 2	None-BC7
23557993	CHEMICAL	GENE	T18	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ MAP kinase @/GENETgt$ ? [SEP] The h-OB were 10 - 100 fold more sensitive to DPHD than transformed osteoblasts : @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased h-OB proliferation at 10nM and , at 100nM , activated @GENETgt$ MAP kinase @/GENETgt$ signaling within 30min .	2 9 9 7 6 4 8 9 9 11 9 14 14 9 9 18|15 18 18|15 9 20 18 22 18 18 18 26 18 26 32 32|27 32|27 32 32|27 26 34 32 18	ACTIVATOR
23557993	CHEMICAL	GENE	T5	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ COL1A1 @/GENETgt$ ? [SEP] Subsequently , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated production of bone structural genes , including @GENETgt$ COL1A1 @/GENETgt$ and osteocalcin comparably to 17β-estradiol .	5 5 2|5 5 2|5 5 5 10 10 10 6 10 13 10|11 10 10|11 13 13 19 19 5 5	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T3	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ ICI182780 @/CHEMICALSrc$ and @GENETgt$ estrogen receptor @/GENETgt$ ? [SEP] Effects of DPHD were eliminated by the @GENETgt$ estrogen receptor @/GENETgt$ antagonist @CHEMICALSrc$ ICI182780 @/CHEMICALSrc$ .	5 3 1 5 5 12 12 12|7 12|7 12 12|7 12 9|5 5 9|5 5	ANTAGONIST
23557993	CHEMICAL	GENE	T4	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ RUNX2 @/GENETgt$ ? [SEP] During differentiation , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ promoted early expression of osteoblast transcription factors , @GENETgt$ RUNX2 @/GENETgt$ and osterix .	2 6 6 3|6 6 3|6 6 8 6 12 12 12 8 12 12 12 12 14 14 6	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T20	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ alkaline phosphatase @/GENETgt$ ? [SEP] In long-term differentiation assays , responses of h-OB to DPHD were significant at 10nM , and optimal response in most cases was at 100nM. At 7 - 21 days , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated osteoblast differentiation , indicated by @GENETgt$ alkaline phosphatase @/GENETgt$ activity and osteoblast-specific mRNA production .	4 4 4 12 12 12 8 6 10 6 12 12 14 12 12 12 18 12 21 21 18 23 24 12 29 28 28 29 12 33 33|30 33 33|30 12 35 33 33 33 42 42|37 42|37 42 42|37 37 42 46 46 42 33	None-BC7
23557993	CHEMICAL	GENE	T7	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ RANKL @/GENETgt$ ? [SEP] In h-OB , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased the osteoprotegerin to @GENETgt$ RANKL @/GENETgt$ ratio and supported mineralization more efficiently than 10nM 17β-estradiol .	2 6 6 3|6 6 3|6 6 8 6 12 8|12 12 8|12 6 6 6 14 17 14 20 20 17 6	None-BC7
23557993	CHEMICAL	GENE	T4	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osterix @/GENETgt$ ? [SEP] During differentiation , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ promoted early expression of osteoblast transcription factors , RUNX2 and @GENETgt$ osterix @/GENETgt$ .	2 6 6 3|6 6 3|6 6 8 6 12 12 12 8 12 12 14 14 14 14 6	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T6	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ osteocalcin @/GENETgt$ ? [SEP] Subsequently , DPHD accelerated production of bone structural genes , including COL1A1 and @GENETgt$ osteocalcin @/GENETgt$ comparably to @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	4 4 4 4 4 9 9 9 5 9 12 9 12 12|13 12 12|13 18 18 16|4 4 16|4 4	None-BC7
23557993	CHEMICAL	GENE	T7	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osteoprotegerin @/GENETgt$ ? [SEP] In h-OB , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased the @GENETgt$ osteoprotegerin @/GENETgt$ to RANKL ratio and supported mineralization more efficiently than 10nM 17β-estradiol .	2 6 6 3|6 6 3|6 6 8 6 6 6 12 12 6 6 6 14 17 14 20 20 17 6	None-BC7
23557993	CHEMICAL	GENE	T8	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ osteoprotegerin @/GENETgt$ ? [SEP] In h-OB , DPHD increased the @GENETgt$ osteoprotegerin @/GENETgt$ to RANKL ratio and supported mineralization more efficiently than 10nM @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	2 5 5 5 5 7 5|6 5 5|6 11 11 5 5 5 13 16 13 19 19 16|17 16 16|17 5	None-BC7
23557993	CHEMICAL	GENE	T19	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ alkaline phosphatase @/GENETgt$ ? [SEP] In long-term differentiation assays , responses of h-OB to @CHEMICALSrc$ DPHD @/CHEMICALSrc$ were significant at 10nM , and optimal response in most cases was at 100nM. At 7 - 21 days , DPHD accelerated osteoblast differentiation , indicated by @GENETgt$ alkaline phosphatase @/GENETgt$ activity and osteoblast-specific mRNA production .	4 4 4 13 13 13 8 6 10 9|6 6 9|6 13 13 15 13 13 13 19 13 22 22 19 24 25 13 30 29 29 30 13 33 33 13 35 33 33 33 42 42|37 42|37 42 42|37 37 42 46 46 42 33	None-BC7
23557993	CHEMICAL	GENE	T8	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ RANKL @/GENETgt$ ? [SEP] In h-OB , DPHD increased the osteoprotegerin to @GENETgt$ RANKL @/GENETgt$ ratio and supported mineralization more efficiently than 10nM @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	2 5 5 5 5 7 5 11 8|11 11 8|11 5 5 5 13 16 13 19 19 16|17 16 16|17 5	None-BC7
23557993	CHEMICAL	GENE	T5	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osteocalcin @/GENETgt$ ? [SEP] Subsequently , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated production of bone structural genes , including COL1A1 and @GENETgt$ osteocalcin @/GENETgt$ comparably to 17β-estradiol .	5 5 2|5 5 2|5 5 5 10 10 10 6 10 13 10 13 13 13 13 19 19 5 5	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T1	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ estrogen receptor @/GENETgt$ ? [SEP] Effects of @CHEMICALSrc$ DPHD @/CHEMICALSrc$ were eliminated by the @GENETgt$ estrogen receptor @/GENETgt$ antagonist ICI182780 .	6 3 1|2 1 1|2 6 6 13 13 13|7 13|7 13 13|7 13 6 6	ACTIVATOR
23557993	CHEMICAL	GENE	T6	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ COL1A1 @/GENETgt$ ? [SEP] Subsequently , DPHD accelerated production of bone structural genes , including @GENETgt$ COL1A1 @/GENETgt$ and osteocalcin comparably to @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	4 4 4 4 4 9 9 9 5 9 12 9|11 9 9|11 12 12 18 18 16|4 4 16|4 4	None-BC7
23557993	CHEMICAL	GENE	T17	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ MAP kinase @/GENETgt$ ? [SEP] The h-OB were 10 - 100 fold more sensitive to @CHEMICALSrc$ DPHD @/CHEMICALSrc$ than transformed osteoblasts : DPHD increased h-OB proliferation at 10nM and , at 100nM , activated @GENETgt$ MAP kinase @/GENETgt$ signaling within 30min .	2 9 9 7 6 4 8 9 9 11 9|10 9 9|10 15 15 9 9 18 9 20 18 22 18 18 18 26 18 26 32 32|27 32|27 32 32|27 26 34 32 18	None-BC7
23161873	CHEMICAL	GENE	T3	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , @GENETgt$ alanine transaminase @/GENETgt$ , and aspartate aminotransferase concentrations .	10 10 4 10 4 8 8 5 10 10 12 10|11|12 10|11|12 10|12 10|11|12 12 16|12|13 16|12|13 16|12 16|12|13 12 12 22 23 12 10	None-BC7
23161873	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] To determine whether @GENETgt$ ChREBP @/GENETgt$ is a potential therapeutic target , we decreased hepatic expression of ChREBP with a specific antisense oligonucleotide ( ASO ) in male Sprague-Dawley rats fed either a @CHEMICALSrc$ high-fructose @/CHEMICALSrc$ or high-fat diet .	2 13 10 10|3 10 10|3 10 10 10 8 2 13 13 13 15 13 17 15 22 22 22 22 15 24 22 24 29 29 29 22 13 33 33 37|31 37 37|31 33 33 30 13	None-BC7
23161873	CHEMICAL	GENE	T13	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] @GENETgt$ ChREBP @/GENETgt$ ASO treatment decreased plasma @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ concentrations compared with control ASO treatment in both diet groups .	0|4 4 0|4 4 5 5 9 9|5 9 9|5 5 14 14 14 14 5 18 18 18 14 5	None-BC7
23161873	CHEMICAL	GENE	T15	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ SCD1 @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , FAS , @GENETgt$ SCD1 @/GENETgt$ , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 13 11 15 13 17 15 17 17 17 17|20 17 17|20 17 17 17 13 28 13 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T7	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructose aldolase @/GENETgt$ ? [SEP] This was associated with decreased expression of @GENETgt$ fructose aldolase @/GENETgt$ and fructokinase , reminiscent of inherited disorders of @CHEMICALSrc$ fructose @/CHEMICALSrc$ metabolism .	3 3 3 6 6 3 8 8|6|7 8|6|7 8|6 8|6|7 8 8 8 8 17 17 14 21 16|21 21 16|21 17 3	SUBSTRATE
23161873	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] To determine whether ChREBP is a potential therapeutic target , we decreased hepatic expression of @GENETgt$ ChREBP @/GENETgt$ with a specific antisense oligonucleotide ( ASO ) in male Sprague-Dawley rats fed either a @CHEMICALSrc$ high-fructose @/CHEMICALSrc$ or high-fat diet .	2 12 9 9 9 9 9 7 2 12 12 12 14 12 16 14|15 14 14|15 22 22 22 22 14 24 22 24 29 29 29 22 12 33 33 37|31 37 37|31 33 33 30 12	None-BC7
23161873	CHEMICAL	GENE	T3	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , alanine transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	10 10 4 10 4 8 8 5 10 10 12 10|11|12 10|11|12 10|12 10|11|12 12 17 12 12 12 17|20|23 17|20|23 20|23 17|20|23 12 10	None-BC7
23161873	CHEMICAL	GENE	T8	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In summary , these studies suggest that targeting @GENETgt$ ChREBP @/GENETgt$ may prevent @CHEMICALSrc$ fructose-induced @/CHEMICALSrc$ hypertriglyceridemia but without the improvements in hepatic steatosis and hepatic insulin responsiveness .	2 6 6 5 6 6 12 12 8 8 8 12 6 11|15 15 11|15 12 12 19 19 12 22 22 19 22 26 26 22 6	None-BC7
23161873	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ SCD1 @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , FAS , @GENETgt$ SCD1 @/GENETgt$ , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 14 12 16 14 18 16 18 18 18 18|20 18 18|20 18 18 18 14 29 14 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T6	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructokinase @/GENETgt$ ? [SEP] This was associated with decreased expression of @CHEMICALSrc$ fructose @/CHEMICALSrc$ aldolase and @GENETgt$ fructokinase @/GENETgt$ , reminiscent of inherited disorders of fructose metabolism .	3 3 3 6 6 3 10 10|7 10 10|7 6 10 10 10 10 10 10 18 18 15 21 21 18 3	None-BC7
23161873	CHEMICAL	GENE	T14	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ACC2 @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of @GENETgt$ ACC2 @/GENETgt$ , FAS , SCD1 , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 14 12 16 14 18 16 16 16 18 18 18 18 18 18 18 14 29 14 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ MTTP @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , FAS , SCD1 , and @GENETgt$ MTTP @/GENETgt$ and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 14 12 16 14 18 16 18 18 18 18 18 18 18|23 18 18|23 14 29 14 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] In summary , these studies suggest that targeting ChREBP may prevent @CHEMICALSrc$ fructose-induced @/CHEMICALSrc$ hypertriglyceridemia but without the improvements in hepatic steatosis and hepatic @GENETgt$ insulin @/GENETgt$ responsiveness .	2 6 6 5 6 6 11 11 8 11 6 11|14 14 11|14 11 11 18 18 11 21 21 18 21 26 26|22 26 26|22 21 6	None-BC7
23161873	CHEMICAL	GENE	T14	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ FAS @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , @GENETgt$ FAS @/GENETgt$ , SCD1 , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 14 12 16 14 18 16 18 18 18 18 18 18 18 18 18 14 29 14 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ and @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ? [SEP] In addition to serving as substrates , @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ also increase the expression of key enzymes involved in de novo lipogenesis via the @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ( ChREBP ) .	2 11 4 2 6 4 11 11|7 11 11|7 11 11 13 11 16 16 13 16 21 21 19 17 24 24 24|17|22 24|17|22 24|17|22 24|17|22 24|17 24|17|22 30 24 30 11	None-BC7
23161873	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In addition to serving as substrates , @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ also increase the expression of key enzymes involved in de novo lipogenesis via the carbohydrate response element-binding protein ( @GENETgt$ ChREBP @/GENETgt$ ) .	2 11 4 2 6 4 11 11|7 11 11|7 11 11 13 11 16 16 13 16 21 21 19 17 27 27 27 27 27 17 29 27 27 27 29 11	None-BC7
23161873	CHEMICAL	GENE	T2	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with ChREBP ASO had increased plasma uric acid , alanine transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	11 11 2|5 5 2|5 11 5 9 9 6 11 11 14 14 11 14 17 14 14 14 18|20|23 18|20|23 20|23 18|20|23 14 11	INDIRECT-UPREGULATOR
23161873	CHEMICAL	GENE	T17	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ? [SEP] The role of the @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ in male @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats .	2 2 5 5 2|4|5 2|4|5 2|4|5 2|4|5 2|5 2|4|5 14 14 14|7 14 14|7 2 2	None-BC7
23161873	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] This was associated with an increase in @GENETgt$ insulin-stimulated @/GENETgt$ peripheral @CHEMICALSrc$ glucose @/CHEMICALSrc$ uptake , as assessed by the hyperinsulinemic-euglycemic clamp .	3 3 3 6 6 3 13 13|7 13 13|7 13 9|13 13 9|13 6 3 16 3 20 20 20 16 3	None-BC7
23161873	CHEMICAL	GENE	T15	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ FAS @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , @GENETgt$ FAS @/GENETgt$ , SCD1 , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 13 11 15 13 17 15 17 17|18 17 17|18 17 17 17 17 17 13 28 13 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T3	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , alanine transaminase , and aspartate aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 11 13 11|13 11|13 11|13 11|13 13 18 13 13 13 22 23 13 11	None-BC7
23161873	CHEMICAL	GENE	T4	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ alanine @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma uric acid , @CHEMICALSrc$ alanine @/CHEMICALSrc$ transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	10 10 4 10 4 8 8 5 10 10 13 13 10 13 17|14 17 17|14 13 13 13 18|20|23 18|20|23 20|23 18|20|23 13 10	None-BC7
23161873	CHEMICAL	GENE	T2	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , alanine transaminase , and aspartate aminotransferase concentrations .	12 12 2|5 5 2|5 12 5 10 10|6 10 10|6 6 12 12 15 15 12 15 18 15 15 15 22 23 15 12	None-BC7
23161873	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ aspartate @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , alanine transaminase , and @CHEMICALSrc$ aspartate @/CHEMICALSrc$ aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 11 14 14 11 14 17 14 14 14 18|22 22 18|22 23 14 11	None-BC7
23161873	CHEMICAL	GENE	T15	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ ACC2 @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of @GENETgt$ ACC2 @/GENETgt$ , FAS , SCD1 , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 13 11 15 13 17 16|15 15 16|15 17 17 17 17 17 17 17 13 28 13 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ MTTP @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , FAS , SCD1 , and @GENETgt$ MTTP @/GENETgt$ and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 13 11 15 13 17 15 17 17 17 17 17 17 17|23 17 17|23 13 28 13 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ alanine @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , @CHEMICALSrc$ alanine @/CHEMICALSrc$ transaminase , and aspartate aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 11 14 14 11 14 18|14 18 18|14 14 14 14 22 23 14 11	None-BC7
23161873	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ aspartate @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma uric acid , @GENETgt$ alanine transaminase @/GENETgt$ , and @CHEMICALSrc$ aspartate @/CHEMICALSrc$ aminotransferase concentrations .	10 10 4 10 4 8 8 5 10 10 13 13 10 13 13|14|15 13|14|15 13|15 13|14|15 13 13 17|22 22 17|22 23 13 10	None-BC7
23161873	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ carbohydrate @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In addition to serving as substrates , monosaccharides also increase the expression of key enzymes involved in de novo lipogenesis via the @CHEMICALSrc$ carbohydrate @/CHEMICALSrc$ response element-binding protein ( @GENETgt$ ChREBP @/GENETgt$ ) .	2 10 4 2 6 4 10 10 10 10 12 10 15 15 12 15 20 20 18 16 27 27 27|22 27 27|22 27 27 16 29 27 27 27 29 10	None-BC7
23161873	CHEMICAL	GENE	T2	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with ChREBP ASO had increased plasma uric acid , @GENETgt$ alanine transaminase @/GENETgt$ , and aspartate aminotransferase concentrations .	11 11 2|5 5 2|5 11 5 9 9 6 11 11 14 14 11 14 16|14 16|14 16|14 16|14 14 14 22 23 14 11	INDIRECT-UPREGULATOR
23161873	CHEMICAL	GENE	T7	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructokinase @/GENETgt$ ? [SEP] This was associated with decreased expression of fructose aldolase and @GENETgt$ fructokinase @/GENETgt$ , reminiscent of inherited disorders of @CHEMICALSrc$ fructose @/CHEMICALSrc$ metabolism .	3 3 3 6 6 3 9 9 6 9 9|10 9 9|10 9 9 17 17 14 21 17|21 21 17|21 17 3	SUBSTRATE
17292977	CHEMICAL	GENE	T3	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] Administration of AC3174 resulted in a 4-fold increase in @GENETgt$ insulin @/GENETgt$ concentrations in normal mice following an IP @CHEMICALSrc$ glucose @/CHEMICALSrc$ challenge .	4 3 1 4 8 8 8 4 12 9|12 12 9|12 8 15 15 12 21 21 21 17|21 21 17|21 8 4	INDIRECT-UPREGULATOR
17292977	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ (125)I @/CHEMICALSrc$ and @GENETgt$ adenylate cyclase @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @CHEMICALSrc$ [(125)I]GLP-1 @/CHEMICALSrc$ and activation of @GENETgt$ adenylate cyclase @/GENETgt$ was similar to that of exenatide and GLP-1 .	4 4 4 23 23 7 23 9 7 12 12 7 14 12|13 12 12|13 12 12 19 17|19 17|19 17|19 17|19 23 23 25 23 27 25 27 27 23	None-BC7
17292977	CHEMICAL	GENE	T7	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ adenylate @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of [(125)I]GLP-1 and activation of @CHEMICALSrc$ adenylate @/CHEMICALSrc$ cyclase was similar to that of exenatide and @GENETgt$ GLP-1 @/GENETgt$ .	4 4 4 22 22 7 22 9 7 12 12 7 14 12 12 12 20 17|20 20 17|20 16 22 22 24 22 26 24 26 26 26 26 22	None-BC7
17292977	CHEMICAL	GENE	T6	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ (125)I @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @CHEMICALSrc$ [(125)I]GLP-1 @/CHEMICALSrc$ and activation of adenylate cyclase was similar to that of exenatide and @GENETgt$ GLP-1 @/GENETgt$ .	4 4 4 22 22 7 22 9 7 12 12 7 14 12|13 12 12|13 12 12 20 20 17 22 22 24 22 26 24 26 26 26 26 22	None-BC7
17292977	CHEMICAL	GENE	T7	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ adenylate @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @GENETgt$ [(125)I]GLP-1 @/GENETgt$ and activation of @CHEMICALSrc$ adenylate @/CHEMICALSrc$ cyclase was similar to that of exenatide and GLP-1 .	4 4 4 23 23 7 23 9 7 12 12 7 14 12|13 12 12|13 12 12 21 17|21 21 17|21 17 23 23 25 23 27 25 27 27 23	None-BC7
23348500	CHEMICAL	GENE	T13	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the CPPHA series termed @CHEMICALSrc$ NCFP @/CHEMICALSrc$ ( N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide ) .	1 3 1 3 6 7 3 10 10 1 12 10 20 20 20 15 15 17|20 20 17|20 12 24 24 24 12 24 24|25 25 24|25 29 26 29 10	None-BC7
23348500	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ series termed NCFP ( N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide ) .	1 3 1 3 6 7 3 10 10 1 12 10 20 20 20 15 15 17|20 20 17|20 12 25 25 25|21 25 25|21 12 25 26 29 27 29 10	None-BC7
23348500	CHEMICAL	GENE	T1	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] @CHEMICALSrc$ NCFP @/CHEMICALSrc$ binds to the CPPHA site on @GENETgt$ mGlu5 @/GENETgt$ and potentiates mGlu5-mediated responses in both recombinant and native systems .	0|3 3 0|3 3 7 7 7 3 9 3|7 3 3|7 3 3 14 12 17 17 14 17 17 17 3	DIRECT-REGULATOR
23348500	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ 2-Methyl-6-(phenylethynyl)pyridine @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Previous work has extensively characterized a common allosteric site on @GENETgt$ mGlu5 @/GENETgt$ , termed the MPEP ( @CHEMICALSrc$ 2-Methyl-6-(phenylethynyl)pyridine @/CHEMICALSrc$ ) binding site .	2 5 5 5 5 9 9 9 5 11 9|10 9 9|10 9 9 22 22 22 16|22 22 16|22 22 22 14 5	PART-OF
23348500	CHEMICAL	GENE	T15	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ metabotropic glutamate receptor 5 @/GENETgt$ ? [SEP] A novel @GENETgt$ metabotropic @/GENETgt$ @CHEMICALSrc$ glutamate receptor 5 @/CHEMICALSrc$ positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling .	11 11 2|11 11 2|11 11|3 11|3 11|3 11 11|3 11 11 12 12 16 16 16 12 12 12 20 18 23 23 18 12	None-BC7
23348500	CHEMICAL	GENE	T4	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , NCFP provides greater mGlu5 subtype selectivity than does @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ , making it more suitable for studies of effects on @GENETgt$ mGlu5 @/GENETgt$ in CNS preparations .	4 4 4 4 8 8 8 4 10 4 10 10 10 4 4 17 17 14 19 17 21 19 23 21 21 21 27 27 21 4	None-BC7
23348500	CHEMICAL	GENE	T3	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , @CHEMICALSrc$ NCFP @/CHEMICALSrc$ provides greater mGlu5 subtype selectivity than does CPPHA , making it more suitable for studies of effects on @GENETgt$ mGlu5 @/GENETgt$ in CNS preparations .	5 5 2|5 5 2|5 5 9 9 9 5 11 5 11 5 5 17 17 14 19 17 21 19 23 21 21 21 27 27 21 5	None-BC7
23348500	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ MPEP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Previous work has extensively characterized a common allosteric site on @GENETgt$ mGlu5 @/GENETgt$ , termed the @CHEMICALSrc$ MPEP @/CHEMICALSrc$ ( 2-Methyl-6-(phenylethynyl)pyridine ) binding site .	2 5 5 5 5 9 9 9 5 11 9|10 9 9|10 9 9 22 14|22 22 14|22 22 22 22 22 14 5	PART-OF
23348500	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one @GENETgt$ mGlu5 @/GENETgt$ PAM , @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ ( N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide ) , interacts with a separate allosteric site on mGlu5 .	14 14 6 3|6 6 3|6 14 6 6 6 6 11 8 11 8 14 19 19 19 19 14 21 19 14	None-BC7
23348500	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one mGlu5 PAM , @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ ( N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide ) , interacts with a separate allosteric site on @GENETgt$ mGlu5 @/GENETgt$ .	13 13 5 5 13 5 5|6 5 5|6 10 7 10 7 13 18 18 18 18 13 20 18 18 18 13	DIRECT-REGULATOR
23348500	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ Metabotropic glutamate receptor 5 @/GENETgt$ ? [SEP] @GENETgt$ Metabotropic @/GENETgt$ @CHEMICALSrc$ glutamate receptor 5 @/CHEMICALSrc$ ( mGlu5 ) is a target for the treatment of central nervous system ( CNS ) disorders , such as schizophrenia and Alzheimer 's disease .	0|3 3 0|3 1|3|12 1|3|12 1|3|12 3|12 1|3|12 8 3 8 12 12 12 15 15 12 23 19 19 23 21 23 21 15 23 27 25 23 27 31 31 27 12	None-BC7
23348500	CHEMICAL	GENE	T2	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] NCFP binds to the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ site on @GENETgt$ mGlu5 @/GENETgt$ and potentiates mGlu5-mediated responses in both recombinant and native systems .	2 2 7 7 4|7 7 4|7 2 9 2|7 2 2|7 2 2 14 12 17 17 14 17 17 17 2	None-BC7
23348500	CHEMICAL	GENE	T14	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the CPPHA series termed NCFP ( @CHEMICALSrc$ N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide @/CHEMICALSrc$ ) .	1 3 1 3 6 7 3 10 10 1 12 10 20 20 20 15 15 17|20 20 17|20 12 24 24 24 12 24 25 28 26 26 26 28 10	None-BC7
23348500	CHEMICAL	GENE	T4	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , NCFP provides greater @GENETgt$ mGlu5 @/GENETgt$ subtype selectivity than does @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ , making it more suitable for studies of effects on mGlu5 in CNS preparations .	4 4 4 4 9 9|5 9 9|5 9 4 11 4 10|11 11 10|11 4 4 18 18 15 20 18 22 20 24 22 27 27 22 4	None-BC7
23348500	CHEMICAL	GENE	T3	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , @CHEMICALSrc$ NCFP @/CHEMICALSrc$ provides greater @GENETgt$ mGlu5 @/GENETgt$ subtype selectivity than does CPPHA , making it more suitable for studies of effects on mGlu5 in CNS preparations .	5 5 2|5 5 2|5 5 10 10|5 10 10|5 10 5 12 5 12 5 5 18 18 15 20 18 22 20 24 22 27 27 22 5	None-BC7
23348500	CHEMICAL	GENE	T15	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] A novel metabotropic @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to @GENETgt$ mGlu5 @/GENETgt$ signaling .	10 10 10 10|3 10 10|3 10 10 10 10 11 11 15 15 15 11 11 11 19 17 23 19|23 23 19|23 17 11	None-BC7
23348500	CHEMICAL	GENE	T2	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] NCFP binds to the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ site on mGlu5 and potentiates @GENETgt$ mGlu5-mediated @/GENETgt$ responses in both recombinant and native systems .	2 2 7 7 4|7 7 4|7 2 9 2 2 2 10|14 14 10|14 11 17 17 14 17 17 17 2	None-BC7
23348500	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] @CHEMICALSrc$ NCFP @/CHEMICALSrc$ binds to the CPPHA site on mGlu5 and potentiates @GENETgt$ mGlu5-mediated @/GENETgt$ responses in both recombinant and native systems .	0|3 3 0|3 3 7 7 7 3 9 3 3 3 10|14 14 10|14 11 17 17 14 17 17 17 3	ACTIVATOR
23348500	CHEMICAL	GENE	T11	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one @GENETgt$ mGlu5 @/GENETgt$ PAM , CPPHA ( @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ ) , interacts with a separate allosteric site on mGlu5 .	14 14 6 3|6 6 3|6 14 6 6 10 8 8 8 10 8 14 19 19 19 19 14 21 19 14	None-BC7
23348500	CHEMICAL	GENE	T5	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Metabotropic @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor 5 ( @GENETgt$ mGlu5 @/GENETgt$ ) is a target for the treatment of central nervous system ( CNS ) disorders , such as schizophrenia and Alzheimer 's disease .	4 1|4 4 1|4 12 4 7 4|5 4 4|5 7 12 12 12 15 15 12 23 19 19 23 21 23 21 15 23 27 25 23 27 31 31 27 12	None-BC7
23348500	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one mGlu5 PAM , CPPHA ( @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ ) , interacts with a separate allosteric site on @GENETgt$ mGlu5 @/GENETgt$ .	13 13 5 5 13 5 5 9 8|7 7 8|7 9 7 13 18 18 18 18 13 20 18 18 18 13	DIRECT-REGULATOR
7828655	CHEMICAL	GENE	T6	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptor @/GENETgt$ ? [SEP] There were no detectable levels of @GENETgt$ dopamine D1 receptor @/GENETgt$ mRNA in substantia nigra either in control animals or in animals treated with the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonists .	2 2 5 5 2 11 11|6 11|6 11|6 11 11|6 5 14 14 5 18 18 18 2 18 21 18 21 28 28 28|21 28 28|21 28 22 2	None-BC7
7828655	CHEMICAL	GENE	T10	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 41|34 41 41|34 41 43 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T30	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ Dopamine receptor @/GENETgt$ ? [SEP] @GENETgt$ Dopamine receptor @/GENETgt$ blockade increases dopamine D2 receptor and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNAs in mouse substantia nigra .	0|1|4 0|1|4 1|4 0|1|4 5 5 8 8 5 8 14|7 14|7 14 14|7 14 8 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T9	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 37 37 34 37 37|31 37 37|31 26 37 41 41 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 26	None-BC7
7828655	CHEMICAL	GENE	T18	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 15 11 11 16|21 21 16|21 21 21 11 11 27|21 27|21 27|21 27 27|21 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T13	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 40 40 42 42 34 44 42 44 34 56 56 56 56 56 56|49 56 56|49 56 56 34 25	None-BC7
7828655	CHEMICAL	GENE	T16	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 12 12 16 12 12 16|22 16|22 16|22 22 16|22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T14	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 55 55 55 55 55 55 55 55 51|36 36 51|36 26	None-BC7
7828655	CHEMICAL	GENE	T24	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and dopamine D1 receptors in substantia nigra , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 18 18 17|18|15 17|18|15 18|15 17|18|15 18 18 24 18 27 27 10 5 3 31 29 37 37|30 37 37|30 37 37 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T20	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 43|36|38 43|36|38 43|36|38 43|38 43|36|38 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T9	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 36 36 33 36 33|36 36 33|36 25 36 43|36|38 43|36|38 43|36|38 43|38 43|36|38 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 25	None-BC7
7828655	CHEMICAL	GENE	T13	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 56 56 56 56 56 48|56 56 48|56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T14	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 40 40 42 42 34 44 42 44 34 55 55 55 55 55 55 55 55 34|52 34 34|52 25	None-BC7
7828655	CHEMICAL	GENE	T19	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 11|13|14 11|13|14 11|14 11|13|14 11 21 21 21 11 11 27|20 27|20 27 27|20 27 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T12	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 40|42 42 40|42 44 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T16	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 12 12 16 12 12 21 21 21 12 12 27|21 27|21 27|21 27 27|21 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T12	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 40|42 42 40|42 44 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T11	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36|37 42|36|37 42|36|37 42|37 42|36|37 42 35|38 35 35|38 45 42 45 35 56 56 56 56 56 56 56 56 35 25	ANTAGONIST
7828655	CHEMICAL	GENE	T24	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the dopamine D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 19 19 19 15 19 19|20|21 19|20|21 19|20|21 19|21 19|20|21 27 27 10 5 3 31 29 37 37|29 37 37|29 37 37 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T19	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 15 11 11 16|21 16|21 16|21 21 16|21 11 11 27|19 27|19 27 27|19 27 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T17	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 16|13 16 16|13 11 11 21 21 21 11 11 27|21 27|21 27|21 27 27|21 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T26	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 56 56 56 56 48|56 48|56 48|56 56 48|56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T13	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36|37 42|36|37 42|36|37 42|37 42|36|37 42 35 44 42 44 35 56 56 56 56 56 48|56 56 48|56 56 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T15	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 12 12 16 12 12 16|22 16|22 16|22 22 16|22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T29	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine receptor @/GENETgt$ ? [SEP] @GENETgt$ Dopamine receptor @/GENETgt$ blockade increases @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra .	0|1|4 0|1|4 1|4 0|1|4 5 5 9|3 9 9|3 9 5 9 14 14 14 9 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T20	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 27 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 17|15 17|15 17|15 17|15 17|15 23 23 10 23 27 27 27 27 31 31 27 37 37 35 37 37 27 37 41 41 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 27	None-BC7
7828655	CHEMICAL	GENE	T14	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36|37 42|36|37 42|36|37 42|37 42|36|37 42 35 44 42 44 35 55 55 55 55 55 55 55 55 35|51 35 35|51 25	None-BC7
7828655	CHEMICAL	GENE	T28	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ receptor blockade increases @GENETgt$ dopamine D2 receptor @/GENETgt$ and glutamic acid decarboxylase mRNAs in mouse substantia nigra .	0|3 3 0|3 4 5 5 4|5|6 4|5|6 4|5|6 5|6 4|5|6 6 14 14 14 6 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T12	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36|37 42|36|37 42|36|37 42|37 42|36|37 42 35 44 40|42 42 40|42 44 35 56 56 56 56 56 56 56 56 35 25	ANTAGONIST
7828655	CHEMICAL	GENE	T9	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 37 37 34 37 37|31 37 37|31 26 37 41 41 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 26	None-BC7
7828655	CHEMICAL	GENE	T8	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Glutamic acid decarboxylase @/GENETgt$ ? [SEP] @GENETgt$ Glutamic acid decarboxylase @/GENETgt$ mRNA was expressed in several regions of the mid-brain but only that expressed in substantia nigra was altered by treatment with @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS )	0|5 0|5 0|5 5 0|5 7 7 7 10 10 7 13 13 10 7 17 17 22 20 20 17 22 7 24 22 28 28|22 28 28|22 24 24 24 33 33 30 7	None-BC7
7828655	CHEMICAL	GENE	T22	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5 7 10 5 12 10 15 15 10 20 20 17|20 20 17|20 15 20 20|22 20|22 20|22 20|22 20|22 28 28 10 5 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	None-BC7
7828655	CHEMICAL	GENE	T12	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 40 40 42 42 34 44 41|42 42 41|42 44 34 56 56 56 56 56 56 56 56 34 25	ANTAGONIST
7828655	CHEMICAL	GENE	T26	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 43|35|38 43|35|38 43|35|38 43|38 43|35|38 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T17	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 12 12 17|12 17 17|12 12 12 22 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T4	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] There were no detectable levels of @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	2 2 5 5 2 7 5|6|7 5|6|7 5|6|7 5|7 5|6|7 5 2 14 12 20 12|20 20 12|20 20 20 14 24 23 24 12 2	None-BC7
7828655	CHEMICAL	GENE	T23	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5 7 10 5 12 10 15 15 10 18 18 17|18|15 17|18|15 18|15 17|18|15 18 18|19 18 18|19 25 18 28 28 10 5 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	None-BC7
7828655	CHEMICAL	GENE	T28	T55	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ receptor blockade increases dopamine D2 receptor and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNAs in mouse substantia nigra .	0|3 3 0|3 4 5 5 8 8 5 8 8|14 8|14 8|14 14 8|14 8 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T11	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 40 40 42 42 34|39 34 34|39 45 42 45 34 56 56 56 56 56 56 56 56 34 25	ANTAGONIST
7828655	CHEMICAL	GENE	T18	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 11|13|14 11|13|14 11|14 11|13|14 11 22|15 22 22|15 22 22 11 11 27 27 27 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T27	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	20 3 1 3 6 3 8 9 6 15 15 11|15 15 11|15 15 9 18 18 6 6 20 23 23 20 27 27 27 20 20 20 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 20	None-BC7
7828655	CHEMICAL	GENE	T17	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 12 12 17|11 17 17|11 12 12 22 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T16	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|10 0|1|10 1|10 0|1|10 1 8|2 8 8|2 8 1 10 10 13 13 10 13 13 17 13 13 22 22 22 13 13 27 27 27 13 29 10 34 34 31 34 29 10	None-BC7
7828655	CHEMICAL	GENE	T14	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 55 55 55 55 55 55 55 55 51|36 36 51|36 26	None-BC7
7828655	CHEMICAL	GENE	T26	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 27 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 20|13 20|13 20 20|13 12 23 23 10 23 27 27 27 27 31 31 27 37 37 35 37 37 27 37 41 41 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 27	None-BC7
7828655	CHEMICAL	GENE	T25	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	20 3 1|2 1 1|2 3 7 3 9 10 7 15 15 15 15 10 18 18 7 7 20 23 23 20 27 27 27 20 20 20 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 20	INDIRECT-UPREGULATOR
7828655	CHEMICAL	GENE	T27	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of dopamine D2 receptor mRNA by about 34 % .	20 3 1 3 6 3 8 9 6 15 15 11|15 15 11|15 15 9 18 18 6 6 20 23 23 20 25 25|20|23 25|20|23 25|20|23 25|20 25|20|23 20 20 32 30 37 37 37 37 32 41 40 41 30 20	None-BC7
7828655	CHEMICAL	GENE	T15	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 12 12 12|13|15 12|13|15 12|15 12|13|15 12 22 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T26	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 22 26 26 26 26 30 30 26 35 35 34 35 32|26|35 32|26|35 26|35 32|26|35 35 41 41 43 43 35 45 43 45 35 56 56 56 56 56 56 56 56 35 26	None-BC7
7828655	CHEMICAL	GENE	T11	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36|38 36 36|38 45 42 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T7	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Glutamic acid @/CHEMICALSrc$ decarboxylase mRNA was expressed in several regions of the mid-brain but only that expressed in substantia nigra was altered by treatment with @GENETgt$ dopamine receptor @/GENETgt$ antagonists.(ABSTRACT TRUNCATED AT 250 WORDS )	0|5 0|5 5 0|5 5 7 7 7 10 10 7 13 13 10 7 17 17 22 20 20 17 22 7 24 22 26 24|26|23 24|26|23 24|26 24|26|23 24 24 33 33 30 7	None-BC7
7828655	CHEMICAL	GENE	T5	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine receptor @/GENETgt$ ? [SEP] There were no detectable levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptor mRNA in substantia nigra either in control animals or in animals treated with the @GENETgt$ dopamine receptor @/GENETgt$ antagonists .	2 2 5 5 2 11 11|6 11 11|6 11 11 5 14 14 5 18 18 18 2 18 21 18 21 28 28 28|23 28|23 28 28|23 22 2	None-BC7
7828655	CHEMICAL	GENE	T2	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	20 3 1 3 6 3 8 9 6 12 12 9|11|12 9|11|12 9|11|12 9|12 9|11|12 18 18 6 6 20 23 23 20 27 27 27 20 20 20 31 29 37 37|29 37 37|29 37 37 31 41 40 41 29 20	None-BC7
7828655	CHEMICAL	GENE	T13	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 39 39 41 41 35 43 41 43 35 56 56 56 56 56|49 56 56|49 56|50 56|50 56 56|50 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T15	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 12 12 16 12 12 21 21 21 12 12 27|21 27|21 27|21 27 27|21 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T18	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 12 12 16 12 12 22|15 22 22|15 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T18	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 12 12 16 12 12 14|22 22 14|22 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T23	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the dopamine D2 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 19 19 19 15 19 19|20 19 19|20 24 19 27 27 10 5 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T19	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 12 12 16 12 12 21 21 21 12 12 27|19 27|19 27 27|19 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T1	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of dopamine D2 receptor mRNA by about 34 % .	20 3 1 3 6 3 8 9 6 12 12 9|11|12 9|11|12 9|11|12 9|12 9|11|12 18 18 6 6 20 23 23 20 28 28|21 28 28|21 28 20 20 20 32 30 37 37 37 37 32 41 40 41 30 20	None-BC7
7828655	CHEMICAL	GENE	T22	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 and dopamine D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 20 20 17|20 20 17|20 15 20 20 24 20 27 27 10 5 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T9	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 36 36 33 36 33|36 36 33|36 25 36 40 40 42 42 36 44 42 44 36 56 56 56 56 56|49 56|49 56|49 56 56|49 56 36 25	None-BC7
7828655	CHEMICAL	GENE	T11	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36|38 36 36|38 45 42 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T21	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the dopamine D2 and dopamine D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5|6 5 5|6 7 11 5 13 11 16 16 11 20 20 20 16 20 20 24 20 27 27 11 5 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	INDIRECT-UPREGULATOR
7828655	CHEMICAL	GENE	T17	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 11 11 16|13 16 16|13 11 11 16|22 16|22 16|22 22 16|22 11 11 27 27 27 11 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T15	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 10 3 3|5 3|5 3|5 3|5 3|5 10 10 13 13 10 13 13 17 13 13 22 22 22 13 13 27 27 27 13 29 10 34 34 31 34 29 10	None-BC7
7828655	CHEMICAL	GENE	T13	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 56 56 56 56 56 48|56 56 48|56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T11	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 39 39 41 41 40|35 35 40|35 44 41 44 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T1	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	19 3 1 3 6 3 8 9 6 14 14 14 14 9 17 17 6 6 19 22 22 19 27 27|23 27 27|23 27 19 19 19 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 19	None-BC7
7828655	CHEMICAL	GENE	T29	T55	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine receptor blockade increases @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNAs in mouse substantia nigra .	2 3 4 4 8|4 8 8|4 8 4 8 8|14 8|14 8|14 14 8|14 8 18 18 18 4 4	None-BC7
7828655	CHEMICAL	GENE	T25	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of dopamine D2 receptor mRNA by about 34 % .	20 3 1|2 1 1|2 3 7 3 9 10 7 15 15 15 15 10 18 18 7 7 20 23 23 20 25 25|20|23 25|20|23 25|20|23 25|20 25|20|23 20 20 32 30 37 37 37 37 32 41 40 41 30 20	None-BC7
7828655	CHEMICAL	GENE	T10	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 41|34 41 41|34 41 43 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T2	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	19 3 1 3 6 3 8 9 6 14 14 14 14 9 17 17 6 6 19 22 22 19 24 24|19|23 24|19|23 24|19|23 24|19 24|19|23 19 19 31 29 37 37|29 37 37|29 37 37 31 41 40 41 29 19	None-BC7
7828655	CHEMICAL	GENE	T14	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 39 39 41 41 35 43 41 43 35 55 55 55 55 49|55 49|55 49|55 55 49|55 55 35|51 35 35|51 25	ANTAGONIST
7828655	CHEMICAL	GENE	T30	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine receptor blockade increases @GENETgt$ dopamine D2 receptor @/GENETgt$ and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNAs in mouse substantia nigra .	2 3 4 4 4|5 4|5 4|5 4|5 4|5 5 6|14 6|14 14 6|14 14 5 18 18 18 4 4	None-BC7
7828655	CHEMICAL	GENE	T21	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and dopamine D1 receptors in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5|6 5 5|6 7 11 5 13 11 16 16 11 19 19 16|17|19 16|17|19 16|19 16|17|19 19 19 25 19 28 28 11 5 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	INHIBITOR
7828655	CHEMICAL	GENE	T12	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 39 39 41 41 35 43 41|42 41 41|42 43 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T19	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 12 12 16 12 12 21 21 21 12 12 27|20 27|20 27 27|20 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T16	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 12 12 12|13|15 12|13|15 12|15 12|13|15 12 22 22 22 12 12 27 27 27 12 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T10	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 35 35 33 35 35 25 35 40|36 40 40|36 40 42 42 35 44 42 44 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T10	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 21 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 41|35 41 41|35 41 43 43 34 45 43 45 34 56 56 56 56 56 56 56 56 34 25	None-BC7
7828655	CHEMICAL	GENE	T21	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the dopamine D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5|6 5 5|6 7 11 5 13 11 16 16 11 20 20 20 16 20 20|22 20|22 20|22 20|22 20|22 28 28 11 5 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	INHIBITOR
7828655	CHEMICAL	GENE	T20	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 22 26 26 26 26 30 30 26 35 35 34 35 33|26|35 33|26|35 26|35 33|26|35 35 41 41 43 43 35 45 43 45 35 56 56 56 56 56 56 56 56 35 26	None-BC7
7828655	CHEMICAL	GENE	T3	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] There were no detectable levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	2 2 5 5 2 10 10|6 10 10|6 10 5 5 2 14 12 20 20|14 20|14 20|14 20 20|14 14 24 23 24 12 2	None-BC7
7828655	CHEMICAL	GENE	T25	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of dopamine D2 receptor mRNA by about 34 % .	21 3 1|2 1 1|2 3 7 3 9 10 7 13 13 10|11|13 10|11|13 10|11|13 10|13 10|11|13 19 19 7 7 21 24 24 21 28 28 28 21 21 21 32 30 37 37 37 37 32 41 40 41 30 21	INHIBITOR
7828655	CHEMICAL	GENE	T20	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 22 26 26 26 26 30 30 26 36 36 34 36 36 26 36 40 40 42 42 36 44 42 44 36 56 56 56 56 56|49 56|49 56|49 56 56|49 56 36 26	None-BC7
15456329	CHEMICAL	GENE	T18	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Compared with @GENETgt$ COX-2 @/GENETgt$ selective inhibitors , @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ exhibits similar anti-inflammatory and analgesic properties in patients with arthritis and there is no evidence of excess GI or other forms of complications to date .	6 6 2|6 6 2|6 6 10 10 10|6 10 10|6 10 15 15 12 12 10 17 10 19 17 10 22 10 24 22 27 27 24 27 30 27 32 30 34 24 22	INHIBITOR
15456329	CHEMICAL	GENE	T15	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] This has been attributed mainly to the non-acidic chemical properties of @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ but also to its @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor profile .	4 4 4 4 4 10 10 10 10 4 12 10|11 10 10|11 10 21 21 21 16|21 21 16|21 21 10 4	INHIBITOR
15456329	CHEMICAL	GENE	T19	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 6-MNA @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ ? [SEP] Nabumetone itself is non-acidic and , following absorption , it undergoes extensive first-pass metabolism to form the main circulating active metabolite ( @CHEMICALSrc$ 6-MNA @/CHEMICALSrc$ ) which is a much more potent inhibitor of preferentially @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ .	4 1 4 4 4 4 8 11 11 11 4 14 14 11 16 11 21 21 21 21 16 23 21|22 21 21|22 23 32 32 32 30 31 32 21 35 35 32|33|35 32|33|35 32|35 32|33|35 4	INHIBITOR
15456329	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Nabumetone @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Nabumetone @/CHEMICALSrc$ itself is non-acidic and , following absorption , it undergoes extensive first-pass metabolism to form the main circulating active metabolite ( 6-MNA ) which is a much more potent inhibitor of preferentially @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ .	0|5 5 0|5 1 5 5 5 5 9 12 12 12 5 15 15 12 17 12 22 22 22 22 17 24 22 24 32 32 32 30 31 32 22 35 35 32|33|35 32|33|35 32|35 32|33|35 5	INHIBITOR
15456329	CHEMICAL	GENE	T15	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] This has been attributed mainly to the non-acidic chemical properties of @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ but also to its @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor profile .	4 4 4 4 4 10 10 10 10 4 12 10|11 10 10|11 10 21 21 21 16|21 21 16|21 21 10 4	INHIBITOR
17258485	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ human vitamin C transporter @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the @GENETgt$ human @/GENETgt$ @CHEMICALSrc$ vitamin C transporter @/CHEMICALSrc$ SVCT1 ( SLC23A1 ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 15 15 8|15 15 8|15 9|15 9|15 9|15 15 9|15 6 17 15 17 20 20 20 20 24 22 26 24 29 29 26 20	None-BC7
17258485	CHEMICAL	GENE	T23	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 10 6 4|5 4 4|5 10 10 10 15 15 12 15 10 10 10 20 20 10 23 23 20 26 26 23 23 20 33 32 32 33 35 35 10 37 35 40 40 37 40 37 46 46 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 60 60 72 72|70 72|70 72|70 72|70 72 77 72 60 60 35	None-BC7
17258485	CHEMICAL	GENE	T25	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 58 58 58 57|58|49 57|58|49 49|58 57|58|49 62 58 62 58 58 67 65 67 58 58 72 72|69|70 72|69|70 72|70 72|69|70 72 77 72 58 58 34	INHIBITOR
17258485	CHEMICAL	GENE	T6	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Phorbol 12-myristate 13 acetate @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] @CHEMICALSrc$ Phorbol 12-myristate 13 acetate @/CHEMICALSrc$ ( PMA ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	0|1|20 0|1|20 0|1|20 0|1|20 1|20 0|1|20 7 1 7 1 13 13 13 1 15 10|13|15 10|13|15 10|13|15 13|15 10|13|15 1 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T24	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ Na(+) @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with @CHEMICALSrc$ Na(+ ) @/CHEMICALSrc$ ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 15 10|11|15 10|11|15 11|15 10|11|15 15 9 9 9 20 20 9 23 23 20 26 26 23 23 20 33 32 32 33 35 35 9 37 35 40 40 37 40 37 46 46 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 60 60 72 72|69|70 72|69|70 72|70 72|69|70 72 77 72 60 60 35	None-BC7
17258485	CHEMICAL	GENE	T1	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ EIPA @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( @CHEMICALSrc$ EIPA @/CHEMICALSrc$ ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64|65 64 64|65 66 59 59 72 72|70 72|70 72|70 72|70 72 77 72 59 59 34	None-BC7
17258485	CHEMICAL	GENE	T28	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ Vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Vitamin C @/CHEMICALSrc$ transport and @GENETgt$ SVCT1 @/GENETgt$ transporter expression in chick renal proximal tubule cells in culture .	0|4 0|4 4 0|4 4 4 8|3 8 8|3 9 4 15 15 15 15 15 9 17 9 4	None-BC7
17258485	CHEMICAL	GENE	T8	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ phorbol ester @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( PMA ) , the @CHEMICALSrc$ phorbol ester @/CHEMICALSrc$ activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	4 4 4 20 6 4 6 4 13 9|13 9|13 13 9|13 4 15 12|13|15 12|13|15 12|13|15 13|15 12|13|15 4 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T26	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ DIDS @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( @CHEMICALSrc$ DIDS @/CHEMICALSrc$ ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59|60 59 59|60 61 59 59 67 65 67 59 59 73 73 70 73 73|75 73|75 73|75 73|75 59 59 34	None-BC7
17258485	CHEMICAL	GENE	T27	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59|63 59 59|63 67 64 67 59 59 73 73 70 73 73|75 73|75 73|75 73|75 59 59 34	INHIBITOR
17258485	CHEMICAL	GENE	T12	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , sodium-dependent @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter ( @GENETgt$ SVCT1 @/GENETgt$ ) in the chick renal proximal tubule .	2 3 3 5 3 14 14 14 8 8 10|14 10|14 14 10|14 5 16 13|14 14 13|14 16 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T23	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 10 6 4|5 4 4|5 10 10 10 15 15 12 15 10 10 10 20 20 10 23 23 20 26 26 23 23 20 33 32 32 33 35 35 10 37 35 40 40 37 40 37 46 46 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 60 60 73 73 70 73 73|75 73|75 73|75 73|75 60 60 35	None-BC7
17258485	CHEMICAL	GENE	T4	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-nitro-2(3-phenylpropylamino)benzoic acid @/CHEMICALSrc$ and @GENETgt$ chloride channel @/GENETgt$ ? [SEP] There was no inhibition , however , by the @GENETgt$ chloride channel @/GENETgt$ blocker @CHEMICALSrc$ 5-nitro-2(3-phenylpropylamino)benzoic acid @/CHEMICALSrc$ ( NPPB ) .	2 2 4 2 2 2 2 14 14 9|14 9|14 14 9|14 14 2|11|14 2|11|14 2|14 2|11|14 18 14 18 2	INHIBITOR
17258485	CHEMICAL	GENE	T25	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 58 58 58 57|58|49 57|58|49 49|58 57|58|49 62 58 62 58 58 67 65 67 58 58 73 73 70 73 72|73|75 72|73|75 73|75 72|73|75 58 58 34	None-BC7
17258485	CHEMICAL	GENE	T11	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , @CHEMICALSrc$ sodium-dependent @/CHEMICALSrc$ vitamin C transporter ( @GENETgt$ SVCT1 @/GENETgt$ ) in the chick renal proximal tubule .	2 3 3 5 3 14 14 14 8 8|9 8 8|9 14 14 5 16 14 14 14 16 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T7	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ PMA @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( @CHEMICALSrc$ PMA @/CHEMICALSrc$ ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	4 4 4 20 6 4|5 4 4|5 6 4 13 13 13 4 15 13|15 13|15 13|15 13|15 13|15 4 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T9	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( PMA ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ .	4 4 4 19 6 4 6 4 12 12 12 4 14 12|13|14 12|13|14 12|13|14 12|14 12|13|14 4 19 23 22 23 19 28 28 28 28 23 30 26|28 28 26|28 19	None-BC7
17258485	CHEMICAL	GENE	T2	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and @CHEMICALSrc$ sodium-proton @/CHEMICALSrc$ exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64 66 59 59 71 69|70|71 69|70|71 69|71 69|70|71 71 72|77 77 72|77 71 59 59 34	None-BC7
17258485	CHEMICAL	GENE	T5	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ NPPB @/CHEMICALSrc$ and @GENETgt$ chloride channel @/GENETgt$ ? [SEP] There was no inhibition , however , by the @GENETgt$ chloride channel @/GENETgt$ blocker 5-nitro-2(3-phenylpropylamino)benzoic acid ( @CHEMICALSrc$ NPPB @/CHEMICALSrc$ ) .	2 2 4 2 2 2 2 15 15 9|15 9|15 15 9|15 15 15 2 17 14|15 15 14|15 17 2	INHIBITOR
17258485	CHEMICAL	GENE	T10	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SLC23A1 @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the human @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter SVCT1 ( @GENETgt$ SLC23A1 @/GENETgt$ ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 14 14 14 9|14 9|14 14 9|14 14 6 16 13|14 14 13|14 16 20 20 20 20 24 22 26 24 29 29 26 20	None-BC7
17258485	CHEMICAL	GENE	T24	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Na(+) @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with @CHEMICALSrc$ Na(+ ) @/CHEMICALSrc$ ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 15 10|11|15 10|11|15 11|15 10|11|15 15 9 9 9 20 20 9 23 23 20 26 26 23 23 20 33 32 32 33 35 35 9 37 35 40 40 37 40 37 46 46 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 60 60 73 73 70 73 72|73|75 72|73|75 73|75 72|73|75 60 60 35	None-BC7
17258485	CHEMICAL	GENE	T11	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ vitamin C transporter @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , @CHEMICALSrc$ sodium-dependent @/CHEMICALSrc$ @GENETgt$ vitamin C transporter @/GENETgt$ ( SVCT1 ) in the chick renal proximal tubule .	2 3 3 5 3 12 12 12 8 8|9 8 8|9 10|12|5 10|12|5 10|12|5 12|5 10|12|5 17 12 17 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T26	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ DIDS @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( @CHEMICALSrc$ DIDS @/CHEMICALSrc$ ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59|60 59 59|60 61 59 59 67 65 67 59 59 72 72|70 72|70 72|70 72|70 72 77 72 59 59 34	INHIBITOR
17258485	CHEMICAL	GENE	T10	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the human @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter @GENETgt$ SVCT1 @/GENETgt$ ( SLC23A1 ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 14 14 14 9|14 9|14 14 9|14 14 11|6 6 11|6 17 14 17 20 20 20 20 24 22 26 24 29 29 26 20	None-BC7
17258485	CHEMICAL	GENE	T27	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59|63 59 59|63 67 64 67 59 59 72 72|70 72|70 72|70 72|70 72 77 72 59 59 34	None-BC7
17258485	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ EIPA @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( @CHEMICALSrc$ EIPA @/CHEMICALSrc$ ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 11 14 9 9 9 19 19 9 22 22 19 25 25 22 22 19 32 31 31 32 34 34 9 36 34 39 39 36 39 36 45 45 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64|65 64 64|65 66 59 59 73 73 70 73 73|75 73|75 73|75 73|75 59 59 34	INHIBITOR
23152189	CHEMICAL	GENE	T20	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ TCDD @/CHEMICALSrc$ decreased the expression of the glucose transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	0|3 3 0|3 3 5 3 9 9 9 5 9 9 9 9 9 3 3 19 19 19 15 3 3 23 21 26 26 23 26 29 26 3	INDIRECT-DOWNREGULATOR
23152189	CHEMICAL	GENE	T5	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ oxygen @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive @CHEMICALSrc$ oxygen @/CHEMICALSrc$ species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 34 31 15 15 38 15 44 44 44 36|44 44 36|44 38 46 44 46 44 50 44 15	None-BC7
23152189	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] Cotreatment of cells with chemical antioxidants or the enzyme @GENETgt$ catalase @/GENETgt$ blocked the @CHEMICALSrc$ TCDD-mediated @/CHEMICALSrc$ acceleration of keratinocyte cornified envelope formation , an endpoint of terminal differentiation .	12 3 1 6 6 1 6 10 10 9|6 6 9|6 12 16 16|12 16 16|12 12 21 21 21 21 16 16 24 16 27 27 24 12	None-BC7
23152189	CHEMICAL	GENE	T7	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	0|4 0|4 4 0|4 9 6 9|3 9 9|3 6 10 10 12 10 15 15 12 17 12 10 10 21 10 25 25 25 21 25 25 10 10 29 33 33 30 10	None-BC7
23152189	CHEMICAL	GENE	T8	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	3 3 8 5 8|4 8 8|4 5 9 9 11 9 14 14 11 16 11|14 11 11|14 9 9 21 9 25 25 25 21 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T20	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ glucose transporter @/GENETgt$ ? [SEP] @CHEMICALSrc$ TCDD @/CHEMICALSrc$ decreased the expression of the @GENETgt$ glucose transporter @/GENETgt$ , SLC2A1 , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	0|3 3 0|3 3 5 3 8 8 8|5|6 8|5|6 8|5 8|5|6 8 8 8 3 3 19 19 19 15 3 3 23 21 26 26 23 26 29 26 3	INDIRECT-DOWNREGULATOR
23152189	CHEMICAL	GENE	T8	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ? [SEP] @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ( AHR ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	0|1|8 0|1|8 0|1|8 8|1 0|1|8 6 8 6 9 9 11 9 14 14 11 16 11|12 11 11|12 9 9 21 9 25 25 25 21 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T21	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] TCDD decreased the expression of the @CHEMICALSrc$ glucose @/CHEMICALSrc$ transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	2 2 4 2 9 9 9|6 9 9|6 4 9 9 9 9 9 2 2 19 19 19 15 2 2 23 21 26 26 23 26 29 26 2	None-BC7
23152189	CHEMICAL	GENE	T8	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( AHR ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	3 3 7 5 7 5 8 8 10 8 13 13 10 15 10|14 10 10|14 8 8 20 8 24 24 24 20 24 24 8 8 28 32 32 29|30 29 29|30 8	None-BC7
23152189	CHEMICAL	GENE	T2	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione disulfide @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the @CHEMICALSrc$ GSH/glutathione disulfide @/CHEMICALSrc$ ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 16 8 14 5|14 5|14 14 5|14 8 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 39 16 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
23152189	CHEMICAL	GENE	T9	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the AHR .	3 3 8 5 8|4 8 8|4 5 9 9 11 9 14 14 11 16 11 9 9 20 9 25 25 25|21 25 25|21 20 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T7	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ receptor ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	0|4 0|4 4 0|4 8 6 8 6 9 9 11 9 14 14 11 16 11 9 9 20 9 24 24 24 20 24 24 9 9 28 32 32 29 29 29 9	None-BC7
23152189	CHEMICAL	GENE	T22	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] TCDD decreased the expression of the glucose transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ .	2 2 4 2 8 8 8 4 8 8|9 8 8|9 8 2 2 18 18 18 14 2 2 22 20 25 25 22 25 28 25|26 25 25|26 2	None-BC7
23152189	CHEMICAL	GENE	T9	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ? [SEP] @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the AHR .	0|1|8 0|1|8 0|1|8 8|1 0|1|8 6 8 6 9 9 11 9 14 14 11 16 11 9 9 20 9 25 25 25|19 25 25|19 20 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T9	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	3 3 7 5 7 5 8 8 10 8 13 13 10 15 10 8 8 19 8 24 24 24|21 24 24|21 19 24 24 8 8 28 32 32 29|30 29 29|30 8	None-BC7
23152189	CHEMICAL	GENE	T22	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ and @GENETgt$ glucose transporter @/GENETgt$ ? [SEP] TCDD decreased the expression of the @GENETgt$ glucose transporter @/GENETgt$ , SLC2A1 , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ .	2 2 4 2 7 7 4|6|7 4|6|7 4|7 4|6|7 7 7 7 2 2 18 18 18 14 2 2 22 20 25 25 22 25 28 25 25 25 2	None-BC7
23152189	CHEMICAL	GENE	T1	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the @CHEMICALSrc$ GSH/glutathione @/CHEMICALSrc$ disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 16 8 14 5|14 14 5|14 14 8 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 39 16 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
23152189	CHEMICAL	GENE	T4	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and @CHEMICALSrc$ ATP @/CHEMICALSrc$ production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 35|27 35 35|27 31 15 15 39 15 44 44 44 44 39 46 44 46 44 50 44 15	None-BC7
23152189	CHEMICAL	GENE	T6	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ hydrogen peroxide @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , @CHEMICALSrc$ hydrogen peroxide @/CHEMICALSrc$ .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 34 31 15 15 38 15 43 43 43 43 38 45 43 45 43 48|42|43 48|42|43 48|43 48|42|43 15	None-BC7
23152189	CHEMICAL	GENE	T3	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 11|15 15 11|15 15 21 15 24 24 21 24 24 32 32 32 32 32 26 32 35 32 15 15 39 15 44 44 44 44 39 46 44 46 44 50 44 15	INHIBITOR
23152189	CHEMICAL	GENE	T27	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( @/GENETgt$ @CHEMICALSrc$ GSH ) reductase @/CHEMICALSrc$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	9 1|9 1|9 9 1|9 9|2 9|2 9|2 9 9|2 16 9 14 14 14 9 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 39 16 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
11607047	CHEMICAL	GENE	T12	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ and @GENETgt$ 5-HT1A @/GENETgt$ ? [SEP] It enhances , therefore , the release of @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ and @GENETgt$ 5-HT1A-mediated @/GENETgt$ serotonergic transmission .	2 2 2 2 2 7 5 9 8|7 7 8|7 9 9|10 9 9|10 9 2 2	None-BC7
12512695	CHEMICAL	GENE	T10	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study also demonstrated that COX does not play a central role in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats .	3 3 5 5 5 10 10 10 10 5 13 13 10 16 16 10 22 17|22 17|22 22 17|22 22 16 26 26|21 26 26|21 22 5	None-BC7
12512695	CHEMICAL	GENE	T16	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 7 6 3|6 6 3|6 7 7 11 11 11 7 14 14 7 18 18 16 14 18 18 20 26 26 26 26 18 32 32 30 32 30 26 32 18 37 37 18 7 7 7 44 44 44 7 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60 60|54 60 44 62 60 65 65 62 62 62 7	None-BC7
12512695	CHEMICAL	GENE	T4	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 13 4 4 4 4 11|6 11 11|6 11 4 13 13 15 13 18 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of @GENETgt$ Ang II-induced @/GENETgt$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 10 9 10 9|6 6 9|6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T15	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 7 6 3|6 6 3|6 7 7 11 11 11 7 14 14 7 18 18 16 14 18 18 20 26 26 26 26 18 32 32 30 32 30 26 32 18 37 37 18 7 7 7 44 44 44 7 46 44 44 44 46 51 51 46 46 46 44 60 60 60 60 60 44 62 60 65 65 62 62 62 7	None-BC7
12512695	CHEMICAL	GENE	T6	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 10|6 10 10|6 10 4 12 12 14 12 18|13 18|13 18 18|13 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T5	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 9 9 8|4 4 8|4 12 12 14 12 18|13 18|13 18 18|13 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ mouse renin-2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring @GENETgt$ mouse renin-2 @/GENETgt$ gene ( mREN2 rats ) .	3 3 4 4 6 4 10 9 10 9|6 6 9|6 14 14 6 19 19 19 19 14 22 22 19 22 27|22 27|22 27 27|22 23 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T7	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 11 4 4 9 9 4 11 11 13 11 16 16 13 16 19 16 23 20|23 23 20|23 16 11 11 29 29 29 32|27 32 32|27 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T4	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 4 4 10 10 4 12 12 14 12 17 17 14 17 20 17 24 24|20 24 24|20 17 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase @GENETgt$ (COX)-synthetized @/GENETgt$ eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 9 8|11 11 8|11 6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T13	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 32 32|26 32 32|26 30 32 30 25 32 17 37 37 17 6 6 6 45 45 41|45 45 41|45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T14	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 17 37 37 17 6 6 6 44 44 44 6 46 44 46 50 50 46 46 46 44 60 60 52|60 52|60 52|60 60 52|60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T13	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 32 32|26 32 32|26 30 32 30 25 32 17 37 37 17 6 6 6 45 45 41|45 45 41|45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T2	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Urinary @CHEMICALSrc$ NO @/CHEMICALSrc$ , excretion , a marker of total body NO generation , was also decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 1|17 17 1|17 17 17 5 8 5 13 13 13 13 8 5 17 17 17 21 17|21 21 17|21 17 17	None-BC7
12512695	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 2|5 5 2|5 12 5 5 10 10 5 12 12 14 12 17 17 14 17 20 17 23 23 17 12 12 29 29 29 32|27 32 32|27 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 10|6 10 10|6 10 4 12 12 14 12 17 17 14 17 20 17 23 23 17 12 12 29 29 29 32|27 32 32|27 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T14	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26 26 26|22 26 26|22 26 17 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 17 38 38 17 6 6 6 45 45 45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T8	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Our findings indicate that @CHEMICALSrc$ NO @/CHEMICALSrc$ synthesis and/or bioavailability as well as the sensitivity of arterial smooth muscle cells to NO are decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 3 3 23 4|7 7 4|7 23 7 7 7 10 10 14 7 19 19 19 19 14 21 14 23 3 27 27|23 27 27|23 23 3	None-BC7
12512695	CHEMICAL	GENE	T16	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26|20 26 26|20 26 26 26 17 32 32 30 32 30 26 32 17 37 37 17 6 6 6 44 44 44 6 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60 60|54 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T3	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Urinary NO , excretion , a marker of total body @CHEMICALSrc$ NO @/CHEMICALSrc$ generation , was also decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 17 17 17 4 7 4 13 13 13 10|13 13 10|13 7 4 17 17 17 21 17|21 21 17|21 17 17	None-BC7
12512695	CHEMICAL	GENE	T12	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The present study examined the role of @GENETgt$ cyclo-oxygenase @/GENETgt$ (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 10|7 10 10|7 11 6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 7 6 3|6 6 3|6 7 7 11 11 11 7 14 14 7 18 18 16 14 18 18 20 26 26 26 26 18 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 18 38 38 18 7 7 7 45 45 45 7 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 7	None-BC7
12512695	CHEMICAL	GENE	T4	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 4 4 10 10 4 12 12 14 12 17 17 14 17 20 17 23 23 17 12 12 24|30 30 24|30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T6	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 11 4 4 9 9 4 11 11 13 11 17|13 17|13 17 17|13 13 17 20 17 23 23 17 11 11 30|23 30 30|23 30 30 32 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T13	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 32 32|26 32 32|26 30 32 30 25 32 17 37 37 17 6 6 6 44 44 44 6 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60|54 60 60|54 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T7	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 11 4 4 9 9 4 11 11 13 11 17|13 17|13 17 17|13 13 17 20 17 23 23 17 11 11 29 29 29 32|26 32 32|26 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26|20 26 26|20 26 26 26 17 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 17 38 38 17 6 6 6 45 45 45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26|20 26 26|20 26 26 26 17 33 33|26 33 33|26 31 33 31 26 33 17 38 38 17 6 6 6 45 45 45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T15	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 31 31 29 31 29 25 31 17 36 36 17 6 6 6 43 43 43 6 45 43|44 43 43|44 45 50 50 45 45 45 43 60 60 60|54 60|54 60|54 60 60|54 43 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T9	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Our findings indicate that NO synthesis and/or bioavailability as well as the sensitivity of arterial smooth muscle cells to @CHEMICALSrc$ NO @/CHEMICALSrc$ are decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 3 3 23 6 23 6 6 6 9 9 13 6 18 18 18 18 13 20 19|13 13 19|13 23 3 27 27|23 27 27|23 23 3	None-BC7
12512695	CHEMICAL	GENE	T17	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] @GENETgt$ Ang II-induced @/GENETgt$ endothelial dysfunction is associated with perivascular inflammation and increased @CHEMICALSrc$ superoxide @/CHEMICALSrc$ production in the vascular wall .	0|5 0|5 5 0|5 5 7 7 7 10 10 7 7 7 10|15 15 10|15 12 19 19 19 12 7	None-BC7
12512695	CHEMICAL	GENE	T14	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 17 37 37 17 6 6 6 45 45 45|39 45 45|39 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T13	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 7 6 3|6 6 3|6 7 7 11 11 11 7 14 14 7 18 18 16 14 18 18 20 26 26 26 26 18 33 33|26 33 33|26 31 33 31 26 33 18 38 38 18 7 7 7 45 45 45 7 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 7	None-BC7
12512695	CHEMICAL	GENE	T14	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 17 37 37 17 6 6 6 45 45 45|39 45 45|39 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T5	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 9 9 8|4 4 8|4 12 12 14 12 17 17 14 17 20 17 24 24|20 24 24|20 17 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T15	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26 26 26|22 26 26|22 26 17 32 32 30 32 30 26 32 17 37 37 17 6 6 6 44 44 44 6 46 44 44 44 46 51 51 46 46 46 44 60 60 60 60 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T15	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 31 31 29 31 29 25 31 17 36 36 17 6 6 6 44 44 41|44 44 41|44 6 46 44 44 44 46 51 51 46 46 46 44 60 60 60 60 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T12	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( @GENETgt$ mREN2 @/GENETgt$ rats ) .	3 3 4 4 6 4 10 9 10 6 13 13 6 19 19|14 19|14 19 19|14 19 13 22 22 19 22 26 26 23 30 25|30 30 25|30 26 30 4	None-BC7
12512695	CHEMICAL	GENE	T4	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 4 4 10 10 4 12 12 14 12 18|13 18|13 18 18|13 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T6	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 2|5 5 2|5 12 5 5 10 10 5 12 12 14 12 18|13 18|13 18 18|13 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T11	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The present study examined the role of @GENETgt$ cyclo-oxygenase @/GENETgt$ (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 10|7 10 10|7 11 9|6 6 9|6 15 15 6 20 20 20 20 15 23 23 20 23 27 27 24 30 30 27 30 4	PRODUCT-OF
12512695	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 2|5 5 2|5 13 5 5 10 10 8|5 5 8|5 13 13 15 13 18 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T5	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 12 4 4 9 9 8|4 4 8|4 12 12 14 12 17 17 14 17 20 17 23 23 17 12 12 24|30 30 24|30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T11	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( @GENETgt$ mREN2 @/GENETgt$ rats ) .	3 3 4 4 6 4 10 9 10 9|6 6 9|6 14 14 6 19 19 19 19 14 22 22 19 22 26 26 23 30 26|30 30 26|30 26 30 4	None-BC7
12512695	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26|20 26 26|20 26 26 26 17 32 32 30 32 30 26 32 17 37 37 17 6 6 6 44 44 44 6 46 44 44 44 46 51 51 46 46 46 44 60 60 60 60 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T11	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase @GENETgt$ (COX)-synthetized @/GENETgt$ @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 9 8|11 11 8|11 9|6 6 9|6 15 15 6 20 20 20 20 15 23 23 20 23 27 27 24 30 30 27 30 4	PRODUCT-OF
12512695	CHEMICAL	GENE	T10	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study also demonstrated that @GENETgt$ COX @/GENETgt$ does not play a central role in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in mREN2 rats .	3 3 5 5 5 11 11|6 11 11|6 11 11 5 14 14 11 17 17 11 23 17|23 17|23 23 17|23 23 17 26 26 23 5	None-BC7
12512695	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 2|5 5 2|5 13 4|5 5 4|5 5 11 11 5 13 13 15 13 18 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T15	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 31 31 29 31 29 25 31 17 36 36 17 6 6 6 44 44 41|44 44 41|44 6 46 44 44 44 46 51 51 46 46 46 44 60 60 60 60 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 13 4 4 10|6 10 10|6 10 8|4 4 8|4 13 13 15 13 18 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T16	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 31 31 29 31 29 25 31 17 36 36 17 6 6 6 44 44 41|44 44 41|44 6 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60 60|54 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T6	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 11 4 4 9 9 4 11 11 13 11 17|13 17|13 17 17|13 13 17 20 17 24 24|19 24 24|19 17 11 11 30 30 30 32 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T12	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mouse renin-2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring @GENETgt$ mouse renin-2 @/GENETgt$ gene ( mREN2 rats ) .	3 3 4 4 6 4 10 9 10 6 13 13 6 19 19|14 19|14 19 19|14 19 13 22 22 19 22 27|21 27|21 27 27|21 23 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T7	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	4 4 4 11 4 4 9 9 4 11 11 13 11 16 16 13 16 19 16 22 22 16 11 11 24|29 29 24|29 29 29 32|27 32 32|27 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T16	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26 26 26|22 26 26|22 26 17 32 32 30 32 30 26 32 17 37 37 17 6 6 6 44 44 44 6 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60 60|54 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T16	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 25 25 25 25 17 31 31 29 31 29 25 31 17 36 36 17 6 6 6 44 44 41|44 44 41|44 6 46 44 46 50 50 46 46 46 44 60 60 60|54 60|54 60 60|54 60 44 62 60 65 65 62 62 62 6	None-BC7
12512695	CHEMICAL	GENE	T13	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 6 5 5 6 6 10 10 10 6 13 13 6 17 17 15 13 17 17 19 26 26 26|22 26 26|22 26 17 33 33|26 33 33|26 31 33 31 26 33 17 38 38 17 6 6 6 45 45 45 6 47 45 47 51 51 47 47 47 45 60 60 60 60 60 45 62 60 65 65 62 62 62 6	None-BC7
23237733	CHEMICAL	GENE	T9	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 11 11 13 13 13 13 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13 15 16|15 15 16|15 15 15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 43 48 27 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	INHIBITOR
23237733	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13|14 13 13|14 15 15 15 15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 42 48 26 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	None-BC7
23237733	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ chalcone @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with @CHEMICALSrc$ chalcone @/CHEMICALSrc$ structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) .	13 1 5 5 1 9 9|6 9 9|6 5 1 13 13 13 16 16 13 18 16 18 24 24 23 24 28 26 28 28 26|19 19 26|19 31 28 31 13	INHIBITOR
23237733	CHEMICAL	GENE	T5	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1, 1A3, 1A6, 1A7, 1A8, 1A9 and 1A10 @/GENETgt$ ? [SEP] Therefore , the aim of the present study was to investigate the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards important UGT isoforms in the liver and intestine , including @GENETgt$ UGT1A1 , 1A3 , 1A6 , 1A7 , 1A8 , 1A9 and 1A10 @/GENETgt$ .	9 9 4 9 8 8 8 4 9 11 9 13 11 15 13|14 13 13|14 20 20 20 13 23 23 20 23 23 23 28 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 28|23 26|28|23 9	None-BC7
23237733	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 16|15 15 16|15 15 15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 42 48 26 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	None-BC7
23237733	CHEMICAL	GENE	T10	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 42 47 26 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 60 67 67 67 67 67 67 67 60 49 10	None-BC7
23237733	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A6 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , @GENETgt$ UGT1A6 @/GENETgt$ , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13|15 13 13|15 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T9	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A8 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , @GENETgt$ UGT1A8 @/GENETgt$ , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 19|13 13 19|13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T10	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13|14 13 13|14 15 15 15 15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 43 48 27 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	INHIBITOR
23237733	CHEMICAL	GENE	T1	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) .	0|13 13 0|13 1 6 6 1 9 9 6 1 13 13 13 16 16 13 18 16 18 24 24 23 24 28 26 28 28 26|19 19 26|19 31 28 31 13	INHIBITOR
23237733	CHEMICAL	GENE	T2	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] All these results indicated the risk of clinical application of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ on the drug-drug interaction and other possible diseases induced by the inhibition of isoliquiritigenin towards these @GENETgt$ UGT @/GENETgt$ isoforms .	3 3 4 4 6 4 9 9 6 11 9|10 9 9|10 16 16 16 9 16 20 20 16 20 24 24 21 26 24 31 31 27|31 31 27|31 24 4	None-BC7
23237733	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation .	2 2 5 5 2 19 19 13|7 13 13|7 11 13 11 19 19 16 14 14 14 16 2 2	SUBSTRATE
23237733	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) .	0|13 13 0|13 1 6 6 1 9 9 6 1 13 13 13 16 16 13 18 16 18 24 24 23 24 28 26 28 28 19 30 28 28 28 30 13	INHIBITOR
23237733	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation .	2 2 5 5 2 19 19 13 10 9|13 13 9|13 10 19 19 16 14 14 14 16 2 2	SUBSTRATE
23237733	CHEMICAL	GENE	T11	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 41 47 25 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 65|60 60 65|60 67 67 67 67 67 60 49 10	INHIBITOR
23237733	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation .	2 2 5 5 2 19 19 13 10 9|13 13 9|13 10 19 19|12 19 19|12 17 14 17 2 2	SUBSTRATE
23237733	CHEMICAL	GENE	T9	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A3 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , @GENETgt$ UGT1A3 @/GENETgt$ , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T3	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] All these results indicated the risk of clinical application of isoliquiritigenin on the drug-drug interaction and other possible diseases induced by the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards these @GENETgt$ UGT @/GENETgt$ isoforms .	3 3 4 4 6 4 9 9 6 11 9 15 15 15 9 15 19 19 15 19 23 23 20 25 24|23 23 24|23 31 31 27|31 31 27|31 23 4	INHIBITOR
23237733	CHEMICAL	GENE	T8	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] The recombinant @GENETgt$ UGT-catalyzed @/GENETgt$ 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation was used as probe reactions .	10 10 2|10 10 2|10 10 7 5 5 5 7 12 12 12 15 15 12 12	SUBSTRATE
23237733	CHEMICAL	GENE	T11	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 41 47 25 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 60 67 67 67 67 67 67 67 60 49 10	INHIBITOR
23237733	CHEMICAL	GENE	T13	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation .	2 2 5 5 2 19 19 13|7 13 13|7 11 13 11 19 19|12 19 19|12 17 14 17 2 2	SUBSTRATE
23237733	CHEMICAL	GENE	T9	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13 13 13 24|13 13 24|13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T9	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A7 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , @GENETgt$ UGT1A7 @/GENETgt$ , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 17|13 13 17|13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T12	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	0|3 3 0|3 3 6 6 3 19 19 14|7 14 14|7 12 14 12 19 19 17 15 17 3 3	INHIBITOR
23237733	CHEMICAL	GENE	T12	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	0|3 3 0|3 3 6 6 3 19 19 14 11 9|14 14 9|14 11 19 19 17 15 17 3 3	INHIBITOR
23237733	CHEMICAL	GENE	T9	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13|21 13 13|21 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 42 42 49 42 49 9 3	INHIBITOR
23237733	CHEMICAL	GENE	T10	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 42 47 26 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 60 67 67 67 67 67|70 67 67|70 60 49 10	None-BC7
23237733	CHEMICAL	GENE	T11	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 41 47 25 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 60 67 67 67 67 67|70 67 67|70 60 49 10	INHIBITOR
23237733	CHEMICAL	GENE	T11	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and @GENETgt$ UGT1A10 @/GENETgt$ by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 18|15 15 18|15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 42 48 26 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	None-BC7
23237733	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @CHEMICALSrc$ UDP-glucuronosyltransferase @/CHEMICALSrc$ ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	2 2 5 5 2 19 19 14|7 14 14|7 11 9|14 14 9|14 11 19 19 17 15 17 2 2	None-BC7
23237733	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @CHEMICALSrc$ UDP-glucuronosyltransferase @/CHEMICALSrc$ ( @GENETgt$ UGT @/GENETgt$ ) .	12 1 5 5 1 8 8 5 1 12 12 12 15 15 12 17 15 17 23 23 22 23 27 25 27 27 26|18 18 26|18 30 27|28 27 27|28 30 12	None-BC7
23237733	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Therefore , the aim of the present study was to investigate the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards important @GENETgt$ UGT @/GENETgt$ isoforms in the liver and intestine , including UGT1A1 , 1A3 , 1A6 , 1A7 , 1A8 , 1A9 and 1A10 .	9 9 4 9 8 8 8 4 9 11 9 13 11 15 13|14 13 13|14 21 21 17|21 21 17|21 13 24 24 21 24 24 24 29 24 29 29 29 29 29 29 29 29 29 29 29 29 9	None-BC7
23237733	CHEMICAL	GENE	T6	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] The recombinant @GENETgt$ UGT-catalyzed @/GENETgt$ @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation was used as probe reactions .	10 10 2|10 10 2|10 10|3 10 10|3 8 5 8 12 12 12 15 15 12 12	SUBSTRATE
23237733	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ chalcone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with @CHEMICALSrc$ chalcone @/CHEMICALSrc$ structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) .	13 1 5 5 1 9 9|6 9 9|6 5 1 13 13 13 16 16 13 18 16 18 24 24 23 24 28 26 28 28 19 30 28 28 28 30 13	INHIBITOR
23237733	CHEMICAL	GENE	T10	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and @GENETgt$ UGT1A10 @/GENETgt$ by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13 15 15 15 18|15 15 18|15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 43 48 27 50 48 54 54 54 50 56 54 56 56 61 61 50 61 61 61 61 61 68 61 68 68 68 68 68 61 50 10	INHIBITOR
23237733	CHEMICAL	GENE	T10	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 42 47 26 49 47 53 53 53 49 55 53 55 55 60 60 49 60 60 60 60 60 67 65|60 60 65|60 67 67 67 67 67 60 49 10	None-BC7
23361305	CHEMICAL	GENE	T1	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ mitochondrial ATP synthase @/GENETgt$ ? [SEP] It can be hypothesised that impaired mtΔΨ and @GENETgt$ mitochondrial @/GENETgt$ @CHEMICALSrc$ ATP synthase @/CHEMICALSrc$ activity may contribute to episodes of cardiac arrhythmia that occurred unexpectedly in BTHS patients .	4 4 4 4 16 7 16 7 8|14 14 8|14 9|11|14 9|11|14 11|14 9|11|14 7 16 4 18 16 21 21 18 23 21 23 27 27 23 4	None-BC7
9353417	CHEMICAL	GENE	T13	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 dopamine receptor @/GENETgt$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 15 15 10 10|5 10|5 10|5 10 10|5 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 26 26 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 51 51 55 55 59 59 55 65 65 65 65|59 65 65|59 59 69 69 69 59 76 76 73 76 73 73 59 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T20	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 45|39 39 45|39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 dopamine receptor @/GENETgt$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10|5 10|5 10|5 10 10|5 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 26 26 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 49|51 51 49|51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 26 26 36 36 33 46 40 40 46 43 43 40 46 46 36 52 52 52 48|52 52 48|52 46 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T13	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 45 39 39 45 42 42 39 45 45 35 51 51 51 48|51 51 48|51 45 51 51 51 55 55 59 59 55 65 65 65 65|61 65 65|61 59 69 69 69 59 76 76 73 76 73 73 59 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the @GENETgt$ D2 dopamine receptor @/GENETgt$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 26 26 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 51 51 55 55 59 59 55 62 62 59|60|62 59|60|62 59|60|62 59|62 59|60|62 69 69 69 59 76 76 73 76 73 73 59 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T12	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the @GENETgt$ D2 dopamine receptor @/GENETgt$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 45 39 39 45 42 42 39 45 45 35 50 50 50 50 45 50 50|51 50 50|51 50 55 55 59 59 55 62 62 59|60|62 59|60|62 59|60|62 59|62 59|60|62 69 69 69 59 76 76 73 76 73 73 59 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T9	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ pimozide @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( molindone and @CHEMICALSrc$ pimozide @/CHEMICALSrc$ ) and atypical ( remoxipride ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 17 5 5 17 7 5 7 8|7 7 8|7 7 5 5 15 13 15 18 18 20 18 25 24|20 24 24|20 25 20 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 46 40 40|37 40 40|37 46 43 43 40 46 46 35 51 51 51 51 46 51 51 51 51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T16	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 37|39 39 37|39 39 39 39 39 39 39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T12	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 45 39 39 45 42 42 39 45 45 35 51 51 51 48|51 51 48|51 45 51 51 51 51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	ANTAGONIST
9353417	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 33|37 37 33|37 39 39 39 39 39 39 39 39 39 39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T5	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 14 19 19 19 14 25 35 27 35 27 26|27 27 26|27 29 29 27 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T23	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ , in contrast , significantly up-regulated only the level of @GENETgt$ D2-long @/GENETgt$ mRNA in these areas .	0|8 8 0|8 8 5 8 8 8 8 11 11 8 15 11|15 15 11|15 11 18 18 11 8	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( molindone and pimozide ) and atypical ( @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 17 5 5 17 7 5 7 7 7 5 5 14 12|13 12 12|13 14 18 18 20 18 25 24|20 24 24|20 25 20 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T2	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and haloperidol ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 16|14 14 16|14 19 19 19 14 26 35 28 35 28 28 30 30 28 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T25	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and olanzapine failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 16|21 21 16|21 17 17 5 24 24 21 26 24 24 24 26 26 31 26 34 34 24 38 38 38 24 38 41 38 21	None-BC7
9353417	CHEMICAL	GENE	T11	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 16 16 11 11|5 11 11|5 11|6 11|6 11 11|6 4 16 16 15 16 2 20 20 20 16 23 23 20 27 27 27 16 27 32 32 32 27 27 27 37 37 34 47 41 41 47 44 44 41 47 47 37 52 52 52 52 47 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T1	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and olanzapine failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 20 17 17 5 23 23 20 25 23 25 25|26 25 25|26 30 25 33 33 23 37 37 37 23 37 40 37|38 37 37|38 20	None-BC7
9353417	CHEMICAL	GENE	T6	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ risperidone @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , olanzapine and @CHEMICALSrc$ risperidone @/CHEMICALSrc$ ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 14 19 19 19 14 25 35 27 35 27 27 29 28|29 29 28|29 27 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T7	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 14 19 19 19 14 25 34 27 34 27 27 29 29 27 34 14 34 35 35 39 34|36 34 34|36 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T13	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 54 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 45 39 39 45 42 42 39 45 45 35 50 50 50 50 45 50 50 50 54 54 58 58 54 63 63 60|63 63 60|63 58|61|63 58|61|63 58|63 58|61|63 69 69 69 58 76 76 73 76 73 73 58 78 76 81 81 78 54	None-BC7
9353417	CHEMICAL	GENE	T25	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and olanzapine failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 16|21 21 16|21 17 17 5 24 24 21 26 24 26 26 26 26 31 26 34 34 24 38 38 38 24 38 41 38 21	None-BC7
9353417	CHEMICAL	GENE	T18	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 41|39 39 41|39 39 39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T24	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 16|19|12 16|19|12 16|19 16|19|12 12 23 23 23 10 23 23 28 28 23 31 31 10 35 35 35 31 38 38 35 40 38 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 6	None-BC7
9353417	CHEMICAL	GENE	T1	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and olanzapine failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 20 17 17 5 23 23 20 25 24|23 23 24|23 25 25 30 25 33 33 23 37 37 37 23 37 40 37|38 37 37|38 20	None-BC7
9353417	CHEMICAL	GENE	T27	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] Differential regulation of @GENETgt$ D2 and D4 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs in the primate cerebral cortex vs. neostriatum : effects of chronic treatment with typical and atypical antipsychotic drugs .	2 2 4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 8|11|4 8|11|4 8|11 8|11|4 4 16 16 16 16 2 16 16 2 2 23 23 20 29 29 25 25 25 23 2	None-BC7
9353417	CHEMICAL	GENE	T21	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ risperidone @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and @CHEMICALSrc$ risperidone @/CHEMICALSrc$ ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 39 39 39|47 39 39|47 39 6	None-BC7
9353417	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , @CHEMICALSrc$ clozapine @/CHEMICALSrc$ , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 35|39 39 35|39 39 39 39 39 39 39 39 39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T22	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ , a @GENETgt$ D2 @/GENETgt$ antagonist that lacks antipsychotic activity , was also included .	0|15 15 0|15 1 7 3|7 7 3|7 1 9 7 11 9 1 15 15 15 15	ANTAGONIST
9353417	CHEMICAL	GENE	T8	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ molindone @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( @CHEMICALSrc$ molindone @/CHEMICALSrc$ and pimozide ) and atypical ( remoxipride ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 17 5 5 17 7 5|6 5 5|6 7 7 7 5 5 15 13 15 18 18 20 18 25 24|20 24 24|20 25 20 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T11	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 26 26 36 36 33 47 41 41|37 41 41|37 47 44 44 41 47 47 36 52 52 52 52 47 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 73 73 60 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T4	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( @CHEMICALSrc$ clozapine @/CHEMICALSrc$ , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 14 19 19 19 14 25 35 27 24|35 35 24|35 27 27 30 30 27 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T3	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 19 19 19 19 14 19 18|19 19 18|19 19 14 26 35 28 35 28 28 30 30 28 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T19	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ pimozide @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , @CHEMICALSrc$ pimozide @/CHEMICALSrc$ , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 43|39 39 43|39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T26	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 21 17 17|18 17 17|18 5 24 24 21 26 24 26 26 26 26 31 26 34 34 24 38 38 38 24 38 41 38 21	None-BC7
9353417	CHEMICAL	GENE	T13	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 25 25 35 35 32 46 40 40|37 40 40|37 46 43 43 40 46 46 35 51 51 51 51 46 51 51 51 55 55 59 59 55 65 65 65 65|61 65 65|61 59 69 69 69 59 76 76 73 76 73 73 59 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T17	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ molindone @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , @CHEMICALSrc$ molindone @/CHEMICALSrc$ , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 18|10|11|12 10|18|12 18|10|11|12 12 22 22 22 10 22 22 27 27 22 30 30 10 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 39 39 39 39 39 39 6	None-BC7
9353417	CHEMICAL	GENE	T26	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 8 15 15 15 5 15 21 17 17|18 17 17|18 5 24 24 21 26 24 24 24 26 26 31 26 34 34 24 38 38 38 24 38 41 38 21	None-BC7
14585280	CHEMICAL	GENE	T6	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including phenylbutyrate ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 20 7 7 7 3 7 10 7 12 10|11 10 10|11 12 7 17 3 19 17 20 22 20 25 25 22 27 30 27 27 25 33 33 25 33 33 39 35|39 39 35|39 35 20	None-BC7
14585280	CHEMICAL	GENE	T5	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 20 7 7 7 3 7 10 9|7 7 9|7 13 10 13 7 17 3 19 17 20 22 20 25 25 22 27 30 27 27 25 33 33 25 33 33 39 35|39 39 35|39 35 20	None-BC7
14585280	CHEMICAL	GENE	T7	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including phenylbutyrate ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of @CHEMICALSrc$ PB @/CHEMICALSrc$ and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 20 8 8|4 8|4 8 8|4 3 8 11 8 13 11 13 8 17 3 19 17 20 22 20 25 25 22 27 24|31 31 24|31 27 27 25 34 34 25 34 34 39 39 36 20	None-BC7
14585280	CHEMICAL	GENE	T8	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ and @GENETgt$ HDAC @/GENETgt$ ? [SEP] The sequential administration of a " first generation " demethylating agent and @GENETgt$ HDAC @/GENETgt$ inhibitors gave preliminary evidence of a reduced methylation of target genes , as also described with @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ .	3 3 16 11 11 11 8 11 11 11 3 11 12|15 15 12|15 11 16 18 16 22 22 22 18 25 25 22 16 29 29 16 31 29 29 29 16	None-BC7
14585280	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-azacytidine @/CHEMICALSrc$ and @GENETgt$ DNA methyltransferase @/GENETgt$ ? [SEP] For these reasons , the use of irreversible @GENETgt$ DNA methyltransferase @/GENETgt$ inhibitors , such as @CHEMICALSrc$ 5-azacytidine @/CHEMICALSrc$ and Decitabine , appears to be a promising option for the treatment of MDS and acute myeloid leukemia .	3 3 21 21 6 21 12 12 8|12 8|12 12 8|12 6 12 16 14 12|13 12 12|13 16 16 6 21 26 26 26 26 21 29 29 26 31 29 31 35 35 31 21	INHIBITOR
14585280	CHEMICAL	GENE	T7	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including phenylbutyrate ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of @CHEMICALSrc$ PB @/CHEMICALSrc$ and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 19 7 7 7 3 7 10 7 12 10 12 7 16 3 18 16 19 21 19 24 24 21 26 25|30 30 25|30 26 26 24 33 33 24 33 33 39 35|39 39 35|39 35 19	None-BC7
14585280	CHEMICAL	GENE	T6	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including phenylbutyrate ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 21 8 8|4 8|4 8 8|4 3 8 11 8 13 10|11 11 10|11 13 8 18 3 20 18 21 23 21 26 26 23 28 31 28 28 26 34 34 26 34 34 39 39 36 21	INHIBITOR
14585280	CHEMICAL	GENE	T5	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 21 8 8|4 8|4 8 8|4 3 8 11 8 8 8 14 11 14 8 18 3 20 18 21 23 21 26 26 23 28 31 28 28 26 34 34 26 34 34 39 39 36 21	INHIBITOR
14585280	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ and @GENETgt$ DNA methyltransferase @/GENETgt$ ? [SEP] For these reasons , the use of irreversible @GENETgt$ DNA methyltransferase @/GENETgt$ inhibitors , such as 5-azacytidine and @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ , appears to be a promising option for the treatment of MDS and acute myeloid leukemia .	3 3 21 21 6 21 12 12 8|12 8|12 12 8|12 6 12 16 14 12 16 16|15 16 16|15 6 21 26 26 26 26 21 29 29 26 31 29 31 35 35 31 21	INHIBITOR
23211364	CHEMICAL	GENE	T4	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] The observed effects of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ were ablated by neutralizing the effects of @GENETgt$ BDNF @/GENETgt$ .	3 3 8 5 3|4 3 3|4 8 8 10 8 12 10 14 12 12 12 8	None-BC7
23211364	CHEMICAL	GENE	T5	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ PD-123319 @/CHEMICALSrc$ and @GENETgt$ AT2 @/GENETgt$ ? [SEP] Treatment with the @GENETgt$ AT2 @/GENETgt$ antagonist @CHEMICALSrc$ PD-123319 @/CHEMICALSrc$ significantly reduced tube-like formation in endothelial cells .	10 7 7 3|7 7 3|7 7 1|5 1 1|5 10 10 12 10 15 15 12 10	ANTAGONIST
23211364	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In conclusion , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ exerts a proangiogenic effect on brain microvascular endothelial cells treated with @GENETgt$ angiotensin II @/GENETgt$ .	2 6 6 3|6 6 3|6 6 9 9 6 14 14 14 14 9 14 17 17|15 17|15 17|15 17|15 6	None-BC7
23211364	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II type 1 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ is an @GENETgt$ angiotensin II type 1 receptor @/GENETgt$ blocker ( ARB ) that has been to shown to limit ischemic stroke and improve stroke outcome .	0|11 11 0|11 11 11 11|3 11|3 11|3 11|3 11|3 11 11|3 11 13 11 13 19 19 19 19 11 21 19 23 21 21 21 27 25 11	INHIBITOR
23211364	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] Accordingly , spontaneously hypertensive rats were treated with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ , and brain tissue samples were collected for quantification of @GENETgt$ BDNF @/GENETgt$ expression .	7 7 4 5 7 7 7 9 8|7 7 8|7 7 7 15 15 17 17 7 19 17 23 19|23 23 19|23 19 17	None-BC7
23211364	CHEMICAL	GENE	T10	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) angiotensin II alone or in combination with candesartan ( 0.16 µM ) to assess the effect of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ treatment and @GENETgt$ BDNF @/GENETgt$ involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 23 12 23 15 15 12 15 12 12 21 21 18 21 9 23 23 23 28 23 30 28 33 33 30 33 36 9 38 36 42 42|39 42 42|39 38 42 42|46 46 42|46 42 49 49 38 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T2	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ significantly increased the expression of @GENETgt$ BDNF @/GENETgt$ in the SHR ( P < 0.05 ) .	0|4 4 0|4 4 4 6 4 8 6 6 6 12 12 6 15 15 12 15 15 4	INDIRECT-UPREGULATOR
23211364	CHEMICAL	GENE	T9	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) angiotensin II alone or in combination with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ ( 0.16 µM ) to assess the effect of candesartan treatment and @GENETgt$ BDNF @/GENETgt$ involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 23 12 23 15 15 12 15 12 12 21 21 18 21 9 23 23 23 28 23 30 28|29 28 28|29 34 34 30 34 37 9 39 37 42 42 39 42 42|46 46 42|46 42 49 49 39 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) @GENETgt$ angiotensin II @/GENETgt$ alone or in combination with candesartan ( 0.16 µM ) to assess the effect of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ treatment and BDNF involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 23 12 23 15 15 12 15 12 12 21 21 18 21 9|22|23 9|22|23 9|23 9|22|23 23 23 29 23 31 29 34 34 31 34 37 9 39 37 43 43|38 43 43|38 39 43 46 43 49 49 39 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T9	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) @GENETgt$ angiotensin II @/GENETgt$ alone or in combination with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ ( 0.16 µM ) to assess the effect of candesartan treatment and BDNF involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 23 12 23 15 15 12 15 12 12 21 21 18 21 9|22|23 9|22|23 9|23 9|22|23 23 23 29 23 31 28|29 29 28|29 35 35 31 35 38 9 40 38 43 43 40 43 46 43 49 49 40 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ vascular endothelial growth factor @/GENETgt$ ? [SEP] In experimental stroke , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ induces a proangiogenic effect that is partly attributable to @GENETgt$ vascular endothelial growth factor @/GENETgt$ .	3 3 7 7 4|7 7 4|7 7 10 10 7 14 14 14 10 16 16|14 16|14 16|14 16|14 16|14 16|14 7	None-BC7
23211364	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ AngII @/GENETgt$ ? [SEP] In addition , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ reversed the antiangiogenic effect of the 1-µM dose of @GENETgt$ AngII @/GENETgt$ ( P = 0.0001 ) .	2 6 6 3|6 6 3|6 6 9 9 6 13 13 13 9 15 13 13 13 19 19 13 19 19 6	None-BC7
23624810	CHEMICAL	GENE	T8	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic oxytocin and @GENETgt$ oxytocin receptor @/GENETgt$ antagonist , alone and in combination , in order to manipulate brain @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13 16 17|21 17|21 21 17|21 16 13 24 8 26 8 8 29 8 31 29 33 35|30 35 35|30 31 31 38 31 41 41 38 44 44 38 8	None-BC7
23624810	CHEMICAL	GENE	T8	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @GENETgt$ oxytocin @/GENETgt$ and oxytocin receptor antagonist , alone and in combination , in order to manipulate brain @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13|15 13 13|15 16 21 21 16 13 24 8 26 8 8 29 8 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 8	None-BC7
23624810	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic oxytocin and @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ receptor antagonist , alone and in combination , in order to manipulate brain @GENETgt$ oxytocin @/GENETgt$ functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13 16 17|21 21 17|21 21 16 13 24 8 26 8 8 29 8 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 8	None-BC7
23624810	CHEMICAL	GENE	T5	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and oxytocin receptor antagonist , alone and in combination , in order to manipulate brain @GENETgt$ oxytocin @/GENETgt$ functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13|15 13 13|15 16 21 21 16 13 24 8 26 8 8 29 8 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 8	None-BC7
23624810	CHEMICAL	GENE	T6	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @GENETgt$ oxytocin @/GENETgt$ and @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ receptor antagonist , alone and in combination , in order to manipulate brain oxytocin functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13|15 13 13|15 16 17|22 22 17|22 22 16 13 25 8 27 8 8 30 8 32 30 34 35 32 32 38 32 41 41 38 44 44 38 8	None-BC7
23624810	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ antagonist , alone and in combination , in order to manipulate brain oxytocin functioning and to assess their behavioral response to an intruder .	8 8 4 8 8 8 8 8 8 8 13 13 10 16 16 13|15 13 13|15 16 17|22 17|22 22 17|22 16 13 25 8 27 8 8 30 8 32 30 34 35 32 32 38 32 41 41 38 44 44 38 8	None-BC7
10626836	CHEMICAL	GENE	T9	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 21 21 18 24 24 21 30 30 30 30 30 24 21 18 36 36 36 32 38 36 38 42 42 38 45 45 42 47 45 47 47 47 47 51 51 53 47 47 58 56|57 56 56|57 64 64|59 64|59 64 64|59 56 18	None-BC7
10626836	CHEMICAL	GENE	T11	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|12 12 9|12 13 7 1 17 17 14 19 19 22 22 19 25 25 22 32 32 32|26 32|26 32 32|26 32 25 22 19 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T9	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|10|13 9|10|13 10|13 9|10|13 7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 56|57 57 56|57 64 64 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T3	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 22 19|22 22 19|22 18 25 25 22 31 31 31 31 31 25 22 18 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|59 64|59 64 64|59 57 18	None-BC7
10626836	CHEMICAL	GENE	T6	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 13 3 6 3 10 10|7 10 10|7 6 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @GENETgt$ AMPA receptors @/GENETgt$ , is ineffective on the non-desensitizing GluR3(L507Y ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	13 13 13 3 6 3 8 8|6|7 8|6|7 8|6 8|6|7 3 13 13 19 19 19 19 19 13 13 13 13 24 22 26 24|23 24 24|23 30 30 24 13	None-BC7
10626836	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	19 4 4 1 4 7 4 12 12 11 12 11|7 7 11|7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 57 57 64 64 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T3	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 22 19|22 22 19|22 18 25 25 22 32 32 32|26 32|26 32 32|26 32 25 22 18 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 18	ACTIVATOR
10626836	CHEMICAL	GENE	T11	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	19 4 4 1 4 7 4 13 13 9|12 12 9|12 13 7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|59 64|59 64 64|59 57 19	None-BC7
10626836	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	12 12 12 3 6 3 9 9 6 3 12 12 19 19 19 19|15 19 19|15 19 12 12 12 12 24 22 26 24 24 24 30 30 24 12	ACTIVATOR
10626836	CHEMICAL	GENE	T15	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Lithium @/CHEMICALSrc$ and @GENETgt$ gluR3 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Lithium @/CHEMICALSrc$ modulates desensitization of the glutamate receptor subtype @GENETgt$ gluR3 @/GENETgt$ in Xenopus oocytes .	0|3 3 0|3 3 3 10 10 10 10 10 8|4 4 8|4 14 14 4 3	None-BC7
10626836	CHEMICAL	GENE	T3	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|10|13 9|10|13 10|13 9|10|13 7 1 17 17 14 19 19 23 18|23 23 18|23 19 26 26 23 32 32 32 32 32 26 23 19 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 18 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 56|57 57 56|57 64 64 64 57 18	None-BC7
10626836	CHEMICAL	GENE	T11	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	20 4 4 1 4 7 4 13 13 9|12 12 9|12 13 11|7 7 11|7 1 18 18 15 20 20 23 23 20 26 26 23 32 32 32 32 32 26 23 20 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 20	None-BC7
10626836	CHEMICAL	GENE	T1	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the glutamate binding site blocks desensitization of @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors .	37 37 37 8 8 8 8 3 8 8 8 15 15 15 15 8 15 19 19 15 15 15 21 21 21 27 27 21 27 31 31 37 36 36 36 36 31 37 37 42 42|38 42 42|38 38 37	None-BC7
10626836	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 12 12 11 12 11|7 7 11|7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 38 33|38 38 33|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T14	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of AMPA receptors .	38 38 38 8 8 8 8 3 8 8 8 15 15 15 15 8 15 19 19 15 15 15 21 21 21 27 27 21 27 31 31 38 37 37 32|37 37 32|37 37 31 38 38 42 42 39 38	None-BC7
10626836	CHEMICAL	GENE	T16	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ gluR3 @/GENETgt$ ? [SEP] Lithium modulates desensitization of the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor subtype @GENETgt$ gluR3 @/GENETgt$ in Xenopus oocytes .	2 2 2 10 10 10|5 10 10|5 10 10 8|3 3 8|3 14 14 3 2	None-BC7
10626836	CHEMICAL	GENE	T14	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant GluR3(L507Y ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of @GENETgt$ AMPA receptors @/GENETgt$ .	37 37 37 8 8 8 8 3 8 14 14 14 14 8 14 18 18 14 14 14 20 20 20 26 26 20 26 30 30 37 36 36 32|36 36 32|36 36 30 37 37 40 40|38 40|38 40|38 40|38 37	None-BC7
10626836	CHEMICAL	GENE	T10	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	19 4 4 1 4 7 4 13 13 9|10|13 9|10|13 10|13 9|10|13 7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|58 64 64|58 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T3	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 12 12 11 12 11|7 7 11|7 1 17 17 14 19 19 23 19|23 23 19|23 19 26 26 23 32 32 32 32 32 26 23 19 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T14	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of AMPA receptors .	38 38 38 8 8 8 8 3 8 8 8 15 15 15 15 8 15 19 19 15 15 15 21 21 21 27 27 21 27 31 31 38 37 37 32|37 37 32|37 37 31 38 38 42 42 39 38	None-BC7
10626836	CHEMICAL	GENE	T4	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Lithium 's effects on @GENETgt$ GluR3 @/GENETgt$ desensitization are distinct from the effects of @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ on desensitization .	3 1 9 7 4|7 7 4|7 3 9 9 12 12 9 14 12 12 12 17 12 9	None-BC7
10626836	CHEMICAL	GENE	T8	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 21 21 18 24 24 21 30 30 30 30 30 24 21 18 37 33|37 37 33|37 37 32 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|59 64|59 64 64|59 57 18	None-BC7
10626836	CHEMICAL	GENE	T15	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Lithium @/CHEMICALSrc$ modulates desensitization of the @GENETgt$ glutamate receptor @/GENETgt$ subtype gluR3 in Xenopus oocytes .	0|3 3 0|3 3 3 11 11 11|5 11|5 11 11|5 11 4 14 14 4 3	None-BC7
10626836	CHEMICAL	GENE	T2	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Neuron , 21 ( 1998 ) 907 - 918 ) further confirms that @CHEMICALSrc$ lithium @/CHEMICALSrc$ enhances @GENETgt$ GluR3 @/GENETgt$ responses by reducing desensitization , since lithium 's effects are reversed in this mutant .	12 1 1 5 1 5 9 9 5 5 12 12 16 16|13 16 16|13 12 19|15 19 19|15 16 21 16 21 16 29 27 25 29 29 16 32 32 29 12	ACTIVATOR
10626836	CHEMICAL	GENE	T8	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|10|13 9|10|13 10|13 9|10|13 7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 38 32|38 38 32|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T10	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 18 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|58 64 64|58 64 57 18	None-BC7
10626836	CHEMICAL	GENE	T6	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 13 3 6 3 10 10|7 10 10|7 6 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 2|13 13 2|13 3 7 3 10 10 7 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T5	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type @GENETgt$ AMPA receptors @/GENETgt$ , is ineffective on the non-desensitizing GluR3(L507Y ) mutant , but has synergistic effects with lithium on wild-type receptors .	14 14 2|14 14 2|14 3 7 3 9 9|7 9|7 9|7 9|7 3 14 14 20 20 20 20 20 14 14 14 14 25 23 27 25 30 30 25 14	ACTIVATOR
10626836	CHEMICAL	GENE	T10	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	19 4 4 1 4 7 4 12 12 11 12 11|7 7 11|7 1 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 19 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 48 48 52 52 54 48 48 59 57 64 64|59 64 64|59 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 2|13 13 2|13 3 7 3 10 10 7 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	12 12 12 3 6 3 9 9 6 3 12 12 19 19 19 19|15 19 19|15 19 12 12 12 12 24 22 26 24 24 24 30 30 24 12	ACTIVATOR
10626836	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the glutamate binding site blocks desensitization of @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors .	37 37 37 8 8 8 8 3 8 8 8 15 15 15 15 8 15 19 19 15 15 15 21 21 21 27 27 21 27 31 31 37 36 36 36 36 31 37 37 42 42|38 42 42|38 38 37	None-BC7
10626836	CHEMICAL	GENE	T8	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	18 4 4 1 4 7 4 12 12 11 12 7 1 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 18 38 32|38 38 32|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 49 49 53 53 55 49 49 60 58 64 64 64 58 18	None-BC7
10626836	CHEMICAL	GENE	T13	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Science , 9(266 ) ( 1994 ) 1709 - 1713 ) greatly attenuates the @CHEMICALSrc$ lithium-induced @/CHEMICALSrc$ potentiation of @GENETgt$ GluR3 @/GENETgt$ .	3 3 13 13 6 13 6 10 10 6 13 13 13 17 17|14 17 17|14 13 19 17 17 17 13	ACTIVATOR
23536522	CHEMICAL	GENE	T9	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , catalase ( CAT ) and glutathione-S-transferase ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 34|31 34 34|31 30 36 34 36 23 49 41 39 41 39 39 46 44 44 44 46 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T9	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 34|31 34 34|31 30 36 34 36 23 49|37 49 49|37 42 39 42 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T11	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49 40 38|39 38 38|39 40 38 42|38 38 42|38 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T7	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione-S-transferase ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 34 31 36 34 36 23 49 41 39 41 39 39 46 44 44 44 46 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T15	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] MCT-induced pulmonary hypertension resulted in decreased @CHEMICALSrc$ GSH @/CHEMICALSrc$ level , decreased GST and SOD activities and increased @GENETgt$ CAT @/GENETgt$ activity in lung and liver tissues of both male and female rats .	3 3 4 4 9 9 9|6 9 9|6 4 4 4 11 12 12 12 11 20 16|20 20 16|20 4 22 20 22 22 22 28 28 31 28 28 22 4	None-BC7
23536522	CHEMICAL	GENE	T15	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] MCT-induced pulmonary hypertension resulted in decreased @CHEMICALSrc$ GSH @/CHEMICALSrc$ level , decreased @GENETgt$ GST @/GENETgt$ and SOD activities and increased CAT activity in lung and liver tissues of both male and female rats .	3 3 4 4 9 9 9|6 9 9|6 4 4 4 10|11 11 10|11 12 12 12 11 20 20 4 22 20 22 22 22 28 28 31 28 28 22 4	None-BC7
23536522	CHEMICAL	GENE	T1	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] In addition , the lung and liver @CHEMICALSrc$ GSH @/CHEMICALSrc$ level and @GENETgt$ GST @/GENETgt$ and SOD levels were higher in female control rats compared to male control rats .	2 18 18 5 18 5 5 10|7 10 10|7 5 10 10|5 5 10|5 5 5 5 18 18 22 22 22 18 18 27 27 27 23 18	None-BC7
23536522	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 34 31 36 34 34 34 36 23 49 42 40 42 40 40 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T8	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ superoxide dismutase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and @GENETgt$ superoxide dismutase @/GENETgt$ ( SOD ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 33|31 33|31 33|31 33|31 37 33 37 23 49 42 40 42 40 40 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T15	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] MCT-induced pulmonary hypertension resulted in decreased @CHEMICALSrc$ GSH @/CHEMICALSrc$ level , decreased GST and @GENETgt$ SOD @/GENETgt$ activities and increased CAT activity in lung and liver tissues of both male and female rats .	3 3 4 4 9 9 9|6 9 9|6 4 4 4 11 12 12 12 12 12 11 20 20 4 22 20 22 22 22 28 28 31 28 28 22 4	None-BC7
23536522	CHEMICAL	GENE	T9	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 34|31 34 34|31 30 36 34 36 23 49 41 39 39 39 41 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T11	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49 40 38 40 38 42|38 38 42|38 46 43|44 43 43|44 46 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 34 31 36 34 36 23 49 41 39 39 39 41 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T10	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ superoxide dismutase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @GENETgt$ superoxide dismutase @/GENETgt$ ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 32|30|31 32|30|31 32|30 32|30|31 36 32 36 23 49 41 39 41 39 41|39 39 41|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T8	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 34 31 36 34 36 23 49 41 39 39 39 41 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T11	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33|34 33 33|34 35 23 49 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T14	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ MCT @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] @CHEMICALSrc$ MCT-induced @/CHEMICALSrc$ pulmonary hypertension resulted in decreased GSH level , decreased GST and SOD activities and increased @GENETgt$ CAT @/GENETgt$ activity in lung and liver tissues of both male and female rats .	0|4 4 0|4 4 5 5 9 9 9 5 5 5 11 12 12 12 11 20 16|20 20 16|20 5 22 20 22 22 22 28 28 31 28 28 22 5	ACTIVATOR
23536522	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ glutathione-S-transferase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , catalase ( CAT ) and @GENETgt$ glutathione-S-transferase @/GENETgt$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 34|31 34 34|31 30 36 34 36 23 49 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T10	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49|37 49 49|37 41 38 41 38 42|38 38 42|38 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T7	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ glutathione-S-transferase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @GENETgt$ glutathione-S-transferase @/GENETgt$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 34 31 36 34 36 23 49 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T9	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 34|31 34 34|31 30 36 34 34 34 36 23 49 42 40 42 40 40 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T8	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione-S-transferase ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 34 31 36 34 36 23 49 41 39 41 39 39 46 44 44 44 46 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T10	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49 40 38|39 38 38|39 40 38 42|38 38 42|38 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T7	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ superoxide dismutase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and @GENETgt$ superoxide dismutase @/GENETgt$ ( SOD ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 33|31 33|31 33|31 33|31 37 33 37 23 49 42 40 42 40 40 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T14	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ MCT @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] @CHEMICALSrc$ MCT-induced @/CHEMICALSrc$ pulmonary hypertension resulted in decreased GSH level , decreased GST and @GENETgt$ SOD @/GENETgt$ activities and increased CAT activity in lung and liver tissues of both male and female rats .	0|4 4 0|4 4 5 5 9 9 9 5 5 5 11 12 12 12 12 12 11 20 20 5 22 20 22 22 22 28 28 31 28 28 22 5	INHIBITOR
23536522	CHEMICAL	GENE	T8	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 34 31 36 34 36 23 49|37 49 49|37 42 39 42 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T8	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 34 31 36 34 34 34 36 23 49 42 40 42 40 40 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] In addition , the lung and liver @CHEMICALSrc$ GSH @/CHEMICALSrc$ level and GST and @GENETgt$ SOD @/GENETgt$ levels were higher in female control rats compared to male control rats .	2 18 18 5 18 5 5 10|7 10 10|7 5 10 5 5 12|5 5 12|5 5 18 18 22 22 22 18 18 27 27 27 23 18	None-BC7
23536522	CHEMICAL	GENE	T11	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49|37 49 49|37 41 38 41 38 42|38 38 42|38 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T11	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ superoxide dismutase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @GENETgt$ superoxide dismutase @/GENETgt$ ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 32|30|31 32|30|31 32|30 32|30|31 36 32 36 23 49 41 39 41 39 41|39 39 41|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T10	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33 35 23 49 40 38 40 38 42|38 38 42|38 46 43|44 43 43|44 46 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T10	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 30 30 28 30 30 23 30 33 30 35 33|34 33 33|34 35 23 49 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T14	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ MCT @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] @CHEMICALSrc$ MCT-induced @/CHEMICALSrc$ pulmonary hypertension resulted in decreased GSH level , decreased @GENETgt$ GST @/GENETgt$ and SOD activities and increased CAT activity in lung and liver tissues of both male and female rats .	0|4 4 0|4 4 5 5 9 9 9 5 5 5 10|11 11 10|11 12 12 12 11 20 20 5 22 20 22 22 22 28 28 31 28 28 22 5	INHIBITOR
23536522	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 25|31 31 25|31 29 31 31 23 31 34 31 36 34 36 23 49|37 49 49|37 42 39 42 39 39 47 45 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23536522	CHEMICAL	GENE	T8	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione-S-transferase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @GENETgt$ glutathione-S-transferase @/GENETgt$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 19 15 19 17 15 17 21 21 21 23 21 23 31 31 28 27|31 31 27|31 31 23 31 34 31 36 34 36 23 49 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 51 53 56 53 53 59 57 51	None-BC7
23198810	CHEMICAL	GENE	T2	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ human NAD(P)H:quinone oxidoreductase isozyme 1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated @GENETgt$ human NAD(P)H : @/GENETgt$ @CHEMICALSrc$ quinone oxidoreductase isozyme 1 @/CHEMICALSrc$ ( hNQO1 ) .	7 5 5 5 1 7 7 7 11 11 7 15 15 15 11 15 18 15 21 21 18 23 28 25 28 25 25 21 36 36 36 31 34 31 36 28 40 40 40 40|44|28|39 40|44|28|39 40|44|28|39 40|44|28 40|44|28|39 40|44 40|44 40|44 40|44 40|44 40|44 50 44 50 7	None-BC7
23198810	CHEMICAL	GENE	T1	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ human NAD(P)H:quinone oxidoreductase isozyme 1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted @CHEMICALSrc$ quinone @/CHEMICALSrc$ substrate by the cancer-associated @GENETgt$ human NAD(P)H : quinone oxidoreductase isozyme 1 @/GENETgt$ ( hNQO1 ) .	7 5 5 5 1 7 7 7 11 11 7 15 15 15 11 15 18 15 21 21 18 23 28 25 28 25 25 21 37 37 37 31 34 31 34|37 37 34|37 28 41 41 41 41|28|39 41|28|39 41|28|39 41|28|39 41|28|39 41|28|39 41|28|39 41|28 41|28|39 50 41 50 7	SUBSTRATE
23198810	CHEMICAL	GENE	T5	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ hNQO1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the @CHEMICALSrc$ quinone @/CHEMICALSrc$ quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H : quinone oxidoreductase isozyme 1 ( @GENETgt$ hNQO1 @/GENETgt$ ) .	7 5 5 5 1 7 7 7 11 11 7 16 16 16|13 16 16|13 11 16 19 16 22 22 19 24 29 26 29 26 26 22 37 37 37 32 35 32 37 29 42 42 42 42 29 46 46 46 42 46 49 46|47 46 46|47 49 7	None-BC7
23198810	CHEMICAL	GENE	T2	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ hNQO1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H : @CHEMICALSrc$ quinone @/CHEMICALSrc$ oxidoreductase isozyme 1 ( @GENETgt$ hNQO1 @/GENETgt$ ) .	7 5 5 5 1 7 7 7 11 11 7 15 15 15 11 15 18 15 21 21 18 23 28 25 28 25 25 21 36 36 36 31 34 31 36 28 41 41 41 41 28 46 42|46 46 42|46 46 41 46 49 46|47 46 46|47 49 7	None-BC7
23198810	CHEMICAL	GENE	T5	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ human NAD(P)H:quinone oxidoreductase isozyme 1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the @CHEMICALSrc$ quinone @/CHEMICALSrc$ quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated @GENETgt$ human NAD(P)H : quinone oxidoreductase isozyme 1 @/GENETgt$ ( hNQO1 ) .	7 5 5 5 1 7 7 7 11 11 7 16 16 16|13 16 16|13 11 16 19 16 22 22 19 24 29 26 29 26 26 22 37 37 37 32 35 32 37 29 41 41 41 41|29|39 41|29|39 41|29|39 41|29|39 41|29|39 41|29|39 41|29|39 41|29 41|29|39 50 41 50 7	None-BC7
23198810	CHEMICAL	GENE	T1	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ quinone @/CHEMICALSrc$ and @GENETgt$ hNQO1 @/GENETgt$ ? [SEP] Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher , an event that immediately occurs only after highly selective , two-electron reduction of the sterically and conformationally restricted @CHEMICALSrc$ quinone @/CHEMICALSrc$ substrate by the cancer-associated human NAD(P)H : quinone oxidoreductase isozyme 1 ( @GENETgt$ hNQO1 @/GENETgt$ ) .	7 5 5 5 1 7 7 7 11 11 7 15 15 15 11 15 18 15 21 21 18 23 28 25 28 25 25 21 37 37 37 31 34 31 34|37 37 34|37 28 42 42 42 42 28 46 46 46 42 46 49 46|47 46 46|47 49 7	SUBSTRATE
11426832	CHEMICAL	GENE	T11	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ probencid @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and @CHEMICALSrc$ probencid @/CHEMICALSrc$ for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 10|5 5 10|5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T9	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 17 5 3 5 5|6 5 5|6 5 5 5 5 14 3|12 3 3|12 17 17 17 17 17 17 21 21 17 17 17 31 29 27 31 38 31 31 33 33 35 35 17 40 41 17 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T11	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ probencid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and @CHEMICALSrc$ probencid @/CHEMICALSrc$ for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 10|5 5 10|5 14 3 16 16 16 16 16 16 20 20 16 16 16 31 28 26 26 26 31 38 31 31 33 33 35 35 16 40 41 16 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T10	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 16 5 3 5 5 5 8|5 5 8|5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 40	None-BC7
11426832	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ 8-(noradamantan-3-yl)-1,3-dipropylxanthine @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , cilastatin , KW-3902 ( @CHEMICALSrc$ 8-(noradamantan-3-yl)-1,3-dipropylxanthine @/CHEMICALSrc$ ) and probenecid significantly inhibited human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6 6 6 12 10|11 10 10|11 12 6 6 18 18 18 19 19 19 19 25 25 19 29 29 29 18 18	None-BC7
11426832	CHEMICAL	GENE	T9	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5|6 5 5|6 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 31 28 26 26 26 31 38 31 31 33 33 35 35 16 40 41 16 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T1	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 45 45 41 41 45 39 47 45 47 48|47 47 48|47 53 53 47 55 45 45 61 56|61 61 56|61 61 45 63 64 61 39	None-BC7
11426832	CHEMICAL	GENE	T9	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5|6 5 5|6 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T11	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ probencid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and @CHEMICALSrc$ probencid @/CHEMICALSrc$ for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 10|5 5 10|5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T4	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4|5 4 4|5 6 6 6 6 13 11 13 6 6 18 18 18 19 19 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T8	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3|4 3 3|4 5 5 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 31 28 26 26 26 31 38 31 31 33 33 35 35 16 40 41 16 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T13	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ probenecid @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and @CHEMICALSrc$ probenecid @/CHEMICALSrc$ could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 5 13 3|12 3 3|12 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 47 47 42 42 42 42 47 40 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T5	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6|7 6 6|7 6 6 13 11 13 6 6 18 18 17|18 18 17|18 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T1	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 45 45 41 41 45 39 47 45 47 47 52 52 47 54 45 45 60 56|60 60 56|60 60 45 62 64|60 64 64|60 60 39	INHIBITOR
11426832	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5|6 5 5|6 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 5 13 3|12 3 3|12 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 61 56|61 61 56|61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T13	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ probenecid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and @CHEMICALSrc$ probenecid @/CHEMICALSrc$ could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 46 41 41|42 41 41|42 46 39 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 39	None-BC7
11426832	CHEMICAL	GENE	T9	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 16 5 3 5 5|6 5 5|6 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 40	None-BC7
11426832	CHEMICAL	GENE	T10	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 17 5 3 5 5 5 8|5 5 8|5 5 5 14 3|12 3 3|12 17 17 17 17 17 17 21 21 17 17 17 31 29 27 31 38 31 31 33 33 35 35 17 40 41 17 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T6	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6 6 9|6 6 9|6 13 10 13 6 6 18 18 17|18 18 17|18 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T11	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ probencid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and @CHEMICALSrc$ probencid @/CHEMICALSrc$ for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 16 5 3 5 5 5 5 5 10|5 5 10|5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 40	None-BC7
11426832	CHEMICAL	GENE	T13	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ probenecid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and @CHEMICALSrc$ probenecid @/CHEMICALSrc$ could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 30 27 25|26 25 25|26 30 37 30 30 32 32 34 34 15 39 40 15 47 47 42 42 42 42 47 40 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T6	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6 6 9|6 6 9|6 13 10 13 6 6 18 18 18 19 19 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T13	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ probenecid @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and @CHEMICALSrc$ probenecid @/CHEMICALSrc$ could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 46 41 41|42 41 41|42 46 39 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 39	None-BC7
11426832	CHEMICAL	GENE	T4	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4|5 4 4|5 6 6 6 6 13 11 13 6 6 18 18 17|18 18 17|18 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T10	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 8|5 5 8|5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 31 28 26 26 26 31 38 31 31 33 33 35 35 16 40 41 16 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T12	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 40|46 46 40|46 41 41 46 39 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 39	INHIBITOR
11426832	CHEMICAL	GENE	T13	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ probenecid @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and @CHEMICALSrc$ probenecid @/CHEMICALSrc$ could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 46 41 41|42 41 41|42 46 39 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 39	None-BC7
11426832	CHEMICAL	GENE	T12	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 5 5 5 13 3|12 3 3|12 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 47 40|47 47 40|47 42 42 47 40 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T7	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ 8-(noradamantan-3-yl)-1,3-dipropylxanthine @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , cilastatin , KW-3902 ( @CHEMICALSrc$ 8-(noradamantan-3-yl)-1,3-dipropylxanthine @/CHEMICALSrc$ ) and probenecid significantly inhibited @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6 6 6 12 10|11 10 10|11 12 6 6 18 18 17|18 18 17|18 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T8	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3|4 3 3|4 5 5 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T8	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 and probencid for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 17 5 3|4 3 3|4 5 5 5 5 5 5 14 3|12 3 3|12 17 17 17 17 17 17 21 21 17 17 17 31 29 27 31 38 31 31 33 33 35 35 17 40 41 17 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T12	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 40|46 46 40|46 41 41 46 39 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 39	INHIBITOR
11426832	CHEMICAL	GENE	T1	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 45 45 41 41 45 39 47 45|46 45 45|46 47 47 53 53 47 55 45 45 61 56|61 61 56|61 61 45 63 64 61 39	None-BC7
11426832	CHEMICAL	GENE	T10	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 8|5 5 8|5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T11	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ probencid @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and @CHEMICALSrc$ probencid @/CHEMICALSrc$ for @GENETgt$ human-OAT1 @/GENETgt$ were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 17 5 3 5 5 5 5 5 10|5 5 10|5 14 3|12 3 3|12 17 17 17 17 17 17 21 21 17 17 17 31 29 27 31 38 31 31 33 33 35 35 17 40 41 17 47 47 43 43 47 41 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 41	INHIBITOR
11426832	CHEMICAL	GENE	T12	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 30 27 25|26 25 25|26 30 37 30 30 32 32 34 34 15 39 40 15 47 40|47 47 40|47 42 42 47 40 49 47 49 49 54 54 49 56 47 47 61 61 61 47 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T5	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] Organic anion transport inhibitors including betamipron , @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ , KW-3902 ( 8-(noradamantan-3-yl)-1,3-dipropylxanthine ) and probenecid significantly inhibited human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion uptake in a dose-dependent manner .	4 4 4 18 6 4 6 6|7 6 6|7 6 6 13 11 13 6 6 18 18 18 19 19 19 19 25 25 19 29 29 29 18 18	INHIBITOR
11426832	CHEMICAL	GENE	T12	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 29 27 25 29 36 29 29 31 31 33 33 15 38 39 15 46 40|46 46 40|46 41 41 46 39 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 39	None-BC7
11426832	CHEMICAL	GENE	T8	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only @GENETgt$ human-OAT3-mediated @/GENETgt$ one .	3 3 16 5 3|4 3 3|4 5 5 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 60 60 60 46 62 64|60 64 64|60 60 40	None-BC7
11426832	CHEMICAL	GENE	T10	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , @CHEMICALSrc$ KW-3902 @/CHEMICALSrc$ and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and @GENETgt$ human-OAT3-mediated @/GENETgt$ organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3 5 5 5 8|5 5 8|5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 48 48 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T1	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ and @GENETgt$ human-OAT3 @/GENETgt$ ? [SEP] The Ki values of betamipron , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for @GENETgt$ human-OAT3 @/GENETgt$ were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo , whereas @CHEMICALSrc$ cilastatin @/CHEMICALSrc$ could inhibit only human-OAT3-mediated one .	3 3 15 5 3 5 5 5 5 5 5 13 3 15 15 15 15 15 15 19 19 15 15 15 30 27 25|26 25 25|26 30 37 30 30 32 32 34 34 15 39 40 15 46 46 42 42 46 40 48 46 48 48 53 53 48 55 46 46 61 56|61 61 56|61 61 46 63 64 61 40	None-BC7
11426832	CHEMICAL	GENE	T8	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ betamipron @/CHEMICALSrc$ and @GENETgt$ human-OAT1 @/GENETgt$ ? [SEP] The Ki values of @CHEMICALSrc$ betamipron @/CHEMICALSrc$ , cilastatin , KW-3902 and probencid for human-OAT1 were 23.6 , 1470 , 7.82 and 12.1 microM , whereas those for human-OAT3 were 48.3 , 231 , 3.70 and 9.0 microM. These results suggest that betamipron and probenecid could inhibit both @GENETgt$ human-OAT1- @/GENETgt$ and human-OAT3-mediated organic anion transport in vivo , whereas cilastatin could inhibit only human-OAT3-mediated one .	3 3 16 5 3|4 3 3|4 5 5 5 5 5 5 14 3 16 16 16 16 16 16 20 20 16 16 16 30 28 26 30 37 30 30 32 32 34 34 16 39 40 16 46 46 42 42 46 40 48 46 46 46 48 48 54 54 48 56 46 46 61 61 61 46 63 64 61 40	None-BC7
10047461	CHEMICAL	GENE	T7	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ p27(kip1) @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and kilobase DNA fragmentation may correlate with the reduction of @GENETgt$ p27(kip1 ) @/GENETgt$ expression and the increase in cyclin E and cdk2 kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 18 18 15 20 25|19 25 25|19 20 20 25 15 27 10 30 30 27 32 32|30 32|30 32|30 32|30 30 10 38 10 41 41 45 41 44 41 38 3	INDIRECT-DOWNREGULATOR
10047461	CHEMICAL	GENE	T11	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ p21 @/GENETgt$ ? [SEP] Twenty-four hours following the initial 2-h treatment with @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ , human A253 head and neck squamous carcinoma cells , not expressing p53 and @GENETgt$ p21(WAF1 @/GENETgt$ ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases .	2 30 7 7 7 7 2 9 8|7 7 8|7 9 14 14 9 14 9 19 19 9 9 22 7 22 23 23 23 23 7 2 30 30 34 33 34 30 38 38 38 34 42 42 42 38 46 46 46 34 48 46 50 46 50 50 50 30	None-BC7
10047461	CHEMICAL	GENE	T7	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of @GENETgt$ thymidylate synthase @/GENETgt$ by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in cyclin E and cdk2 kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 17 16|17|15 16|17|15 17|15 16|17|15 21 18|26 26 18|26 21 21 26 15 28 10 31 31 28 33 31 33 31 10 38 10 41 41 45 41 44 41 38 3	INHIBITOR
10047461	CHEMICAL	GENE	T16	T61	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ Cyclin E @/GENETgt$ ? [SEP] @GENETgt$ Cyclin E-cdk2 @/GENETgt$ activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ .	0|4 0|4 4 0|4 6 6 6 10 10 10 6 10 10 15 15 12 15 22 22 22 22 22 16|19 16 16|19 6	None-BC7
10047461	CHEMICAL	GENE	T2	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ indicate that increased @GENETgt$ cyclin E-cdk2 @/GENETgt$ protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance .	2 17 5 5 2 9 9 9 5 9 10 13 5 15 13|14 13 13|14 17 26 24 24|18 24|18 24 24|18 24 26 26 17 29 29 26 32 32 29 32 37 37 37 32 17	INDIRECT-UPREGULATOR
10047461	CHEMICAL	GENE	T10	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of @GENETgt$ thymidylate synthase @/GENETgt$ by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ .	3 3 3 3 6 3 8 3 11 11 8 11 15 15 12 21 21 21 18 18 15 23 21|22|23 21|22|23 21|23 21|22|23 27 24|21 21 24|21 3	INHIBITOR
10047461	CHEMICAL	GENE	T8	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ p53 @/GENETgt$ ? [SEP] The changes in cell cycle regulatory proteins associated with growth inhibition and DNA damage by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ are not @GENETgt$ p53 @/GENETgt$ dependent .	2 22 7 7 7 7 2 7 11 11 8 11 14 11 16 14|15 14 14|15 22 22 18|22 22 18|22 22 22	None-BC7
10047461	CHEMICAL	GENE	T13	T55	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ treatment resulted in the decrease in p27(kip1 ) expression , with an increase in @GENETgt$ cyclin E @/GENETgt$ and cdk2 protein expression and kinase activities 24 h after a 2-h exposure .	0|3 3 0|3 4 4 7 7 4 9 11 9 7 4 15 15 4 17 17|15 17|15 17|15 17|15 17 22 23 17 17 17 17 28 15 32 32 32 15 4	INDIRECT-UPREGULATOR
10047461	CHEMICAL	GENE	T2	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin @GENETgt$ E-cdk2 @/GENETgt$ protein overexpression and growth inhibition by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance .	2 18 5 5 2 10 10 10|7 10 10|7 5 10 11 14 5 16 14 14 14 18 26 24 24 24 24 26 26 18 29 29 26 32 32 29 32 37 37 37 32 18	INHIBITOR
10047461	CHEMICAL	GENE	T6	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in cyclin E and @GENETgt$ cdk2 @/GENETgt$ kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 19 16|19 19 16|19 15 21 25 21 21 25 15 27 10 30 30 27 32 30 32 30 10 37 10 40 40 45 40 40|44 44 40|44 40 37 3	None-BC7
10047461	CHEMICAL	GENE	T13	T57	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ kinase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ treatment resulted in the decrease in p27(kip1 ) expression , with an increase in cyclin E and cdk2 protein expression and @GENETgt$ kinase @/GENETgt$ activities 24 h after a 2-h exposure .	0|3 3 0|3 4 4 7 7 4 9 11 9 7 4 15 15 4 18 18 15 18 21 22 18 18 18|22 18 18|22 18 28 15 32 32 32 15 4	ACTIVATOR
10047461	CHEMICAL	GENE	T3	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] The studies with dThyd rescue from @GENETgt$ cyclin E-cdk2 @/GENETgt$ protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase and resultant dNTP pool imbalance .	2 17 5 5 2 10 10|6 10|6 10 10|6 5 10 11 14 5 16 14 17 25 23 23 23 23 25 25 17 28 28 25 32 32|27 32 32|27 28 32 37 37 37 32 17	None-BC7
10047461	CHEMICAL	GENE	T13	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ p27(kip1) @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ treatment resulted in the decrease in @GENETgt$ p27(kip1 ) @/GENETgt$ expression , with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure .	0|3 3 0|3 4 4 7 7 4 9 9|12|7 9|12|7 9|12 9|12|7 7 4 16 16 4 19 19 16 19 22 23 19 19 19 19 28 16 32 32 32 16 4	INDIRECT-DOWNREGULATOR
10047461	CHEMICAL	GENE	T2	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ indicate that increased cyclin @GENETgt$ E-cdk2 @/GENETgt$ protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance .	2 17 5 5 2 9 9 9 5 9 10 13 5 15 13|14 13 13|14 17 26 24 24 24|19 24 24|19 24 26 26 17 29 29 26 32 32 29 32 37 37 37 32 17	INDIRECT-UPREGULATOR
10047461	CHEMICAL	GENE	T3	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased @GENETgt$ cyclin E-cdk2 @/GENETgt$ protein expression is associated with effective inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase and resultant dNTP pool imbalance .	2 16 5 5 2 9 9 9 5 9 10 13 5 15 13 16 25 23 18|23 18|23 23 18|23 23 25 25 16 28 28 25 32 32|27 32 32|27 28 32 37 37 37 32 16	None-BC7
10047461	CHEMICAL	GENE	T15	T63	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] Cyclin @GENETgt$ E-cdk2 @/GENETgt$ activation is associated with cell cycle arrest and inhibition of DNA replication induced by the @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase inhibitor Tomudex .	4 1|4 4 1|4 6 6 6 10 10 10 6 10 10 15 15 12 15 23 23 17|23 23 17|23 23 23 16 6	None-BC7
10047461	CHEMICAL	GENE	T16	T62	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the @GENETgt$ thymidylate synthase @/GENETgt$ inhibitor @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ .	3 3 5 5 5 9 9 9 5 9 9 14 14 11 14 22 22 17|22 17|22 22 17|22 22 19|15 15 19|15 5	INHIBITOR
10047461	CHEMICAL	GENE	T6	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in @GENETgt$ cyclin E @/GENETgt$ and cdk2 kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 19 16|19 19 16|19 15 21 25 21 21 25 15 27 10 30 30 27 32 30 32 30 10 37 10 39 45|37|39 45|37|39 45|39 45|37|39 39 44 39 37 3	None-BC7
10047461	CHEMICAL	GENE	T7	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in cyclin E and @GENETgt$ cdk2 @/GENETgt$ kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 18 18 15 20 25|19 25 25|19 20 20 25 15 27 10 30 30 27 32 30 32 30 10 37 10 40 40 45 40 40|44 44 40|44 40 37 3	ACTIVATOR
10047461	CHEMICAL	GENE	T6	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ kinase @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in cyclin E and cdk2 @GENETgt$ kinase @/GENETgt$ activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 19 16|19 19 16|19 15 21 25 21 21 25 15 27 10 30 30 27 32 30 32 30 10 37 10 40 40 45 40 43 40|41 40 40|41 37 3	None-BC7
10047461	CHEMICAL	GENE	T16	T63	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] Cyclin @GENETgt$ E-cdk2 @/GENETgt$ activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ .	4 1|4 4 1|4 6 6 6 10 10 10 6 10 10 15 15 12 15 22 22 22 22 22 16|20 16 16|20 6	None-BC7
10047461	CHEMICAL	GENE	T11	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ WAF1 @/GENETgt$ ? [SEP] Twenty-four hours following the initial 2-h treatment with @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ , human A253 head and neck squamous carcinoma cells , not expressing p53 and @GENETgt$ p21(WAF1 @/GENETgt$ ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases .	2 30 7 7 7 7 2 9 8|7 7 8|7 9 14 14 9 14 9 19 19 9 9 22 7 22 23 23 23 23 7 2 30 30 34 33 34 30 38 38 38 34 42 42 42 38 46 46 46 34 48 46 50 46 50 50 50 30	None-BC7
10047461	CHEMICAL	GENE	T13	T56	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ treatment resulted in the decrease in p27(kip1 ) expression , with an increase in cyclin E and @GENETgt$ cdk2 @/GENETgt$ protein expression and kinase activities 24 h after a 2-h exposure .	0|3 3 0|3 4 4 7 7 4 9 11 9 7 4 15 15 4 18 18 15 18 18|22 22 18|22 23 18 18 18 18 28 15 32 32 32 15 4	INDIRECT-UPREGULATOR
10047461	CHEMICAL	GENE	T15	T61	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ Cyclin E @/GENETgt$ ? [SEP] @GENETgt$ Cyclin E-cdk2 @/GENETgt$ activation is associated with cell cycle arrest and inhibition of DNA replication induced by the @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase inhibitor Tomudex .	0|4 0|4 4 0|4 6 6 6 10 10 10 6 10 10 15 15 12 15 23 23 16|23 23 16|23 23 23 16 6	None-BC7
10047461	CHEMICAL	GENE	T1	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ ( ZD1694 ) is a specific antifolate-based @GENETgt$ thymidylate synthase @/GENETgt$ inhibitor active in a variety of solid tumor malignancies .	0|13 13 0|13 4 1 4 13 13 13 13 8|13 8|13 13 8|13 13 13 17 17 14 21 21 21 17 13	INHIBITOR
10047461	CHEMICAL	GENE	T7	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in @GENETgt$ cyclin E @/GENETgt$ and cdk2 kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 18 18 15 20 25|19 25 25|19 20 20 25 15 27 10 30 30 27 32 30 32 30 10 37 10 39 45|37|39 45|37|39 45|39 45|37|39 39 44 39 37 3	ACTIVATOR
10047461	CHEMICAL	GENE	T11	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ p53 @/GENETgt$ ? [SEP] Twenty-four hours following the initial 2-h treatment with @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ , human A253 head and neck squamous carcinoma cells , not expressing @GENETgt$ p53 @/GENETgt$ and p21(WAF1 ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases .	2 30 7 7 7 7 2 9 8|7 7 8|7 9 14 14 9 14 9 19 19 9 9 22 7 21|22 22 21|22 23 23 7 2 30 30 34 33 34 30 38 38 38 34 42 42 42 38 46 46 46 34 48 46 50 46 50 50 50 30	None-BC7
10047461	CHEMICAL	GENE	T3	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin @GENETgt$ E-cdk2 @/GENETgt$ protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase and resultant dNTP pool imbalance .	2 17 5 5 2 10 10 10|7 10 10|7 5 10 11 14 5 16 14 17 25 23 23 23 23 25 25 17 28 28 25 32 32|28 32 32|28 28 32 37 37 37 32 17	None-BC7
10047461	CHEMICAL	GENE	T14	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ ZD1694 @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] Tomudex ( @CHEMICALSrc$ ZD1694 @/CHEMICALSrc$ ) is a specific antifolate-based @GENETgt$ thymidylate synthase @/GENETgt$ inhibitor active in a variety of solid tumor malignancies .	13 3 1|2 1 1|2 3 13 13 13 13 8|13 8|13 13 8|13 13 13 17 17 14 21 21 21 17 13	None-BC7
10047461	CHEMICAL	GENE	T2	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ thymidylate synthase @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of @GENETgt$ thymidylate synthase @/GENETgt$ and resultant dNTP pool imbalance .	2 17 5 5 2 9 9 9 5 9 10 13 5 15 13|14 13 13|14 17 25 23 23 23 23 25 25 17 28 28 25 30 28|30 28|30 28|30 28|30 30 37 37 37 30 17	INHIBITOR
10047461	CHEMICAL	GENE	T6	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ p27(kip1) @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of @GENETgt$ p27(kip1 ) @/GENETgt$ expression and the increase in cyclin E and cdk2 kinase activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 19 16|19 19 16|19 15 21 25 21 21 25 15 27 10 30 30 27 32 32|30 32|30 32|30 32|30 30 10 38 10 41 41 45 41 44 41 38 3	None-BC7
10047461	CHEMICAL	GENE	T2	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ cyclin E @/GENETgt$ ? [SEP] The studies with dThyd rescue from @GENETgt$ cyclin E-cdk2 @/GENETgt$ protein overexpression and growth inhibition by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance .	2 18 5 5 2 10 10|6 10|6 10 10|6 5 10 11 14 5 16 13|14 14 13|14 18 26 24 24 24 24 26 26 18 29 29 26 32 32 29 32 37 37 37 32 18	INHIBITOR
10047461	CHEMICAL	GENE	T3	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ and @GENETgt$ cdk2 @/GENETgt$ ? [SEP] The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin @GENETgt$ E-cdk2 @/GENETgt$ protein expression is associated with effective inhibition of @CHEMICALSrc$ thymidylate @/CHEMICALSrc$ synthase and resultant dNTP pool imbalance .	2 16 5 5 2 9 9 9 5 9 10 13 5 15 13 16 25 23 23 19|23 23 19|23 23 25 25 16 28 28 25 32 32|28 32 32|28 28 32 37 37 37 32 16	None-BC7
10047461	CHEMICAL	GENE	T7	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and @GENETgt$ kinase @/GENETgt$ ? [SEP] These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by @CHEMICALSrc$ Tomudex @/CHEMICALSrc$ and kilobase DNA fragmentation may correlate with the reduction of p27(kip1 ) expression and the increase in cyclin E and cdk2 @GENETgt$ kinase @/GENETgt$ activities .	2 3 3 10 8 8 8 10 10 3 13 13 10 15 13 18 18 15 20 25|19 25 25|19 20 20 25 15 27 10 30 30 27 32 30 32 30 10 37 10 40 40 45 40 43 40|41 40 40|41 37 3	ACTIVATOR
9950599	CHEMICAL	GENE	T1	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ beta-hydroxyisobutyryl @/CHEMICALSrc$ and @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , glutamine cyclotransferase decreased 10-fold , whereas @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ , alternative splicing factor 2 , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme @/CHEMICALSrc$ A hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 8 8 7 8 8 8 8 8 8|11|12 8|11|12 8|11|12 8|12 8|11|12 12 19 19 12 19 12 12 26|19 26 26|19 26 27 8 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T9	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamine @/CHEMICALSrc$ and @GENETgt$ alternative splicing factor 2 @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , @CHEMICALSrc$ glutamine @/CHEMICALSrc$ cyclotransferase decreased 10-fold , whereas cytokine-inducible nuclear protein , @GENETgt$ alternative splicing factor 2 @/GENETgt$ , and beta-hydroxyisobutyryl-coenzyme A hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 9 9 8|5 8 8|5 9 9 9 9 9 15 15 9 15 17|15 17|15 17|15 17|15 17|15 17|15 15 15 26 26 27 9 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T1	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ beta-hydroxyisobutyryl @/CHEMICALSrc$ and @GENETgt$ glutamine cyclotransferase @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , @GENETgt$ glutamine cyclotransferase @/GENETgt$ decreased 10-fold , whereas cytokine-inducible nuclear protein , alternative splicing factor 2 , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme @/CHEMICALSrc$ A hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 9 9 9|5|6 9|5|6 9|6 9|5|6 9 9 9 9 15 15 9 15 19 19 15 19 15 15 26|20 26 26|20 26 27 9 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T9	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamine @/CHEMICALSrc$ and @GENETgt$ beta-hydroxyisobutyryl-coenzyme A hydrolase @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , @CHEMICALSrc$ glutamine @/CHEMICALSrc$ cyclotransferase decreased 10-fold , whereas cytokine-inducible nuclear protein , alternative splicing factor 2 , and @GENETgt$ beta-hydroxyisobutyryl-coenzyme A hydrolase @/GENETgt$ increased 2- , 4- , and 10-fold , respectively .	4 4 4 9 9 8|5 8 8|5 9 9 9 9 9 15 15 9 15 19 19 15 19 15 15 27|21|23 27|21|23 27|21|23 27|23 27|21|23 9 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T7	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ nicotinamide adenine dinucleotide @/CHEMICALSrc$ and @GENETgt$ cytochrome b @/GENETgt$ ? [SEP] In stressed cells , mitochondrial transcripts @CHEMICALSrc$ nicotinamide adenine dinucleotide @/CHEMICALSrc$ ( NADH ) dehydrogenase subunit 4 and @GENETgt$ cytochrome b @/GENETgt$ were downregulated 4-fold .	3 3 15 3 6 15 7|6|15 7|6|15 7|6|15 7|15 7|6|15 15 15 15 15 22 15 15 18|14|15 18|14|15 18|15 18|14|15 22 22 22 22	None-BC7
9950599	CHEMICAL	GENE	T2	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ coenzyme A @/CHEMICALSrc$ and @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , glutamine cyclotransferase decreased 10-fold , whereas @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ , alternative splicing factor 2 , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme A @/CHEMICALSrc$ hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 8 8 7 8 8 8 8 8 8|11|12 8|11|12 8|11|12 8|12 8|11|12 12 19 19 12 19 12 12 26|19 26|19 26 26|19 27 8 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T8	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 4 @/GENETgt$ ? [SEP] In stressed cells , mitochondrial transcripts @GENETgt$ nicotinamide adenine dinucleotide ( @/GENETgt$ @CHEMICALSrc$ NADH ) dehydrogenase subunit 4 @/CHEMICALSrc$ and cytochrome b were downregulated 4-fold .	3 3 12 3 6 12 12|6|7 12|6|7 12|6|7 12|6|7 12|7 12|6|7 12|22|7 12|22|7 12|22|7 12|22|7 12|22|7 12|22 12|22|7 12 20 12 22 22 22 22	None-BC7
9950599	CHEMICAL	GENE	T2	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ coenzyme A @/CHEMICALSrc$ and @GENETgt$ alternative splicing factor 2 @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , glutamine cyclotransferase decreased 10-fold , whereas cytokine-inducible nuclear protein , @GENETgt$ alternative splicing factor 2 @/GENETgt$ , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme A @/CHEMICALSrc$ hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 8 8 7 8 8 8 8 8 14 14 8 14 16|14|15 16|14|15 16|14|15 16|14|15 16|14 16|14|15 14 14 18|26 18|26 26 18|26 27 8 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T3	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ cytochrome b @/GENETgt$ ? [SEP] Analysis of mitochondrial transcripts in a 24-hour time course showed that @CHEMICALSrc$ NADH @/CHEMICALSrc$ dehydrogenase subunit 4 mRNA decreased by 2-fold as early as 1 hour after oxidative stress , whereas the rate of decrease was slower for @GENETgt$ cytochrome b @/GENETgt$ , cytochrome oxidase III , and 16S rRNA .	10 4 4 1 9 9 9 9 1 10 18 17|11 17 17|11 17 17 17 18 10 20 18 22 18 25 25 18 28 28 18 18 18 32 36 34 32 36 18 38 36|38 36|38 36|38 36|38 38 43 38 43 38 38 48 38 10	None-BC7
9950599	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ beta-hydroxyisobutyryl @/CHEMICALSrc$ and @GENETgt$ alternative splicing factor 2 @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , glutamine cyclotransferase decreased 10-fold , whereas cytokine-inducible nuclear protein , @GENETgt$ alternative splicing factor 2 @/GENETgt$ , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme @/CHEMICALSrc$ A hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 8 8 7 8 8 8 8 8 14 14 8 14 16|14|15 16|14|15 16|14|15 16|14|15 16|14 16|14|15 14 14 18|26 26 18|26 26 27 8 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ cytochrome oxidase III @/GENETgt$ ? [SEP] Analysis of mitochondrial transcripts in a 24-hour time course showed that @CHEMICALSrc$ NADH @/CHEMICALSrc$ dehydrogenase subunit 4 mRNA decreased by 2-fold as early as 1 hour after oxidative stress , whereas the rate of decrease was slower for cytochrome b , @GENETgt$ cytochrome oxidase III @/GENETgt$ , and 16S rRNA .	10 4 4 1 9 9 9 9 1 10 18 17|11 17 17|11 17 17 17 18 10 20 18 22 18 25 25 18 28 28 18 18 18 32 36 34 32 36 18 39 39 36 39 41|39 41|39 41|39 41|39 41|39 39 39 48 39 10	None-BC7
9950599	CHEMICAL	GENE	T9	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamine @/CHEMICALSrc$ and @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , @CHEMICALSrc$ glutamine @/CHEMICALSrc$ cyclotransferase decreased 10-fold , whereas @GENETgt$ cytokine-inducible nuclear protein @/GENETgt$ , alternative splicing factor 2 , and beta-hydroxyisobutyryl-coenzyme A hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 9 9 8|5 8 8|5 9 9 9 9 9 9|11|13 9|11|13 9|11|13 9|13 9|11|13 13 20 20 13 20 13 13 26 26 27 9 27 28 28 28 28 28 27 27 27	None-BC7
9950599	CHEMICAL	GENE	T8	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ cytochrome b @/GENETgt$ ? [SEP] In stressed cells , mitochondrial transcripts nicotinamide adenine dinucleotide ( @CHEMICALSrc$ NADH @/CHEMICALSrc$ ) dehydrogenase subunit 4 and @GENETgt$ cytochrome b @/GENETgt$ were downregulated 4-fold .	3 3 15 3 6 15 15 9 15 15 10|15 15 10|15 15 15 22 15 15 16|18|15 16|18|15 18|15 16|18|15 22 22 22 22	None-BC7
9950599	CHEMICAL	GENE	T2	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ coenzyme A @/CHEMICALSrc$ and @GENETgt$ glutamine cyclotransferase @/GENETgt$ ? [SEP] Of the cytoplasmic mRNAs , @GENETgt$ glutamine cyclotransferase @/GENETgt$ decreased 10-fold , whereas cytokine-inducible nuclear protein , alternative splicing factor 2 , and @CHEMICALSrc$ beta-hydroxyisobutyryl-coenzyme A @/CHEMICALSrc$ hydrolase increased 2- , 4- , and 10-fold , respectively .	4 4 4 9 9 9|5|6 9|5|6 9|6 9|5|6 9 9 9 9 15 15 9 15 19 19 15 19 15 15 26|20 26|20 26 26|20 27 9 27 28 28 28 28 28 27 27 27	None-BC7
18480678	CHEMICAL	GENE	T12	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ l-MPH @/CHEMICALSrc$ and @GENETgt$ MPH receptor @/GENETgt$ ? [SEP] The importance of MPH chirality to central nervous system @GENETgt$ MPH receptor @/GENETgt$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures , whereas @CHEMICALSrc$ l-MPH @/CHEMICALSrc$ binding is nonspecific .	2 15 5 5 2 13 8 13 13 9|10|13 9|10|13 10|13 9|10|13 2 15 15 19 19 19 15 19 23 23 20 23 27 27 23 23 23 32|27 32 32|27 34 34 15 34	None-BC7
18480678	CHEMICAL	GENE	T26	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ l-MPH @/CHEMICALSrc$ and @GENETgt$ dopamine transporter @/GENETgt$ ? [SEP] In both rodent and primate animal models , the binding of radiolabeled d-MPH to @GENETgt$ dopamine transporter @/GENETgt$ was found to be selective , saturable , and reversible , whereas binding of @CHEMICALSrc$ l-MPH @/CHEMICALSrc$ was diffuse and nonspecific .	3 3 19 3 3 7 3 19 10 19 13 13 10 15 10|14|15 10|14|15 10|15 10|14|15 19 19 22 22 19 22 22 22 22 22 22 22 35 32 29|30 30 29|30 35 22 35 35 19	DIRECT-REGULATOR
18480678	CHEMICAL	GENE	T14	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ norepinephrine transporter @/GENETgt$ ? [SEP] threo-methylphenidate inhibits the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ transporter and the @GENETgt$ norepinephrine transporter @/GENETgt$ , resulting in elevations of these monoamines after impulse release .	2 2 6 3|6 6 3|6 2 6 9 9|6|7 9|6|7 9|6 9|6|7 2 2 15 13 18 18 15 21 21 13 2	None-BC7
18480678	CHEMICAL	GENE	T8	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ threo-methylphenidate @/CHEMICALSrc$ and @GENETgt$ dopamine transporter @/GENETgt$ ? [SEP] @CHEMICALSrc$ threo-methylphenidate @/CHEMICALSrc$ inhibits the @GENETgt$ dopamine transporter @/GENETgt$ and the norepinephrine transporter , resulting in elevations of these monoamines after impulse release .	0|3 3 0|3 3 5 3|5 3|5 3|5 3|5 5 11 11 5 3 3 15 13 18 18 15 21 21 13 3	INHIBITOR
18480678	CHEMICAL	GENE	T24	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ d-MPH @/CHEMICALSrc$ and @GENETgt$ dopamine transporter @/GENETgt$ ? [SEP] In both rodent and primate animal models , the binding of radiolabeled @CHEMICALSrc$ d-MPH @/CHEMICALSrc$ to @GENETgt$ dopamine transporter @/GENETgt$ was found to be selective , saturable , and reversible , whereas binding of l-MPH was diffuse and nonspecific .	3 3 20 3 3 7 3 20 10 20 13 13 10|12 10 10|12 16 16|10|14 16|10|14 16|10 16|10|14 20 20 23 23 20 23 23 23 23 23 23 23 35 33 31 35 23 35 35 20	DIRECT-REGULATOR
18480678	CHEMICAL	GENE	T9	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ MPH @/CHEMICALSrc$ and @GENETgt$ MPH receptor @/GENETgt$ ? [SEP] The importance of @CHEMICALSrc$ MPH @/CHEMICALSrc$ chirality to central nervous system @GENETgt$ MPH receptor @/GENETgt$ targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures , whereas l-MPH binding is nonspecific .	2 16 6 3|6 6 3|6 2 14 9 14 14 9|11|14 9|11|14 11|14 9|11|14 2 16 16 20 20 20 16 20 24 24 21 24 28 28 24 24 24 32 34 34 16 34	None-BC7
18480678	CHEMICAL	GENE	T16	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ and @GENETgt$ dopamine transporter @/GENETgt$ ? [SEP] threo-methylphenidate inhibits the @GENETgt$ dopamine transporter @/GENETgt$ and the @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ transporter , resulting in elevations of these monoamines after impulse release .	2 2 4 2|3|4 2|3|4 2|4 2|3|4 4 11 11|6 11 11|6 4 2 2 15 13 18 18 15 21 21 13 2	None-BC7
18480678	CHEMICAL	GENE	T17	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ monoamines @/CHEMICALSrc$ and @GENETgt$ dopamine transporter @/GENETgt$ ? [SEP] threo-methylphenidate inhibits the @GENETgt$ dopamine transporter @/GENETgt$ and the norepinephrine transporter , resulting in elevations of these @CHEMICALSrc$ monoamines @/CHEMICALSrc$ after impulse release .	2 2 4 2|3|4 2|3|4 2|4 2|3|4 4 10 10 4 2 2 14 12 17 17 14 14 14 21 21 12 2	SUBSTRATE
18480678	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ d-MPH @/CHEMICALSrc$ and @GENETgt$ MPH receptor @/GENETgt$ ? [SEP] The importance of MPH chirality to central nervous system @GENETgt$ MPH receptor @/GENETgt$ targeting has culminated in human imaging studies revealing that @CHEMICALSrc$ d-MPH @/CHEMICALSrc$ binds specifically to striatal structures , whereas l-MPH binding is nonspecific .	2 15 5 5 2 13 8 13 13 9|10|13 9|10|13 10|13 9|10|13 2 15 15 19 19 19 15 19 24 24|19 24 24|19 20 24 28 28 24 24 24 32 34 34 15 34	None-BC7
18480678	CHEMICAL	GENE	T8	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ threo-methylphenidate @/CHEMICALSrc$ and @GENETgt$ norepinephrine transporter @/GENETgt$ ? [SEP] @CHEMICALSrc$ threo-methylphenidate @/CHEMICALSrc$ inhibits the dopamine transporter and the @GENETgt$ norepinephrine transporter @/GENETgt$ , resulting in elevations of these monoamines after impulse release .	0|3 3 0|3 3 6 6 3 6 9 9|6|7 9|6|7 9|6 9|6|7 3 3 15 13 18 18 15 21 21 13 3	INHIBITOR
18480678	CHEMICAL	GENE	T17	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ monoamines @/CHEMICALSrc$ and @GENETgt$ norepinephrine transporter @/GENETgt$ ? [SEP] threo-methylphenidate inhibits the dopamine transporter and the @GENETgt$ norepinephrine transporter @/GENETgt$ , resulting in elevations of these @CHEMICALSrc$ monoamines @/CHEMICALSrc$ after impulse release .	2 2 5 5 2 5 8 8|5|7 8|5|7 8|5 8|5|7 2 2 14 12 17 17 14 14 14 21 21 12 2	SUBSTRATE
8697470	CHEMICAL	GENE	T4	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ FVIIa @/GENETgt$ ? [SEP] Infusion of FVIIa failed to restore CFVs in ridogrel e @CHEMICALSrc$ ATA @/CHEMICALSrc$ treated rabbits ( 1 of 7 and 0 of 8 rabbits , respectively ) , showing that activation of extrinsic coagulation by @GENETgt$ FVIIa @/GENETgt$ was overcome by inhibition of platelet function .	4 3 1 4 6 4 6 9 14 14 10|14 14 10|14 14 6 23 23 18 16 18 22 22 18 14 23 23 23 4 4 38 38 33 33 30 35 33|30 30 33|30 38 28 40 38 43 43 40 4	None-BC7
8697470	CHEMICAL	GENE	T1	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ thromboxane A2 receptor @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and @GENETgt$ thromboxane A2 receptor @/GENETgt$ antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 80|85 80|85 80|85 85 80|85 79 88 88 85 88 91 88 91 71 98 98 97 98 71 98|99|95 98|99|95 98|99 98|99|95 103 99 103 99 107 99 114 114 114 114 114 114 107 117 117 114 117 120 117 120 71	None-BC7
8697470	CHEMICAL	GENE	T5	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ thrombin @/GENETgt$ ? [SEP] Activated partial thromboplastin time , and ex vivo platelet aggregation in response to @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ thrombin @/GENETgt$ , were not different after FVIIai infusion , while prothrombin time was slightly but significantly prolonged as compared to baseline values .	4 4 4 4 4 4 10 7 10 22 12 10 14 12|13 12 12|13 14 14|15 14 14|15 10 22 22 4 25 25 22 22 34 29 34 34 34 31 34 22 36 34 39 39 36 22	None-BC7
8697470	CHEMICAL	GENE	T1	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ von Willebrand factor @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet glycoprotein @GENETgt$ Ib/von Willebrand factor @/GENETgt$ interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 84 84 84 79 87 87 84 87 90 87 90 71 97 97 96 97 71 97|98 97|98 97|98 97|98 102 98 102 98 106 98 114 114 114 114|107 114|107 114|107 114 114|107 106 117 117 114 117 120 117 120 71	INHIBITOR
8697470	CHEMICAL	GENE	T2	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ glycoprotein Ib @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet @GENETgt$ glycoprotein Ib/von @/GENETgt$ Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 84 84 84 79 87 87 84 87 90 87 90 71 97 97 96 97 71 99 97 101 99|100 99 99|100 101 99 106 99 114 114 114|107 114|107 114 114|107 114 114 106 117 117 114 117 120 117 120 71	INHIBITOR
8697470	CHEMICAL	GENE	T1	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ thromboxane A2 synthetase @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual @GENETgt$ thromboxane A2 synthetase @/GENETgt$ inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 80 80 80|75 80|75 80|75 80 80|75 72 80 85 85 85 80 88 88 85 88 91 88 91 71 98 98 97 98 71 98|99|95 98|99|95 98|99 98|99|95 103 99 103 99 107 99 114 114 114 114 114 114 107 117 117 114 117 120 117 120 71	None-BC7
8697470	CHEMICAL	GENE	T2	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ human recombinant FVIIai @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of @GENETgt$ human recombinant FVIIai @/GENETgt$ ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 39 37|38|39 37|38|39 37|38|39 37|39 37|38|39 45 45 39 48 48 45 45 20 52 53 20 53 54 58 58 54 61 61 58 64 64 61 64 67 64 67 13 71 72 13 72 73 80 80 80 80 80 73 80 85 85 85 80 88 88 85 88 91 88 91 72 98 98 97 98 72 100 98 102 98|100 100 98|100 102 100 107 100 114 114 114 114 114 114 107 117 117 114 117 120 117 120 72	None-BC7
8697470	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ rabbit TF @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against @GENETgt$ rabbit TF @/GENETgt$ ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 59 57|58|59 57|58|59 57|59 57|58|59 64 64 59 64 67 64 67 13 71 72 13 72 73 80 80 80 80 80 73 80 85 85 85 80 88 88 85 88 91 88 91 72 98 98 97 98 72 96|98|99 96|98|99 98|99 96|98|99 103 99 103 99 107 99 114 114 114 114 114 114 107 117 117 114 117 120 117 120 72	None-BC7
8697470	CHEMICAL	GENE	T5	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ FVIIai @/GENETgt$ ? [SEP] Activated partial thromboplastin time , and ex vivo platelet aggregation in response to @CHEMICALSrc$ ADP @/CHEMICALSrc$ and thrombin , were not different after @GENETgt$ FVIIai @/GENETgt$ infusion , while prothrombin time was slightly but significantly prolonged as compared to baseline values .	4 4 4 4 4 4 10 7 10 21 12 10 14 12|13 12 12|13 14 14 10 21 21 4 25 25|21 25 25|21 21 21 34 29 34 34 34 31 34 21 36 34 39 39 36 21	None-BC7
8697470	CHEMICAL	GENE	T2	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ von Willebrand factor @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet glycoprotein @GENETgt$ Ib/von Willebrand factor @/GENETgt$ interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 84 84 84 79 87 87 84 87 90 87 90 71 97 97 96 97 71 99 97 101 99|100 99 99|100 101 99 106 99 114 114 114 114|108 114|108 114|108 114 114|108 106 117 117 114 117 120 117 120 71	INHIBITOR
8697470	CHEMICAL	GENE	T4	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ FVIIa @/GENETgt$ ? [SEP] Infusion of @GENETgt$ FVIIa @/GENETgt$ failed to restore CFVs in ridogrel e @CHEMICALSrc$ ATA @/CHEMICALSrc$ treated rabbits ( 1 of 7 and 0 of 8 rabbits , respectively ) , showing that activation of extrinsic coagulation by FVIIa was overcome by inhibition of platelet function .	5 3 1|2 1 1|2 5 7 5 7 10 15 15 10|15 15 10|15 15 7 24 24 19 17 19 23 23 19 15 24 24 24 5 5 38 38 34 34 31 36 31 38 29 40 38 43 43 40 5	None-BC7
8697470	CHEMICAL	GENE	T2	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ thromboxane A2 receptor @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and @GENETgt$ thromboxane A2 receptor @/GENETgt$ antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 80|85 80|85 80|85 85 80|85 79 88 88 85 88 91 88 91 71 98 98 97 98 71 100 98 102 98|100 100 98|100 102 100 107 100 114 114 114 114 114 114 107 117 117 114 117 120 117 120 71	None-BC7
8697470	CHEMICAL	GENE	T1	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ glycoprotein Ib @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet @GENETgt$ glycoprotein Ib/von @/GENETgt$ Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 79 79 79 79 79 72 79 84 84 84 79 87 87 84 87 90 87 90 71 97 97 96 97 71 97|98 97|98 97|98 97|98 102 98 102 98 106 98 114 114 106|114 106|114 114 106|114 114 114 106 117 117 114 117 120 117 120 71	INHIBITOR
8697470	CHEMICAL	GENE	T2	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ thromboxane A2 synthetase @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual @GENETgt$ thromboxane A2 synthetase @/GENETgt$ inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 60 60 57 63 63 60 63 66 63 66 13 70 71 13 71 72 80 80 80|75 80|75 80|75 80 80|75 72 80 85 85 85 80 88 88 85 88 91 88 91 71 98 98 97 98 71 100 98 102 98|100 100 98|100 102 100 107 100 114 114 114 114 114 114 107 117 117 114 117 120 117 120 71	None-BC7
8697470	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ ATA @/CHEMICALSrc$ and @GENETgt$ rabbit TF @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of human recombinant FVIIai ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against @GENETgt$ rabbit TF @/GENETgt$ ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received aurintrycarboxilic acid ( @CHEMICALSrc$ ATA @/CHEMICALSrc$ ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 41 41 41 37 44 44 41 47 47 44 44 20 51 52 20 52 53 57 57 53 59 57|58|59 57|58|59 57|59 57|58|59 64 64 59 64 67 64 67 13 71 72 13 72 73 80 80 80 80 80 73 80 85 85 85 80 88 88 85 88 91 88 91 72 98 98 97 98 72 100 98 102 99|100 100 99|100 102 100 107 100 114 114 114 114 114 114 107 117 117 114 117 120 117 120 72	None-BC7
8697470	CHEMICAL	GENE	T1	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ and @GENETgt$ human recombinant FVIIai @/GENETgt$ ? [SEP] After CFVs were observed for 30 min , the animals were randomly divided in four groups : 5 animals received via a small catheter ( 26 G ) placed proximally to the stenosis , an intra-arterial infusion of @GENETgt$ human recombinant FVIIai @/GENETgt$ ( 0.1 mg/kg/min for 10 min ) ; 9 animals received AP-1 , a monoclonal antibody against rabbit TF ( 0.1 mg/kg i.v . bolus ) ; 7 animals received ridogrel , a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist ( 10 mg/kg i.v . bolus ) ; finally , 8 rabbits received @CHEMICALSrc$ aurintrycarboxilic acid @/CHEMICALSrc$ ( ATA ) , an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction ( 10 mg/kg i.v . bolus ) .	4 4 4 13 7 7 4 13 10 13 13 13 13 16 16 13 13 19 20 13 24 24 24 20 27 27 24 27 24 29 33 33 29 33 37 37 33 39 37|38|39 37|38|39 37|38|39 37|39 37|38|39 45 45 39 48 48 45 45 20 52 53 20 53 54 58 58 54 61 61 58 64 64 61 64 67 64 67 13 71 72 13 72 73 80 80 80 80 80 73 80 85 85 85 80 88 88 85 88 91 88 91 72 98 98 97 98 72 98|99|95 98|99|95 98|99 98|99|95 103 99 103 99 107 99 114 114 114 114 114 114 107 117 117 114 117 120 117 120 72	None-BC7
23323829	CHEMICAL	GENE	T8	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ anthracene @/CHEMICALSrc$ and @GENETgt$ erythropoietin @/GENETgt$ ? [SEP] Design and application of @CHEMICALSrc$ anthracene @/CHEMICALSrc$ derivative with aggregation-induced emission charateristics for visualization and monitoring of @GENETgt$ erythropoietin @/GENETgt$ unfolding .	1 1 1 7 4|7 7 4|7 1 11 11 11 7 13 11 13 13 19 19|15 19 19|15 13 1	None-BC7
23323829	CHEMICAL	GENE	T4	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for @GENETgt$ EPO @/GENETgt$ shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ , the unfolding process of EPO using guanidine hydrochloride is monitored , which indicates three steps for the folding structures of EPO to transform to random coil .	3 3 7 5 3|4 3 3|4 7 9 7 11 9 15 15 15 17 15 18 7 21 21 18 23 21 21 21 23 28 28 35 30 28 28 33 31 35 7 35 38 35 40 38 44 44 44 40 46 44 48 40 51 51 48 7	None-BC7
23323829	CHEMICAL	GENE	T2	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ 9,10-bis[4-(3-sulfonatopropoxyl)-styryl]anthracene sodium salt @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] A nonemissive anthracene derivative , that is @CHEMICALSrc$ 9,10-bis[4-(3-sulfonatopropoxyl)-styryl]anthracene sodium salt @/CHEMICALSrc$ ( BSPSA ) , with aggregation-induced emission ( AIE ) charateristics shows a novel phenomenon of AIE when @GENETgt$ EPO @/GENETgt$ is added .	4 4 4 23 4 8 8 8|4|7 8|4|7 8|4|7 8|4 8|4|7 13 8 13 4 18 18 22 20 22 20 23 23 26 26 23 28 26 33 33|26 33 33|26 33 23 23	None-BC7
23323829	CHEMICAL	GENE	T7	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] Computational modeling suggests that the BSPSA luminogens prefer docking in the hydrophobic cavity in the EPO folding structures , and the assembly of @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ in this cavity makes the AIE available , making the monitoring of unfolding of @GENETgt$ EPO @/GENETgt$ possible .	2 3 3 8 7 7 8 3 8 13 13 13 9 18 18 18 18 13 8 8 22 29 24 22|23 22 22|23 28 28 22 8 31 32 29 29 29 36 42 38 36 40 38 38 38 34 3	DIRECT-REGULATOR
23323829	CHEMICAL	GENE	T5	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for @GENETgt$ EPO @/GENETgt$ shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of BSPSA , the unfolding process of EPO using @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ is monitored , which indicates three steps for the folding structures of EPO to transform to random coil .	3 3 7 5 3|4 3 3|4 7 9 7 11 9 15 15 15 17 15 18 7 21 21 18 23 21 23 27 27 35 29 27 27 29|30|31 29|30|31 30|31 29|30|31 35 7 35 38 35 40 38 44 44 44 40 46 44 48 40 51 51 48 7	None-BC7
23323829	CHEMICAL	GENE	T7	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] Computational modeling suggests that the BSPSA luminogens prefer docking in the hydrophobic cavity in the @GENETgt$ EPO @/GENETgt$ folding structures , and the assembly of @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ in this cavity makes the AIE available , making the monitoring of unfolding of EPO possible .	2 3 3 8 7 7 8 3 8 13 13 13 9 19 19 19|15 19 19|15 19 13 8 8 23 30 25 23 23 23 29 29 23 8 32 33 30 30 30 37 42 39 37 41 39 35 3	None-BC7
23323829	CHEMICAL	GENE	T6	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] Computational modeling suggests that the @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ luminogens prefer docking in the hydrophobic cavity in the @GENETgt$ EPO @/GENETgt$ folding structures , and the assembly of BSPSA in this cavity makes the AIE available , making the monitoring of unfolding of EPO possible .	2 3 3 9 8 8|5 8 8|5 9 3 9 14 14 14 10 20 20 20|15 20 20|15 20 14 9 9 24 30 26 24 29 29 24 9 32 33 30 30 30 37 42 39 37 41 39 35 3	DIRECT-REGULATOR
23323829	CHEMICAL	GENE	T4	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for EPO shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ , the unfolding process of @GENETgt$ EPO @/GENETgt$ using guanidine hydrochloride is monitored , which indicates three steps for the folding structures of EPO to transform to random coil .	3 3 6 5 3 6 8 6 10 8 14 14 14 16 14 17 6 20 20 17 22 20|21 20 20|21 22 27 27 35 29 27 27 27 27 33 31 35 6 35 38 35 40 38 44 44 44 40 46 44 48 40 51 51 48 6	None-BC7
23323829	CHEMICAL	GENE	T1	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ anthracene @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] A nonemissive @CHEMICALSrc$ anthracene @/CHEMICALSrc$ derivative , that is 9,10-bis[4-(3-sulfonatopropoxyl)-styryl]anthracene sodium salt ( BSPSA ) , with aggregation-induced emission ( AIE ) charateristics shows a novel phenomenon of AIE when @GENETgt$ EPO @/GENETgt$ is added .	5 5 2|5 5 2|5 23 5 11 11 11 11 5 13 11 13 5 18 18 22 20 22 20 23 23 26 26 23 28 26 33 33|28 33 33|28 33 23 23	None-BC7
23323829	CHEMICAL	GENE	T6	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] Computational modeling suggests that the @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ luminogens prefer docking in the hydrophobic cavity in the EPO folding structures , and the assembly of BSPSA in this cavity makes the AIE available , making the monitoring of unfolding of @GENETgt$ EPO @/GENETgt$ possible .	2 3 3 9 8 8|5 8 8|5 9 3 9 14 14 14 10 19 19 19 19 14 9 9 23 29 25 23 28 28 23 9 31 32 29 29 29 36 42 38 36 40 38 38 38 34 3	None-BC7
23323829	CHEMICAL	GENE	T5	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for EPO shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of BSPSA , the unfolding process of @GENETgt$ EPO @/GENETgt$ using @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ is monitored , which indicates three steps for the folding structures of EPO to transform to random coil .	3 3 6 5 3 6 8 6 10 8 14 14 14 16 14 17 6 20 20 17 22 20 22 26 26 35 28 26|27 26 26|27 26 29|30|31 29|30|31 30|31 29|30|31 35 6 35 38 35 40 38 44 44 44 40 46 44 48 40 51 51 48 6	None-BC7
23323829	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] A nonemissive anthracene derivative , that is 9,10-bis[4-(3-sulfonatopropoxyl)-styryl]anthracene sodium salt ( @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ ) , with aggregation-induced emission ( AIE ) charateristics shows a novel phenomenon of AIE when @GENETgt$ EPO @/GENETgt$ is added .	4 4 4 23 4 10 10 10 10 4 12 10|11 10 10|11 12 4 18 18 22 20 22 20 23 23 26 26 23 28 26 33 33|28 33 33|28 33 23 23	None-BC7
23323829	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for EPO shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of BSPSA , the unfolding process of EPO using @CHEMICALSrc$ guanidine hydrochloride @/CHEMICALSrc$ is monitored , which indicates three steps for the folding structures of @GENETgt$ EPO @/GENETgt$ to transform to random coil .	3 3 6 5 3 6 8 6 10 8 14 14 14 16 14 17 6 20 20 17 22 20 22 26 26 34 28 26 26 29|30 29|30 29|30 29|30 34 6 34 37 34 39 37 43 43 43 39 45 42|43 43 42|43 48 39 51 51 48 6	None-BC7
23323829	CHEMICAL	GENE	T4	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ and @GENETgt$ EPO @/GENETgt$ ? [SEP] The AIE biosensor for EPO shows the limit of detection is 1 × 10(-9 ) M. Utilizing the AIE feature of @CHEMICALSrc$ BSPSA @/CHEMICALSrc$ , the unfolding process of EPO using guanidine hydrochloride is monitored , which indicates three steps for the folding structures of @GENETgt$ EPO @/GENETgt$ to transform to random coil .	3 3 6 5 3 6 8 6 10 8 14 14 14 16 14 17 6 20 20 17 22 20|21 20 20|21 22 27 27 34 29 27 27 32 30 34 6 34 37 34 39 37 43 43 43 39 45 43 43 43 48 39 51 51 48 6	None-BC7
23404739	CHEMICAL	GENE	T1	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Sipholenol A @/CHEMICALSrc$ and @GENETgt$ P-gp @/GENETgt$ ? [SEP] @CHEMICALSrc$ Sipholenol A @/CHEMICALSrc$ , a sipholane triterpene isolated from the Red Sea sponge Callyspongia siphonella , has the ability to reverse multidrug resistance in cancer cells that overexpress P-glycoprotein ( @GENETgt$ P-gp @/GENETgt$ ) .	0|1|17 0|1|17 1|17 0|1|17 1 7 7 1 7 15 15 15 13 15 15 8 1 17 19 17 21 19 23 21 26 26 23 28 26 28 31 28|29 29 28|29 31 17	None-BC7
23404739	CHEMICAL	GENE	T9	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ sipholane triterpene @/CHEMICALSrc$ and @GENETgt$ P-glycoprotein @/GENETgt$ ? [SEP] Sipholenol A , a @CHEMICALSrc$ sipholane triterpene @/CHEMICALSrc$ isolated from the Red Sea sponge Callyspongia siphonella , has the ability to reverse multidrug resistance in cancer cells that overexpress @GENETgt$ P-glycoprotein @/GENETgt$ ( P-gp ) .	2 17 2 5 2|4|5 2|4|5 2|5 2|4|5 5 15 15 15 13 15 15 8 2 17 19 17 21 19 23 21 26 26 23 28 26 26|28 28 26|28 32 29 32 17	None-BC7
23404739	CHEMICAL	GENE	T5	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ sipholanes @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] In breast tumor cells , @GENETgt$ PTK6 @/GENETgt$ promotes growth factor signaling and migration , and as such the semisynthetic @CHEMICALSrc$ sipholanes @/CHEMICALSrc$ were evaluated for their ability to inhibit PTK6 phosphorylation in vitro .	4 4 4 8 8 8|5 8 8|5 8 10 8 10 11 11 8 8 23 20 20 20 18|23 23 18|23 23 8 26 26 23 28 26 30 28 32 28 8	None-BC7
23404739	CHEMICAL	GENE	T3	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ and @GENETgt$ protein tyrosine kinase 6 @/GENETgt$ ? [SEP] A KINOMEscan of @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ against 451 human protein kinases identified @GENETgt$ protein tyrosine kinase 6 @/GENETgt$ ( PTK6 ) as a potential target .	2 14 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 13 13 13 13 2 14 10|14|15 10|14|15 10|14|15 10|14|15 14|15 10|14|15 21 15 21 26 26 26 14 14	DIRECT-REGULATOR
23404739	CHEMICAL	GENE	T3	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ and @GENETgt$ human protein kinases @/GENETgt$ ? [SEP] A KINOMEscan of @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ against 451 @GENETgt$ human protein kinases @/GENETgt$ identified protein tyrosine kinase 6 ( PTK6 ) as a potential target .	2 15 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 11 11 2|11|6 2|11|6 2|11|6 2|11 2|11|6 15 18 18 15 18 21 18 21 26 26 26 15 15	None-BC7
23404739	CHEMICAL	GENE	T4	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ tyrosine @/CHEMICALSrc$ and @GENETgt$ protein tyrosine kinase 6 @/GENETgt$ ? [SEP] A KINOMEscan of 19,20-anhydrosipholenol A 4β-benzoate ester against 451 human protein kinases identified @GENETgt$ protein @/GENETgt$ @CHEMICALSrc$ tyrosine kinase 6 @/CHEMICALSrc$ ( PTK6 ) as a potential target .	2 13 7 7 7 7 2 12 12 12 12 2 13 16|13 16 16|13 16|13|14 16|13|14 16|13|14 16|13 16|13|14 21 16 21 26 26 26 13 13	None-BC7
23404739	CHEMICAL	GENE	T5	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ sipholanes @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] In breast tumor cells , PTK6 promotes growth factor signaling and migration , and as such the semisynthetic @CHEMICALSrc$ sipholanes @/CHEMICALSrc$ were evaluated for their ability to inhibit @GENETgt$ PTK6 @/GENETgt$ phosphorylation in vitro .	4 4 4 7 7 7 7 9 7 9 10 10 7 7 22 19 19 19 18|22 22 18|22 22 7 25 25 22 27 25 26|30 30 26|30 27 32 27 7	INHIBITOR
23404739	CHEMICAL	GENE	T8	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ esters @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] The two analogues with the highest antimigratory activities , sipholenol A 4β-4-chlorobenzoate and 19,20-anhydrosipholenol A 4β-4-chlorobenzoate @CHEMICALSrc$ esters @/CHEMICALSrc$ , also exhibited the most potent inhibition of @GENETgt$ PTK6 @/GENETgt$ phosphorylation inhibition .	3 3 21 8 8 7 8 3 3 11 12 3 12 12 12 17 16|12 12 16|12 3 21 21 25 24 25 21 30 25|30 30 25|30 30 25 21	INHIBITOR
23404739	CHEMICAL	GENE	T4	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ tyrosine @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] A KINOMEscan of 19,20-anhydrosipholenol A 4β-benzoate ester against 451 human protein kinases identified protein @CHEMICALSrc$ tyrosine @/CHEMICALSrc$ kinase 6 ( @GENETgt$ PTK6 @/GENETgt$ ) as a potential target .	2 13 7 7 7 7 2 12 12 12 12 2 13 17 17|14 17 17|14 13 17 20 17|18 17 17|18 20 26 26 26 13 13	None-BC7
23404739	CHEMICAL	GENE	T7	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-4-chlorobenzoate @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] The two analogues with the highest antimigratory activities , sipholenol A 4β-4-chlorobenzoate and @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-4-chlorobenzoate @/CHEMICALSrc$ esters , also exhibited the most potent inhibition of @GENETgt$ PTK6 @/GENETgt$ phosphorylation inhibition .	3 3 21 8 8 7 8 3 3 11 12 3 12 18|12|13 18|12|13 18|12|13 18|12 18|12|13 12 3 21 21 25 24 25 21 30 30|23 30 30|23 30 25 21	INHIBITOR
23404739	CHEMICAL	GENE	T9	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ sipholane triterpene @/CHEMICALSrc$ and @GENETgt$ P-gp @/GENETgt$ ? [SEP] Sipholenol A , a @CHEMICALSrc$ sipholane triterpene @/CHEMICALSrc$ isolated from the Red Sea sponge Callyspongia siphonella , has the ability to reverse multidrug resistance in cancer cells that overexpress P-glycoprotein ( @GENETgt$ P-gp @/GENETgt$ ) .	2 17 2 5 2|4|5 2|4|5 2|5 2|4|5 5 15 15 15 13 15 15 8 2 17 19 17 21 19 23 21 26 26 23 28 26 28 31 28|29 29 28|29 31 17	None-BC7
23404739	CHEMICAL	GENE	T6	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ sipholenol A 4β-4-chlorobenzoate @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] The two analogues with the highest antimigratory activities , @CHEMICALSrc$ sipholenol A 4β-4-chlorobenzoate @/CHEMICALSrc$ and 19,20-anhydrosipholenol A 4β-4-chlorobenzoate esters , also exhibited the most potent inhibition of @GENETgt$ PTK6 @/GENETgt$ phosphorylation inhibition .	3 3 21 8 8 7 8 3 3 9|10|3 9|10|3 9|10|3 10|3 9|10|3 10 10 10 18 10 3 21 21 25 24 25 21 30 30|23 30 30|23 30 25 21	INHIBITOR
23404739	CHEMICAL	GENE	T4	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ tyrosine @/CHEMICALSrc$ and @GENETgt$ human protein kinases @/GENETgt$ ? [SEP] A KINOMEscan of 19,20-anhydrosipholenol A 4β-benzoate ester against 451 @GENETgt$ human protein kinases @/GENETgt$ identified protein @CHEMICALSrc$ tyrosine @/CHEMICALSrc$ kinase 6 ( PTK6 ) as a potential target .	2 14 7 7 7 7 2 10 10 9|10|2 9|10|2 9|10|2 10|2 9|10|2 14 18 18|12 18 18|12 14 18 21 18 21 26 26 26 14 14	None-BC7
23404739	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Sipholenol A @/CHEMICALSrc$ and @GENETgt$ P-glycoprotein @/GENETgt$ ? [SEP] @CHEMICALSrc$ Sipholenol A @/CHEMICALSrc$ , a sipholane triterpene isolated from the Red Sea sponge Callyspongia siphonella , has the ability to reverse multidrug resistance in cancer cells that overexpress @GENETgt$ P-glycoprotein @/GENETgt$ ( P-gp ) .	0|1|17 0|1|17 1|17 0|1|17 1 7 7 1 7 15 15 15 13 15 15 8 1 17 19 17 21 19 23 21 26 26 23 28 26 26|28 28 26|28 32 29 32 17	None-BC7
23404739	CHEMICAL	GENE	T3	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ and @GENETgt$ PTK6 @/GENETgt$ ? [SEP] A KINOMEscan of @CHEMICALSrc$ 19,20-anhydrosipholenol A 4β-benzoate ester @/CHEMICALSrc$ against 451 human protein kinases identified protein tyrosine kinase 6 ( @GENETgt$ PTK6 @/GENETgt$ ) as a potential target .	2 14 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 13 13 13 13 2 14 17 17 14 17 20 17|15 17 17|15 20 26 26 26 14 14	DIRECT-REGULATOR
10403635	CHEMICAL	GENE	T35	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Success of @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ , physostigmine , eptastigmine and @GENETgt$ phosphotriesterase @/GENETgt$ treatments in acute sarin intoxication .	1 3 1|2 1 1|2 3 3 6 6 8 8 8 8 3 16 16 16 12 1	None-BC7
10403635	CHEMICAL	GENE	T11	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] In phosphotriesterase and physostigmine-treated mice , a 4- and 2-fold higher @CHEMICALSrc$ sarin @/CHEMICALSrc$ dose , respectively , was needed to cause a 50 % inhibition of brain @GENETgt$ AChE @/GENETgt$ activity .	2 19 2 2 19 5 14 11 8 8 14 11|14 14 11|14 5 14 5 19 19 19 21 19 25 24 25 21 30 30 26|30 30 26|30 25 19	INHIBITOR
10403635	CHEMICAL	GENE	T25	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , physostigmine , eptastigmine , and an organophosphate hydrolase , @GENETgt$ phosphotriesterase @/GENETgt$ , in acute @CHEMICALSrc$ sarin @/CHEMICALSrc$ intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11 13 13 13 11 20 20 11 20 20|21 20 20|21 20 29 29 25|29 29 25|29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T9	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] Both the phosphotriesterase and physostigmine treatments protected the brain @GENETgt$ AChE @/GENETgt$ activities measured 24 h after @CHEMICALSrc$ sarin @/CHEMICALSrc$ exposure .	3 3 6 3 3 7 7 12 10 9|12 12 9|12 7 7 15 13 19 19|15 19 19|15 13 7	None-BC7
10403635	CHEMICAL	GENE	T27	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The mice received @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ ( 0.06 mg/kg body weight ) , physostigmine ( 0.09 mg/kg body weight ) , the physostigmine derivative eptastigmine ( 0.90 mg/kg body weight ) or @GENETgt$ phosphotriesterase @/GENETgt$ ( 104 U/g , 10.7 microg/g body weight ) 10 min prior to the i.g . administration of sarin .	2 3 3 3 3 3 10 10 10 10 4 10 4 4 18 18 18 18 13 18 23 22 23 3 23 29 29 29 29 24 29 24 24|30 24 24|30 36 36 32 36 39 41 41 36 44 44 36 36 50 50 50 50 45 52 50 3	None-BC7
10403635	CHEMICAL	GENE	T8	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] Both the phosphotriesterase and @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ treatments protected the brain @GENETgt$ AChE @/GENETgt$ activities measured 24 h after sarin exposure .	3 3 7 3 3|4 3 3|4 8 8 13 11 9|13 13 9|13 8 8 16 14 19 19 14 8	None-BC7
10403635	CHEMICAL	GENE	T33	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ Phosphotriesterase @/GENETgt$ ? [SEP] @GENETgt$ Phosphotriesterase @/GENETgt$ was the most effective antidote in @CHEMICALSrc$ sarin @/CHEMICALSrc$ intoxication .	0|7 7 0|7 7 7 6 7 7 11 11|7 11 11|7 7 7	None-BC7
10403635	CHEMICAL	GENE	T22	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ organophosphate hydrolase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ , eptastigmine , and an @GENETgt$ organophosphate hydrolase @/GENETgt$ , phosphotriesterase , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11|12 11 11|12 13 13 13 11 20 18|11|20 18|11|20 11|20 18|11|20 20 20 20 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T8	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Both the @GENETgt$ phosphotriesterase @/GENETgt$ and @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ treatments protected the brain AChE activities measured 24 h after sarin exposure .	3 3 8|2 8 8|2 3 3|4 3 3|4 9 9 13 12 13 9 9 16 14 19 19 14 9	None-BC7
10403635	CHEMICAL	GENE	T36	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Success of pyridostigmine , @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ , eptastigmine and @GENETgt$ phosphotriesterase @/GENETgt$ treatments in acute sarin intoxication .	1 3 1 3 3|4 3 3|4 5 5 8 8 8 8 3 16 16 16 12 1	None-BC7
10403635	CHEMICAL	GENE	T29	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The mice received pyridostigmine ( 0.06 mg/kg body weight ) , physostigmine ( 0.09 mg/kg body weight ) , the @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ derivative eptastigmine ( 0.90 mg/kg body weight ) or @GENETgt$ phosphotriesterase @/GENETgt$ ( 104 U/g , 10.7 microg/g body weight ) 10 min prior to the i.g . administration of sarin .	2 3 3 3 9 9 9 9 4 9 4 4 17 17 17 17 12 17 23 21 20|23 23 20|23 3 23 29 29 29 29 24 29 24 24|30 24 24|30 36 36 32 36 39 41 41 36 44 44 36 36 50 50 50 50 45 52 50 3	None-BC7
10403635	CHEMICAL	GENE	T10	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] In phosphotriesterase and @CHEMICALSrc$ physostigmine-treated @/CHEMICALSrc$ mice , a 4- and 2-fold higher sarin dose , respectively , was needed to cause a 50 % inhibition of brain @GENETgt$ AChE @/GENETgt$ activity .	2 19 2 2|3 2 2|3 19 6 14 12 9 9 14 14 6 14 6 19 19 19 21 19 25 24 25 21 30 30 26|30 30 26|30 25 19	None-BC7
10403635	CHEMICAL	GENE	T20	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ organophosphorus @/CHEMICALSrc$ and @GENETgt$ acetylcholinesterase @/GENETgt$ ? [SEP] The acute toxicity of @CHEMICALSrc$ organophosphorus @/CHEMICALSrc$ ( OP ) compounds in mammals is due to their irreversible inhibition of @GENETgt$ acetylcholinesterase @/GENETgt$ ( AChE ) in the nervous system , which leads to increased synaptic acetylcholine levels .	3 3 18 10 10|4 10 10|4 8 5 8 3 12 3 14 18 14 18 18 18 20 18 18 18 23 20 23 28 28 28 18 28 31 28 36 36 36 36 31 18	INHIBITOR
10403635	CHEMICAL	GENE	T17	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] In conclusion , @GENETgt$ phosphotriesterase @/GENETgt$ and physostigmine were the most effective treatments against @CHEMICALSrc$ sarin @/CHEMICALSrc$ intoxication .	2 12 12 3|12 12 3|12 4 4 12 12 11 12 12 16 16|12 16 16|12 12 12	None-BC7
10403635	CHEMICAL	GENE	T23	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , physostigmine , @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ , and an organophosphate hydrolase , @GENETgt$ phosphotriesterase @/GENETgt$ , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11 13 13|14 13 13|14 13 11 21 21 11 21 21 21 21 21 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T13	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Moreover , the combination of @GENETgt$ phosphotriesterase-physostigmine @/GENETgt$ increased the LD50 value for @CHEMICALSrc$ sarin @/CHEMICALSrc$ 4.3-fold .	8 8 4 8 6 4|5 4 4|5 8 11 11 8 13 11 11 11 8 8	None-BC7
10403635	CHEMICAL	GENE	T28	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The mice received pyridostigmine ( 0.06 mg/kg body weight ) , @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ ( 0.09 mg/kg body weight ) , the physostigmine derivative eptastigmine ( 0.90 mg/kg body weight ) or @GENETgt$ phosphotriesterase @/GENETgt$ ( 104 U/g , 10.7 microg/g body weight ) 10 min prior to the i.g . administration of sarin .	2 3 3 3 9 9 9 9 4 9 4 11|4 4 11|4 18 18 18 18 12 18 23 22 23 3 23 29 29 29 29 24 29 24 24|30 24 24|30 36 36 32 36 39 41 41 36 44 44 36 36 50 50 50 50 45 52 50 3	None-BC7
10403635	CHEMICAL	GENE	T31	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The mice received pyridostigmine ( 0.06 mg/kg body weight ) , physostigmine ( 0.09 mg/kg body weight ) , the physostigmine derivative eptastigmine ( 0.90 mg/kg body weight ) or @GENETgt$ phosphotriesterase @/GENETgt$ ( 104 U/g , 10.7 microg/g body weight ) 10 min prior to the i.g . administration of @CHEMICALSrc$ sarin @/CHEMICALSrc$ .	2 3 3 3 9 9 9 9 4 9 4 4 17 17 17 17 12 17 22 21 22 3 22 28 28 28 28 23 28 23 30|23 23 30|23 35 35 31 35 38 40 40 35 43 43 35 35 49 49 49 49 44 51 49 49 49 3	None-BC7
10403635	CHEMICAL	GENE	T20	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ organophosphorus @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] The acute toxicity of @CHEMICALSrc$ organophosphorus @/CHEMICALSrc$ ( OP ) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ( @GENETgt$ AChE @/GENETgt$ ) in the nervous system , which leads to increased synaptic acetylcholine levels .	3 3 18 10 10|4 10 10|4 8 5 8 3 12 3 14 18 14 18 18 18 20 18 22 20 20 20 22 28 28 28 18 28 31 28 36 36 36 36 31 18	INHIBITOR
10403635	CHEMICAL	GENE	T10	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] In @GENETgt$ phosphotriesterase @/GENETgt$ and @CHEMICALSrc$ physostigmine-treated @/CHEMICALSrc$ mice , a 4- and 2-fold higher sarin dose , respectively , was needed to cause a 50 % inhibition of brain AChE activity .	2 1|20 20 1|20 2 2|3 2 2|3 20 7 15 13 10 10 15 15 7 15 7 20 20 20 22 20 26 25 26 22 30 30 30 26 20	None-BC7
10403635	CHEMICAL	GENE	T34	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The LD50 value for @CHEMICALSrc$ sarin @/CHEMICALSrc$ increased 3.4-fold in mice receiving @GENETgt$ phosphotriesterase @/GENETgt$ .	3 3 7 5 3|4 3 3|4 7 7 10 7 10 10|11 11 10|11 7	None-BC7
10403635	CHEMICAL	GENE	T38	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Success of pyridostigmine , physostigmine , eptastigmine and @GENETgt$ phosphotriesterase @/GENETgt$ treatments in acute @CHEMICALSrc$ sarin @/CHEMICALSrc$ intoxication .	1 3 1 3 3 5 5 7 8|7 7 8|7 3 16 16 16|12 16 16|12 11 1	None-BC7
10403635	CHEMICAL	GENE	T30	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The mice received pyridostigmine ( 0.06 mg/kg body weight ) , physostigmine ( 0.09 mg/kg body weight ) , the physostigmine derivative @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ ( 0.90 mg/kg body weight ) or @GENETgt$ phosphotriesterase @/GENETgt$ ( 104 U/g , 10.7 microg/g body weight ) 10 min prior to the i.g . administration of sarin .	2 3 3 3 9 9 9 9 4 9 4 4 17 17 17 17 12 17 22 21 22 3 22 22 22 29 29 29 29 23 29 23 30|23 23 30|23 36 36 32 36 39 41 41 36 44 44 36 36 50 50 50 50 45 52 50 3	None-BC7
10403635	CHEMICAL	GENE	T21	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ and @GENETgt$ organophosphate hydrolase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ , physostigmine , eptastigmine , and an @GENETgt$ organophosphate hydrolase @/GENETgt$ , phosphotriesterase , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 10 10 11 11 14 14 14 11 20 18|11|20 18|11|20 11|20 18|11|20 20 20 20 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T22	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ , eptastigmine , and an organophosphate hydrolase , @GENETgt$ phosphotriesterase @/GENETgt$ , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11|12 11 11|12 13 13 13 11 21 21 11 21 21 21 21 21 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T24	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ organophosphate @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , physostigmine , eptastigmine , and an @CHEMICALSrc$ organophosphate @/CHEMICALSrc$ hydrolase , @GENETgt$ phosphotriesterase @/GENETgt$ , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11 13 13 13 11 21 18|21 21 18|21 11 21 21 21 21 21 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T9	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Both the @GENETgt$ phosphotriesterase @/GENETgt$ and physostigmine treatments protected the brain AChE activities measured 24 h after @CHEMICALSrc$ sarin @/CHEMICALSrc$ exposure .	3 3 2|7 7 2|7 3 3 8 8 12 11 12 8 8 15 13 19 19|15 19 19|15 13 8	None-BC7
10403635	CHEMICAL	GENE	T11	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] In @GENETgt$ phosphotriesterase @/GENETgt$ and physostigmine-treated mice , a 4- and 2-fold higher @CHEMICALSrc$ sarin @/CHEMICALSrc$ dose , respectively , was needed to cause a 50 % inhibition of brain AChE activity .	2 1|20 20 1|20 2 2 20 6 15 12 9 9 15 11|15 15 11|15 6 15 6 20 20 20 22 20 26 25 26 22 30 30 30 26 20	None-BC7
10403635	CHEMICAL	GENE	T16	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ acetylcholine @/CHEMICALSrc$ and @GENETgt$ AChE @/GENETgt$ ? [SEP] The acute toxicity of organophosphorus ( OP ) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ( @GENETgt$ AChE @/GENETgt$ ) in the nervous system , which leads to increased synaptic @CHEMICALSrc$ acetylcholine @/CHEMICALSrc$ levels .	3 3 17 9 9 7 5 7 3 11 3 13 17 13 17 17 17 19 17 21 19|20 19 19|20 21 27 27 27 17 27 30 27 36 36 36 32|36 36 32|36 30 17	SUBSTRATE
10403635	CHEMICAL	GENE	T23	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ and @GENETgt$ organophosphate hydrolase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , physostigmine , @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ , and an @GENETgt$ organophosphate hydrolase @/GENETgt$ , phosphotriesterase , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11 13 13|14 13 13|14 13 11 20 18|11|20 18|11|20 11|20 18|11|20 20 20 20 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T15	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] In conclusion , @GENETgt$ phosphotriesterase @/GENETgt$ and @CHEMICALSrc$ physostigmine @/CHEMICALSrc$ were the most effective treatments against sarin intoxication .	2 13 13 3|13 13 3|13 4 4|5 4 4|5 13 13 12 13 13 16 16 13 13	None-BC7
10403635	CHEMICAL	GENE	T37	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] Success of pyridostigmine , physostigmine , @CHEMICALSrc$ eptastigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ treatments in acute sarin intoxication .	1 3 1 3 3 5 5|6 5 5|6 7 8|7 7 8|7 3 16 16 16 12 1	None-BC7
10403635	CHEMICAL	GENE	T21	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered @CHEMICALSrc$ pyridostigmine @/CHEMICALSrc$ , physostigmine , eptastigmine , and an organophosphate hydrolase , @GENETgt$ phosphotriesterase @/GENETgt$ , in acute sarin intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 10 10 11 11 14 14 14 11 21 21 11 21 21 21 21 21 29 29 29 10 31 10 33 31 10	None-BC7
10403635	CHEMICAL	GENE	T32	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ Physostigmine @/CHEMICALSrc$ and @GENETgt$ phosphotriesterase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Physostigmine @/CHEMICALSrc$ was also administered with @GENETgt$ phosphotriesterase @/GENETgt$ .	0|5 5 0|5 5 5 5 7 5 5 5 5	None-BC7
10403635	CHEMICAL	GENE	T16	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ acetylcholine @/CHEMICALSrc$ and @GENETgt$ acetylcholinesterase @/GENETgt$ ? [SEP] The acute toxicity of organophosphorus ( OP ) compounds in mammals is due to their irreversible inhibition of @GENETgt$ acetylcholinesterase @/GENETgt$ ( AChE ) in the nervous system , which leads to increased synaptic @CHEMICALSrc$ acetylcholine @/CHEMICALSrc$ levels .	3 3 17 9 9 7 5 7 3 11 3 13 17 13 17 17 17 19 17|18 17 17|18 22 19 22 27 27 27 17 27 30 27 36 36 36 32|36 36 32|36 30 17	SUBSTRATE
10403635	CHEMICAL	GENE	T25	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ sarin @/CHEMICALSrc$ and @GENETgt$ organophosphate hydrolase @/GENETgt$ ? [SEP] The protective actions of intravenously ( i.v . ) administered pyridostigmine , physostigmine , eptastigmine , and an @GENETgt$ organophosphate hydrolase @/GENETgt$ , phosphotriesterase , in acute @CHEMICALSrc$ sarin @/CHEMICALSrc$ intoxication were studied in mice .	3 3 10 5 3 5 5 5 5 10 10 11 11 13 13 13 11 19 11|18|19 11|18|19 11|19 11|18|19 19 19 19 29 29 24|29 29 24|29 10 31 10 33 31 10	None-BC7
23585380	CHEMICAL	GENE	T3	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ PDGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( @GENETgt$ PDGF @/GENETgt$ ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13|14 13 13|14 15 13 21 21 13 23 21 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|79 65 65|79 44	None-BC7
23585380	CHEMICAL	GENE	T2	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ VEGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( @GENETgt$ VEGF @/GENETgt$ ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20|21 20 20|21 22 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65|70 65 65|70 65 77 77 78 65 82 82 82 65 44	None-BC7
23585380	CHEMICAL	GENE	T2	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ PDGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of @GENETgt$ PDGF @/GENETgt$ , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	26 5 5 5 26 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20 22 5 26 43 26 33 33 33 30 30 26 26 26 43 40 40 40 43 43 43 43 45 43 47 45|46 45 45|46 43 43 52 65 57 57 57 57 52 61 61 61 57 65 64 65 43 67 65 67 72 72 72 65|70 65 65|70 65 77 77 78 65 82 82 82 65 43	INDIRECT-UPREGULATOR
23585380	CHEMICAL	GENE	T2	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ VEGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the @GENETgt$ VEGF @/GENETgt$ release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	26 5 5 5 26 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20 22 5 26 44 26 33 33 33 30 30 26 26 26 44 41 41|37 41 41|37 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65|70 65 65|70 65 77 77 78 65 82 82 82 65 44	INDIRECT-UPREGULATOR
23585380	CHEMICAL	GENE	T2	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ PDGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( @GENETgt$ PDGF @/GENETgt$ ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13|14 13 13|14 15 13 21 21 13 23 21 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65|70 65 65|70 65 77 77 78 65 82 82 82 65 44	None-BC7
23585380	CHEMICAL	GENE	T3	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ platelet-derived GF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as @GENETgt$ platelet-derived GF @/GENETgt$ ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	27 5 5 5 27 7 5 7 5 12 10 11|12|5 11|12|5 12|5 11|12|5 16 12 16 12 21 21 12 23 21 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|78 65 65|78 44	None-BC7
23585380	CHEMICAL	GENE	T2	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ vascular endothelial GF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and @GENETgt$ vascular endothelial GF @/GENETgt$ ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13 15 13 17|18|13 17|18|13 17|18|13 18|13 17|18|13 23 18 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65|68 65 65|68 65 77 77 78 65 82 82 82 65 44	None-BC7
23585380	CHEMICAL	GENE	T2	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ platelet-derived GF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as @GENETgt$ platelet-derived GF @/GENETgt$ ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and more than 45 % with HMW core PLGA .	27 5 5 5 27 7 5 7 5 12 10 11|12|5 11|12|5 12|5 11|12|5 16 12 16 12 21 21 12 23 21 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65|69 65 65|69 65 77 77 78 65 82 82 82 65 44	None-BC7
23585380	CHEMICAL	GENE	T3	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ vascular endothelial GF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and @GENETgt$ vascular endothelial GF @/GENETgt$ ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13 15 13 17|18|13 17|18|13 17|18|13 18|13 17|18|13 23 18 23 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|77 65 65|77 44	None-BC7
23585380	CHEMICAL	GENE	T3	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ PDGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of @GENETgt$ PDGF @/GENETgt$ , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	26 5 5 5 26 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20 22 5 26 43 26 33 33 33 30 30 26 26 26 43 40 40 40 43 43 43 43 45 43 47 45|46 45 45|46 43 43 52 65 57 57 57 57 52 61 61 61 57 65 64 65 43 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|79 65 65|79 43	INDIRECT-UPREGULATOR
23585380	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ VEGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( @GENETgt$ VEGF @/GENETgt$ ) , are encapsulated separately in the core and shell domains , respectively , the VEGF release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	27 5 5 5 27 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20|21 20 20|21 22 5 27 44 27 34 34 34 31 31 27 27 27 44 41 41 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|79 65 65|79 44	None-BC7
23585380	CHEMICAL	GENE	T3	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ PLGA @/CHEMICALSrc$ and @GENETgt$ VEGF @/GENETgt$ ? [SEP] When dual angiogenic growth factors ( GFs ) , such as platelet-derived GF ( PDGF ) and vascular endothelial GF ( VEGF ) , are encapsulated separately in the core and shell domains , respectively , the @GENETgt$ VEGF @/GENETgt$ release rate is much greater than that of PDGF , and the difference of the cumulative release percentage between the two GFs is about 30 % on day 7 with LMW core PLGA and more than 45 % with HMW core @CHEMICALSrc$ PLGA @/CHEMICALSrc$ .	26 5 5 5 26 7 5 7 5 13 10 13 5 15 13 15 13 20 20 13 22 20 22 5 26 44 26 33 33 33 30 30 26 26 26 44 41 41|37 41 41|37 41 44 44 44 44 46 44 48 46 44 44 52 65 57 57 57 57 52 61 61 61 57 65 64 65 44 67 65 67 72 72 72 65 65 76 76 77 65 81 81 81 65|79 65 65|79 44	INDIRECT-UPREGULATOR
15276688	CHEMICAL	GENE	T20	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ serotonin @/CHEMICALSrc$ and @GENETgt$ MAO @/GENETgt$ ? [SEP] The first model was induced by tranylcypromine , a nonselective monoamine oxidase ( @GENETgt$ MAO @/GENETgt$ ) inhibitor ( 3.5 mg/kg ) and fluoxetine , a selective @CHEMICALSrc$ serotonin @/CHEMICALSrc$ reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5 7 17 17 17 17 17 17|13 17 17|13 17 7 20 20 17 20 17 17 23 30 30 25|30 30 25|30 30 23 32 30 32 36 36 30 36 5	None-BC7
15276688	CHEMICAL	GENE	T19	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ fluoxetine @/CHEMICALSrc$ and @GENETgt$ monoamine oxidase @/GENETgt$ ? [SEP] The first model was induced by tranylcypromine , a nonselective @GENETgt$ monoamine oxidase @/GENETgt$ ( MAO ) inhibitor ( 3.5 mg/kg ) and @CHEMICALSrc$ fluoxetine @/CHEMICALSrc$ , a selective serotonin reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5 7 17 17 17|10 17|10 17 17|10 17 17 17 7 20 20 17 20 17 17|20 17 17|20 23 30 30 30 30 23 32 30 32 36 36 30 36 5	None-BC7
15276688	CHEMICAL	GENE	T18	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ monoamine @/CHEMICALSrc$ and @GENETgt$ MAO @/GENETgt$ ? [SEP] The first model was induced by tranylcypromine , a nonselective @CHEMICALSrc$ monoamine @/CHEMICALSrc$ oxidase ( @GENETgt$ MAO @/GENETgt$ ) inhibitor ( 3.5 mg/kg ) and fluoxetine , a selective serotonin reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5 7 18 18 10|18 18 10|18 18 18 18|13 18 18|13 18 7 21 21 18 21 18 18 24 30 30 30 30 24 32 30 32 36 36 30 36 5	None-BC7
15276688	CHEMICAL	GENE	T17	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ tranylcypromine @/CHEMICALSrc$ and @GENETgt$ MAO @/GENETgt$ ? [SEP] The first model was induced by @CHEMICALSrc$ tranylcypromine @/CHEMICALSrc$ , a nonselective monoamine oxidase ( @GENETgt$ MAO @/GENETgt$ ) inhibitor ( 3.5 mg/kg ) and fluoxetine , a selective serotonin reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5|6 5 5|6 7 18 18 18 18 18 18|13 18 18|13 18 7 21 21 18 21 18 18 24 30 30 30 30 24 32 30 32 36 36 30 36 5	INHIBITOR
15276688	CHEMICAL	GENE	T21	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ clorgyline @/CHEMICALSrc$ and @GENETgt$ MAO-A @/GENETgt$ ? [SEP] The second model was induced by @CHEMICALSrc$ clorgyline @/CHEMICALSrc$ , an @GENETgt$ MAO-A @/GENETgt$ inhibitor ( 1.2 mg/kg ) and 5-hydroxy-L-tryptophan , a precursor of 5-HT ( 5-HTP ) ( 80 mg/kg ) .	3 3 5 5 5 7 5|6 5 5|6 7 13 9|13 13 9|13 7 16 16 13 16 7 7 7 22 7 24 22 26 24 26 30 30 26 30 5	INHIBITOR
15276688	CHEMICAL	GENE	T20	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ serotonin @/CHEMICALSrc$ and @GENETgt$ monoamine oxidase @/GENETgt$ ? [SEP] The first model was induced by tranylcypromine , a nonselective @GENETgt$ monoamine oxidase @/GENETgt$ ( MAO ) inhibitor ( 3.5 mg/kg ) and fluoxetine , a selective @CHEMICALSrc$ serotonin @/CHEMICALSrc$ reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5 7 17 17 17|10 17|10 17 17|10 17 17 17 7 20 20 17 20 17 17 23 30 30 24|30 30 24|30 30 23 32 30 32 36 36 30 36 5	None-BC7
15276688	CHEMICAL	GENE	T17	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ tranylcypromine @/CHEMICALSrc$ and @GENETgt$ monoamine oxidase @/GENETgt$ ? [SEP] The first model was induced by @CHEMICALSrc$ tranylcypromine @/CHEMICALSrc$ , a nonselective @GENETgt$ monoamine oxidase @/GENETgt$ ( MAO ) inhibitor ( 3.5 mg/kg ) and fluoxetine , a selective serotonin reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5|6 5 5|6 7 18 18 10|18 10|18 18 10|18 18 18 18 7 21 21 18 21 18 18 24 30 30 30 30 24 32 30 32 36 36 30 36 5	INHIBITOR
15276688	CHEMICAL	GENE	T23	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-HT @/CHEMICALSrc$ and @GENETgt$ MAO-A @/GENETgt$ ? [SEP] The second model was induced by clorgyline , an @GENETgt$ MAO-A @/GENETgt$ inhibitor ( 1.2 mg/kg ) and 5-hydroxy-L-tryptophan , a precursor of @CHEMICALSrc$ 5-HT @/CHEMICALSrc$ ( 5-HTP ) ( 80 mg/kg ) .	3 3 5 5 5 7 5 7 12 9|12 12 9|12 7 15 15 12 15 7 7 7 21 7 23 21 21 21 26 23 26 30 30 26 30 5	None-BC7
15276688	CHEMICAL	GENE	T19	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ fluoxetine @/CHEMICALSrc$ and @GENETgt$ MAO @/GENETgt$ ? [SEP] The first model was induced by tranylcypromine , a nonselective monoamine oxidase ( @GENETgt$ MAO @/GENETgt$ ) inhibitor ( 3.5 mg/kg ) and @CHEMICALSrc$ fluoxetine @/CHEMICALSrc$ , a selective serotonin reuptake inhibitor ( SSRI ) ( 10 mg/kg ) .	3 3 5 5 5 7 5 7 17 17 17 17 17 17|13 17 17|13 17 7 20 20 17 20 17 17|21 17 17|21 23 30 30 30 30 23 32 30 32 36 36 30 36 5	None-BC7
15276688	CHEMICAL	GENE	T22	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-hydroxy-L-tryptophan @/CHEMICALSrc$ and @GENETgt$ MAO-A @/GENETgt$ ? [SEP] The second model was induced by clorgyline , an @GENETgt$ MAO-A @/GENETgt$ inhibitor ( 1.2 mg/kg ) and @CHEMICALSrc$ 5-hydroxy-L-tryptophan @/CHEMICALSrc$ , a precursor of 5-HT ( 5-HTP ) ( 80 mg/kg ) .	3 3 5 5 5 7 5 7 12 9|12 12 9|12 7 15 15 12 15 7 16|7 7 16|7 7 22 7 24 22 26 24 26 30 30 26 30 5	None-BC7
15561708	CHEMICAL	GENE	T3	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ABA3 from Arabidopsis thaliana specifically regulates the activity of the @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|2|6 1|2|6 1|2|6 2|6 1|2|6 11 9 9 6 11 11 13 11 18 18 18|12 18 18|12 13 20 18 20 23 20 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T3	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 11|4 11 11|4 9 9 5 11 11 13 11 18 18 18|14 18 18|14 13 20 18 20 23 20 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T25	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ persulfide @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The protein binds a pyridoxal phosphate cofactor and a substrate-derived persulfide intermediate , and site-directed mutagenesis of strictly conserved binding sites for the cofactor and the @CHEMICALSrc$ persulfide @/CHEMICALSrc$ demonstrated that they are essential for @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ activity .	2 3 3 7 7 7 3 7 12 12 12 7 12 3 16 29 21 19 21 21 16 24 24 21 16 27 16|26 16 16|26 3 33 33 33 29 39 33|39 33|39 33|39 39 33|39 33 3	None-BC7
15561708	CHEMICAL	GENE	T14	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase by converting their @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 16|17 16|17 16|17 16|17 17 22 17 24 10 28 28|23 28 28|23 24 31 31 24 34 34 31 10	None-BC7
15561708	CHEMICAL	GENE	T14	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor from the desulfo-form into the sulfo-form .	6 1|2|6 1|2|6 1|2|6 2|6 1|2|6 11 9 9 6 11 11 13 11 17 17 17 13 19 17 19 22 19 24 11 28 28|22 28 28|22 24 31 31 24 34 34 31 11	SUBSTRATE
15561708	CHEMICAL	GENE	T24	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ persulfide @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The protein binds a pyridoxal phosphate cofactor and a substrate-derived @CHEMICALSrc$ persulfide @/CHEMICALSrc$ intermediate , and site-directed mutagenesis of strictly conserved binding sites for the cofactor and the persulfide demonstrated that they are essential for @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ activity .	2 3 3 7 7 7 3 7 13 13 10|13 13 10|13 7 13 3 17 29 22 20 22 22 17 25 25 22 17 28 17 3 33 33 33 29 39 33|39 33|39 33|39 39 33|39 33 3	None-BC7
15561708	CHEMICAL	GENE	T14	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 11|4 11 11|4 9 9 5 11 11 13 11 17 17 17 13 19 17 19 22 19 24 11 28 24|28 28 24|28 24 31 31 24 34 34 31 11	SUBSTRATE
15561708	CHEMICAL	GENE	T20	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfur @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] @GENETgt$ ABA3 @/GENETgt$ is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental @CHEMICALSrc$ sulfur @/CHEMICALSrc$ for iron-sulfur cluster synthesis .	0|6 6 0|6 6 6 6 6 10 10 10 6 10 13 11 16 16 11 18 16 20 18 22 20 24 20 24 27 24|25 24 24|25 32 32 32 20 6	None-BC7
15561708	CHEMICAL	GENE	T3	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 17 17 17|14 17 17|14 12 19 17 19 19|21 19|21 19|21 19|21 25 10 28 28 25 31 31 25 34 34 31 10	DIRECT-REGULATOR
15561708	CHEMICAL	GENE	T10	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 11|4 11 11|4 9 9 5 11 11 13 11 17 17 17 13 19 17 19 19|23 23 19|23 19 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T11	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ AtNFS2 @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial @GENETgt$ AtNFS2 @/GENETgt$ , which are both proposed to be involved in iron-sulfur cluster formation , ABA3 is proposed to be a third and cytosolic NifS-like @CHEMICALSrc$ cysteine @/CHEMICALSrc$ desulfurase in A. thaliana .	3 3 23 3 6 3|5 3 3|5 6 12 12 12 3 15 15 12 19 19 19 15 23 23 23 23 27 27 27 23 27 27 33 33|29 33 33|29 27 36 36 27 23	None-BC7
15561708	CHEMICAL	GENE	T3	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 17 17 17|14 17 17|14 12 16|17|18 16|17|18 17|18 16|17|18 18 23 18 25 10 28 28 25 31 31 25 34 34 31 10	DIRECT-REGULATOR
15561708	CHEMICAL	GENE	T13	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ sulfur transferase @/GENETgt$ ? [SEP] However , the @GENETgt$ sulfur transferase @/GENETgt$ activity of ABA3 is used for post-translational activation of molybdenum enzymes rather than for @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster assembly .	11 11 7 3|7 3|7 7 3|7 11 9 7 11 11 14 14 11 17 17 14 14 18 24 24|18 24 24|18 24 14 11	None-BC7
15561708	CHEMICAL	GENE	T22	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfur @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Although different in its physiological function , the mechanism of @GENETgt$ ABA3 @/GENETgt$ for @CHEMICALSrc$ sulfur @/CHEMICALSrc$ mobilization was found to be similar to NifS proteins .	2 18 6 6 6 2 18 9 18 11 9|10 9 9|10 16 16|12 16 16|12 9 18 18 21 21 18 24 24 21 18	SUBSTRATE
15561708	CHEMICAL	GENE	T15	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfo @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the @CHEMICALSrc$ sulfo-form @/CHEMICALSrc$ .	6 1|2|6 1|2|6 1|2|6 2|6 1|2|6 11 9 9 6 11 11 13 11 17 17 17 13 19 17 19 22 19 24 11 27 27 24 30 30 24 33 33 29|30 30 29|30 11	None-BC7
15561708	CHEMICAL	GENE	T29	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ NifS-like domain @/GENETgt$ ? [SEP] Characterization of the @GENETgt$ NifS-like domain @/GENETgt$ of ABA3 from Arabidopsis thaliana provides insight into the mechanism of @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor sulfuration .	12 4 4 1|3|4 1|3|4 1|4 1|3|4 8 4 11 11 4 12 12 16 16 13 21 21|15 21 21|15 21 16 12	SUBSTRATE
15561708	CHEMICAL	GENE	T27	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of @GENETgt$ ABA3 @/GENETgt$ activates @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and xanthine dehydrogenase in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 6 6 10 8 6|7 6 6|7 10 9|13 13 9|13 10 13 16 13 19 19 10 23 23 23 19 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T4	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ selenocysteine lyase @/GENETgt$ ? [SEP] In addition to its @CHEMICALSrc$ cysteine @/CHEMICALSrc$ desulfurase activity , ABA3-NifS also exhibits @GENETgt$ selenocysteine lyase @/GENETgt$ activity .	2 12 8 8 8|4 8 8|4 8 2 12 12 12 12 16|11 16|11 16 16|11 12 12	None-BC7
15561708	CHEMICAL	GENE	T9	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ AtNFS2 @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial @GENETgt$ AtNFS2 @/GENETgt$ , which are both proposed to be involved in @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster formation , ABA3 is proposed to be a third and cytosolic NifS-like cysteine desulfurase in A. thaliana .	3 3 24 3 6 3|5 3 3|5 6 12 12 12 3 15 15 12 20 20|15 20 20|15 20 15 24 24 24 24 28 28 28 24 28 28 33 33 28 36 36 28 24	PRODUCT-OF
15561708	CHEMICAL	GENE	T9	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial AtNFS2 , which are both proposed to be involved in @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster formation , @GENETgt$ ABA3 @/GENETgt$ is proposed to be a third and cytosolic NifS-like cysteine desulfurase in A. thaliana .	3 3 24 3 6 3 6 11 11 11 3 14 14 11 19 19|15 19 19|15 19 14 24 24|19 24 24|19 24 24 28 28 28 24 28 28 33 33 28 36 36 28 24	PRODUCT-OF
15561708	CHEMICAL	GENE	T22	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfur @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] Although different in its physiological function , the mechanism of ABA3 for @CHEMICALSrc$ sulfur @/CHEMICALSrc$ mobilization was found to be similar to @GENETgt$ NifS @/GENETgt$ proteins .	2 17 6 6 6 2 17 9 17 11 9 15 12|15 15 12|15 9 17 17 20 20 17 24 24|20 24 24|20 20 17	SUBSTRATE
15561708	CHEMICAL	GENE	T12	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ sulfur transferase @/GENETgt$ ? [SEP] However , the @GENETgt$ sulfur transferase @/GENETgt$ activity of ABA3 is used for post-translational activation of @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes rather than for iron-sulfur cluster assembly .	11 11 7 3|7 3|7 7 3|7 11 9 7 11 11 14 14 11 18 18|13 18 18|13 14 14 19 24 24 24 14 11	None-BC7
15561708	CHEMICAL	GENE	T27	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 9|12 12 9|12 9 12 12|14 12|14 12|14 12|14 19 19 9 23 23 23 19 9 9 27 33 33 31 31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T5	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ selenocysteine @/CHEMICALSrc$ and @GENETgt$ cysteine desulfurase @/GENETgt$ ? [SEP] In addition to its @GENETgt$ cysteine desulfurase @/GENETgt$ activity , ABA3-NifS also exhibits @CHEMICALSrc$ selenocysteine @/CHEMICALSrc$ lyase activity .	2 12 8 8 8|4 8|4 8 8|4 2 12 12 12 12 16|10 16 16|10 16 12 12	None-BC7
15561708	CHEMICAL	GENE	T17	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] @GENETgt$ ABA3 @/GENETgt$ is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition of @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ to l-alanine and elemental sulfur for iron-sulfur cluster synthesis .	0|6 6 0|6 6 6 6 6 10 10 10 6 10 13 11 16 16 11 18 16 20 18 22 20 20 20 25 20 25 28 25 32 32 32 20 6	None-BC7
15561708	CHEMICAL	GENE	T23	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ pyridoxal phosphate @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The protein binds a @CHEMICALSrc$ pyridoxal phosphate @/CHEMICALSrc$ cofactor and a substrate-derived persulfide intermediate , and site-directed mutagenesis of strictly conserved binding sites for the cofactor and the persulfide demonstrated that they are essential for @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ activity .	2 3 3 8 8|4 8|4 8 8|4 3 8 13 13 13 8 13 3 17 29 22 20 22 22 17 25 25 22 17 28 17 3 33 33 33 29 39 32|39 32|39 32|39 39 32|39 33 3	None-BC7
15561708	CHEMICAL	GENE	T11	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ cytosolic NifS-like cysteine desulfurase @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial AtNFS2 , which are both proposed to be involved in iron-sulfur cluster formation , ABA3 is proposed to be a third and @GENETgt$ cytosolic NifS-like @/GENETgt$ @CHEMICALSrc$ cysteine desulfurase @/CHEMICALSrc$ in A. thaliana .	3 3 22 3 6 3 6 11 11 11 3 14 14 11 18 18 18 14 22 22 22 22 26 26 26 22 26 26|27|31 26|27|31 26|31 26|27|31 26|28|31 26|28|31 26|31 26|28|31 36 36 26 22	None-BC7
15561708	CHEMICAL	GENE	T28	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of @GENETgt$ ABA3 @/GENETgt$ activates aldehyde oxidase and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 6 6 10 8 6|7 6 6|7 10 12 10 12 16|12 16 16|12 12 19 19 10 23 23 23 19 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T18	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ l-alanine @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to @GENETgt$ NifS @/GENETgt$ proteins that catalyze the decomposition of l-cysteine to @CHEMICALSrc$ l-alanine @/CHEMICALSrc$ and elemental sulfur for iron-sulfur cluster synthesis .	5 5 5 5 5 9 9 9 5 9 12 10 16 16|13 16 16|13 10 18 16 20 18 22 20 24 20|22 20 20|22 24 28 24 32 32 32 20 5	PRODUCT-OF
15561708	CHEMICAL	GENE	T16	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ NH2 @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] @GENETgt$ ABA3 @/GENETgt$ is a two-domain protein with an @CHEMICALSrc$ NH2-terminal @/CHEMICALSrc$ domain sharing significant similarities to NifS proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental sulfur for iron-sulfur cluster synthesis .	0|6 6 0|6 6 6 6 6 11 11 11|7 11 11|7 6 11 14 12 17 17 12 19 17 21 19 23 21 25 21 25 28 25 32 32 32 21 6	PART-OF
15561708	CHEMICAL	GENE	T5	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ selenocysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In addition to its cysteine desulfurase activity , @GENETgt$ ABA3-NifS @/GENETgt$ also exhibits @CHEMICALSrc$ selenocysteine @/CHEMICALSrc$ lyase activity .	2 12 7 7 7 7 2 12 8|12 12 8|12 12 12 16|11 16 16|11 16 12 12	None-BC7
15561708	CHEMICAL	GENE	T6	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ l-selenocysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Although @CHEMICALSrc$ l-selenocysteine @/CHEMICALSrc$ is unlikely to be a natural substrate for @GENETgt$ ABA3 @/GENETgt$ , it is decomposed more efficiently than l-cysteine .	5 1|5 5 1|5 5 17 10 10 10 10 5 12 10 10 10 17 17 17 17 19 17 21 19 17	SUBSTRATE
15561708	CHEMICAL	GENE	T2	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ NifS-like domain @/GENETgt$ ? [SEP] In vitro , the @GENETgt$ NifS-like domain @/GENETgt$ of ABA3 activates aldehyde oxidase and xanthine dehydrogenase in the absence of the C-terminal domain , but in vivo , the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain is required for proper activation of both target enzymes .	2 10 10 5 10|4|5 10|4|5 10|5 10|4|5 9 5 10 12 10 12 15 12 18 18 10 22 22 22 18 10 10 26 33 33 31 26|31 31 26|31 33 33 10 36 36 33 40 40 40 36 33	PART-OF
15561708	CHEMICAL	GENE	T2	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of @GENETgt$ ABA3 @/GENETgt$ activates aldehyde oxidase and xanthine dehydrogenase in the absence of the C-terminal domain , but in vivo , the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain is required for proper activation of both target enzymes .	2 10 10 6 6 10 8 6|7 6 6|7 10 12 10 12 15 12 18 18 10 22 22 22 18 10 10 26 33 33 31 27|31 31 27|31 33 33 10 36 36 33 40 40 40 36 33	PART-OF
15561708	CHEMICAL	GENE	T1	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase in the absence of the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 9|10 9|10 9|10 9|10 10 15 10 18 18 9 23 23 18|23 23 18|23 18 9 9 27 33 33 31 31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T7	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 16|19 19 16|19 16 19 19|21 19|21 19|21 19|21 25 10 28 28 25 31 31 25 34 34 31 10	None-BC7
15561708	CHEMICAL	GENE	T29	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Characterization of the NifS-like domain of @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana provides insight into the mechanism of @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor sulfuration .	12 5 5 5 1 7 5|6 5 5|6 11 11 5 12 12 16 16 13 21 16|21 21 16|21 21 16 12	SUBSTRATE
15561708	CHEMICAL	GENE	T2	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ in the absence of the C-terminal domain , but in vivo , the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 11 9 11 11|12|13 11|12|13 11|13 11|12|13 18 18 9 22 22 22 18 9 9 26 33 33 31 26|31 31 26|31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T9	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ AtNFS1 @/GENETgt$ ? [SEP] Besides mitochondrial @GENETgt$ AtNFS1 @/GENETgt$ and plastidial AtNFS2 , which are both proposed to be involved in @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster formation , ABA3 is proposed to be a third and cytosolic NifS-like cysteine desulfurase in A. thaliana .	3 3 24|2 24 24|2 3 7 3 7 12 12 12 3 15 15 12 20 20|15 20 20|15 20 15 24 24 24 24 28 28 28 24 28 28 33 33 28 36 36 28 24	PRODUCT-OF
15561708	CHEMICAL	GENE	T13	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] However , the sulfur transferase activity of @GENETgt$ ABA3 @/GENETgt$ is used for post-translational activation of molybdenum enzymes rather than for @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster assembly .	11 11 6 6 6 11 8 6|7 6 6|7 11 11 14 14 11 17 17 14 14 18 24 24|19 24 24|19 24 14 11	PRODUCT-OF
15561708	CHEMICAL	GENE	T8	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Although l-selenocysteine is unlikely to be a natural substrate for @GENETgt$ ABA3 @/GENETgt$ , it is decomposed more efficiently than @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ .	4 4 4 16 9 9 9 9 4 11 9|10 9 9|10 16 16 16 16 18 16 20 18 18 18 16	SUBSTRATE
15561708	CHEMICAL	GENE	T11	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ AtNFS1 @/GENETgt$ ? [SEP] Besides mitochondrial @GENETgt$ AtNFS1 @/GENETgt$ and plastidial AtNFS2 , which are both proposed to be involved in iron-sulfur cluster formation , ABA3 is proposed to be a third and cytosolic NifS-like @CHEMICALSrc$ cysteine @/CHEMICALSrc$ desulfurase in A. thaliana .	3 3 2|23 23 2|23 3 7 3 7 12 12 12 3 15 15 12 19 19 19 15 23 23 23 23 27 27 27 23 27 27 33 33|29 33 33|29 27 36 36 27 23	None-BC7
15561708	CHEMICAL	GENE	T18	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ l-alanine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] @GENETgt$ ABA3 @/GENETgt$ is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition of l-cysteine to @CHEMICALSrc$ l-alanine @/CHEMICALSrc$ and elemental sulfur for iron-sulfur cluster synthesis .	0|6 6 0|6 6 6 6 6 10 10 10 6 10 13 11 16 16 11 18 16 20 18 22 20 24 20|22 20 20|22 24 28 24 32 32 32 20 6	None-BC7
15561708	CHEMICAL	GENE	T21	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] @GENETgt$ ABA3 @/GENETgt$ is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental sulfur for @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster synthesis .	0|6 6 0|6 6 6 6 6 10 10 10 6 10 13 11 16 16 11 18 16 20 18 22 20 24 20 24 27 24 32 32|27 32 32|27 32 20 6	None-BC7
15561708	CHEMICAL	GENE	T19	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|6 6 1|6 5 6 4|12 12 4|12 10 10 6 12 12 14 12 18 18 18 14 20 18 20 23 20 25 12 28 28 25 31 31 25 34 34 31 12	None-BC7
15561708	CHEMICAL	GENE	T7	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|2|6 1|2|6 1|2|6 2|6 1|2|6 11 9 9 6 11 11 13 11 17 17 17 13 20|14 20 20|14 17 20 23 20 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T4	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In addition to its @CHEMICALSrc$ cysteine @/CHEMICALSrc$ desulfurase activity , @GENETgt$ ABA3-NifS @/GENETgt$ also exhibits selenocysteine lyase activity .	2 13 8 8 8|4 8 8|4 8 2 13 8|13 13 8|13 13 13 16 16 13 13	None-BC7
15561708	CHEMICAL	GENE	T19	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] The @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|6 6 1|6 5 6 11 9 9 6 11 11 13 11 17 17 17 13 19 17 19 19|21 19|21 19|21 19|21 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T1	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ in the absence of the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 11 9 11 11|12|13 11|12|13 11|13 11|12|13 18 18 9 23 23 18|23 23 18|23 18 9 9 27 33 33 31 31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T1	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of @GENETgt$ ABA3 @/GENETgt$ activates aldehyde oxidase and xanthine dehydrogenase in the absence of the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 6 6 10 8 6|7 6 6|7 10 12 10 12 15 12 18 18 10 23 23 19|23 23 19|23 18 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T15	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfo @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the @CHEMICALSrc$ sulfo-form @/CHEMICALSrc$ .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 16|17 16|17 16|17 16|17 17 22 17 24 10 27 27 24 30 30 24 33 33 30 30 30 10	None-BC7
15561708	CHEMICAL	GENE	T27	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ NifS-like domain @/GENETgt$ ? [SEP] In vitro , the @GENETgt$ NifS-like domain @/GENETgt$ of ABA3 activates @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and xanthine dehydrogenase in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 5 10|4|5 10|4|5 10|5 10|4|5 9 5 10 8|13 13 8|13 10 13 16 13 19 19 10 23 23 23 19 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T15	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfo @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ by converting their molybdenum cofactor from the desulfo-form into the @CHEMICALSrc$ sulfo-form @/CHEMICALSrc$ .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 18 16 18 18|19|20 18|19|20 18|20 18|19|20 24 10 27 27 24 30 30 24 33 33 30 30 30 10	None-BC7
15561708	CHEMICAL	GENE	T9	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ cytosolic NifS-like cysteine desulfurase @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial AtNFS2 , which are both proposed to be involved in @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster formation , ABA3 is proposed to be a third and @GENETgt$ cytosolic NifS-like cysteine desulfurase @/GENETgt$ in A. thaliana .	3 3 23 3 6 3 6 11 11 11 3 14 14 11 19 19|15 19 19|15 19 14 23 23 23 23 27 27 27 23 27 27|29 27|29 27|29 27|29 27|29 27|29 36 36 27 23	None-BC7
15561708	CHEMICAL	GENE	T7	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @CHEMICALSrc$ aldehyde @/CHEMICALSrc$ oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 11|4 11 11|4 9 9 5 11 11 13 11 17 17 17 13 16|20 20 16|20 17 20 23 20 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T15	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfo @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase @GENETgt$ ABA3 @/GENETgt$ from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the @CHEMICALSrc$ sulfo-form @/CHEMICALSrc$ .	5 5 4 5 11|4 11 11|4 9 9 5 11 11 13 11 17 17 17 13 19 17 19 22 19 24 11 27 27 24 30 30 24 33 33 30|31 30 30|31 11	None-BC7
15561708	CHEMICAL	GENE	T28	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ NifS-like domain @/GENETgt$ ? [SEP] In vitro , the @GENETgt$ NifS-like domain @/GENETgt$ of ABA3 activates aldehyde oxidase and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 5 10|4|5 10|4|5 10|5 10|4|5 9 5 10 12 10 12 16|11 16 16|11 12 19 19 10 23 23 23 19 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @GENETgt$ aldehyde oxidase @/GENETgt$ and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 16|17 16|17 16|17 16|17 17 18|23 23 18|23 17 25 10 28 28 25 31 31 25 34 34 31 10	None-BC7
15561708	CHEMICAL	GENE	T21	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to @GENETgt$ NifS @/GENETgt$ proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental sulfur for @CHEMICALSrc$ iron-sulfur @/CHEMICALSrc$ cluster synthesis .	5 5 5 5 5 9 9 9 5 9 12 10 16 16|13 16 16|13 10 18 16 20 18 22 20 24 20 24 27 24 32 32|27 32 32|27 32 20 5	PRODUCT-OF
15561708	CHEMICAL	GENE	T17	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to @GENETgt$ NifS @/GENETgt$ proteins that catalyze the decomposition of @CHEMICALSrc$ l-cysteine @/CHEMICALSrc$ to l-alanine and elemental sulfur for iron-sulfur cluster synthesis .	5 5 5 5 5 9 9 9 5 9 12 10 16 16|13 16 16|13 10 18 16 20 18 22 20 20 20 25 20 25 28 25 32 32 32 20 5	SUBSTRATE
15561708	CHEMICAL	GENE	T19	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] The @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|6 6 1|6 5 6 11 9 9 6 11 11 13 11 17 17 17 13 16|17|18 16|17|18 17|18 16|17|18 18 23 18 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T12	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] However , the sulfur transferase activity of @GENETgt$ ABA3 @/GENETgt$ is used for post-translational activation of @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ enzymes rather than for iron-sulfur cluster assembly .	11 11 6 6 6 11 8 6|7 6 6|7 11 11 14 14 11 18 18|14 18 18|14 14 14 19 24 24 24 14 11	None-BC7
15561708	CHEMICAL	GENE	T16	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ NH2 @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] ABA3 is a two-domain protein with an @CHEMICALSrc$ NH2-terminal @/CHEMICALSrc$ domain sharing significant similarities to @GENETgt$ NifS @/GENETgt$ proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental sulfur for iron-sulfur cluster synthesis .	5 5 5 5 5 10 10 10|7 10 10|7 5 10 13 11 17 17|13 17 17|13 11 19 17 21 19 23 21 25 21 25 28 25 32 32 32 21 5	PART-OF
15561708	CHEMICAL	GENE	T10	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ? [SEP] The @GENETgt$ molybdenum cofactor sulfurase @/GENETgt$ ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form .	6 1|2|6 1|2|6 1|2|6 2|6 1|2|6 11 9 9 6 11 11 13 11 17 17 17 13 19 17 19 17|23 23 17|23 19 25 11 28 28 25 31 31 25 34 34 31 11	None-BC7
15561708	CHEMICAL	GENE	T14	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ and @GENETgt$ xanthine dehydrogenase @/GENETgt$ ? [SEP] The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and @GENETgt$ xanthine dehydrogenase @/GENETgt$ by converting their @CHEMICALSrc$ molybdenum @/CHEMICALSrc$ cofactor from the desulfo-form into the sulfo-form .	5 5 4 5 10 8 8 5 10 10 12 10 16 16 16 12 18 16 18 18|19|20 18|19|20 18|20 18|19|20 24 10 28 28|23 28 28|23 24 31 31 24 34 34 31 10	None-BC7
15561708	CHEMICAL	GENE	T28	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ xanthine @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates @GENETgt$ aldehyde oxidase @/GENETgt$ and @CHEMICALSrc$ xanthine @/CHEMICALSrc$ dehydrogenase in the absence of the C-terminal domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 9|10 9|10 9|10 9|10 10 16|11 16 16|11 10 19 19 9 23 23 23 19 9 9 27 33 33 31 31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T11	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ cysteine @/CHEMICALSrc$ and @GENETgt$ ABA3 @/GENETgt$ ? [SEP] Besides mitochondrial AtNFS1 and plastidial AtNFS2 , which are both proposed to be involved in iron-sulfur cluster formation , @GENETgt$ ABA3 @/GENETgt$ is proposed to be a third and cytosolic NifS-like @CHEMICALSrc$ cysteine @/CHEMICALSrc$ desulfurase in A. thaliana .	3 3 23 3 6 3 6 11 11 11 3 14 14 11 18 18 18 14 23 19|23 23 19|23 23 23 27 27 27 23 27 27 33 33|29 33 33|29 27 36 36 27 23	None-BC7
15561708	CHEMICAL	GENE	T2	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ aldehyde oxidase @/GENETgt$ ? [SEP] In vitro , the NifS-like domain of ABA3 activates @GENETgt$ aldehyde oxidase @/GENETgt$ and xanthine dehydrogenase in the absence of the C-terminal domain , but in vivo , the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain is required for proper activation of both target enzymes .	2 9 9 6 6 9 8 6 9 9|10 9|10 9|10 9|10 10 15 10 18 18 9 22 22 22 18 9 9 26 33 33 31 26|31 31 26|31 33 33 9 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T1	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ C @/CHEMICALSrc$ and @GENETgt$ NifS-like domain @/GENETgt$ ? [SEP] In vitro , the @GENETgt$ NifS-like domain @/GENETgt$ of ABA3 activates aldehyde oxidase and xanthine dehydrogenase in the absence of the @CHEMICALSrc$ C-terminal @/CHEMICALSrc$ domain , but in vivo , the C-terminal domain is required for proper activation of both target enzymes .	2 10 10 5 10|4|5 10|4|5 10|5 10|4|5 9 5 10 12 10 12 15 12 18 18 10 23 23 18|23 23 18|23 18 10 10 27 33 33 31 31 33 33 10 36 36 33 40 40 40 36 33	None-BC7
15561708	CHEMICAL	GENE	T20	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ sulfur @/CHEMICALSrc$ and @GENETgt$ NifS @/GENETgt$ ? [SEP] ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to @GENETgt$ NifS @/GENETgt$ proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental @CHEMICALSrc$ sulfur @/CHEMICALSrc$ for iron-sulfur cluster synthesis .	5 5 5 5 5 9 9 9 5 9 12 10 16 16|13 16 16|13 10 18 16 20 18 22 20 24 20 24 27 24|25 24 24|25 32 32 32 20 5	SUBSTRATE
7911719	CHEMICAL	GENE	T20	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Following inactivation of @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ by @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ treatment , alpha lA-adrenoceptors can fully compensate and mediate inotropic effects by promoting influx of extracellular Ca2 + at least partly via voltage-operated channels .	2 16 4 2|3|4 2|3|4 2|4 2|3|4 10 10|5 10 10|5 2 16 13 16 16 16 16 16 16 20 18 22 18 22 26 26 23 23 29 30 23 33 33 22 16	INHIBITOR
7911719	CHEMICAL	GENE	T22	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptor @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ did not affect the maximal beta-adrenoceptor-mediated inotropic effects in rat right ventricle or the maximal @GENETgt$ alpha 1A-adrenoceptor-mediated @/GENETgt$ contractile effects in rat vas deferens ; it did not alter the potency of isoprenaline in the ventricle and reduced the potency of the alpha-adrenoceptor antagonists in vas deferens only slightly .	7 3 1|2 1 1|2 7 7 7 12 12 12 12 7 16 16 16 12 16 24 24 24|18|20 24|18|20 24|20 24|18|20 24 16 28 28 28 16 7 33 33 33 7 35 33 37 35 40 40 35 33 33 44 42 48 48 48 44 51 51 44 53 42 7	None-BC7
7911719	CHEMICAL	GENE	T20	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha lA-adrenoceptors @/GENETgt$ ? [SEP] Following inactivation of alpha 1B-adrenoceptors by @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ treatment , @GENETgt$ alpha lA-adrenoceptors @/GENETgt$ can fully compensate and mediate inotropic effects by promoting influx of extracellular Ca2 + at least partly via voltage-operated channels .	2 16 5 5 2 9 9|6 9 9|6 2 16 16|9|11 16|9|11 16|11 16|9|11 16 16 16 16 16 20 18 22 18 22 26 26 23 23 29 30 23 33 33 22 16	None-BC7
7911719	CHEMICAL	GENE	T18	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] 6 . We conclude that inotropic effects of @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ in rat heart are mediated mainly by @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ via release of Ca2 + from an intracellular pool .	1 1 4 4 15 7 15 9 8|7 7 8|7 13 13 7 15 4 15 18 16|18|15 16|18|15 18|15 16|18|15 22 15 24 22 22 29 29 29 22 4	None-BC7
7911719	CHEMICAL	GENE	T7	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of 5-methyl-urapidil inhibition experiments in chloroethylclonidine-treated ventricles indicated that only @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ mediate the inotropic effects of @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ following inactivation of the alpha 1B-adrenoceptors .	2 10 6 6 6 2 9 9 6 10 16 13 16|12|13 16|12|13 16|13 16|12|13 10 19 19 16 21 18|19 19 18|19 24 19 28 28 28 24 10	None-BC7
7911719	CHEMICAL	GENE	T23	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ and @GENETgt$ beta-adrenoceptor @/GENETgt$ ? [SEP] Treatment with chloroethylclonidine did not affect the maximal @GENETgt$ beta-adrenoceptor-mediated @/GENETgt$ inotropic effects in rat right ventricle or the maximal alpha 1A-adrenoceptor-mediated contractile effects in rat vas deferens ; it did not alter the potency of @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ in the ventricle and reduced the potency of the alpha-adrenoceptor antagonists in vas deferens only slightly .	6 3 1 6 6 6 12 12 8|12 12 8|12 12 6 16 16 16 12 16 23 23 21 23 23 16 27 27 27 16 6 32 32 32 6 34 32 36 34 34 34 40 40 34 32 32 44 42 48 48 48 44 51 51 44 53 42 6	None-BC7
7911719	CHEMICAL	GENE	T6	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of 5-methyl-urapidil inhibition experiments in @CHEMICALSrc$ chloroethylclonidine-treated @/CHEMICALSrc$ ventricles indicated that only alpha 1A-adrenoceptors mediate the inotropic effects of adrenaline following inactivation of the @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ .	2 11 6 6 6 2 10 10|7 10 10|7 6 11 16 15 15 16 11 19 19 16 21 19 23 19 26 26 24|26|23 24|26|23 26|23 24|26|23 11	INHIBITOR
7911719	CHEMICAL	GENE	T23	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ and @GENETgt$ alpha-adrenoceptor @/GENETgt$ ? [SEP] Treatment with chloroethylclonidine did not affect the maximal beta-adrenoceptor-mediated inotropic effects in rat right ventricle or the maximal alpha 1A-adrenoceptor-mediated contractile effects in rat vas deferens ; it did not alter the potency of @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ in the ventricle and reduced the potency of the @GENETgt$ alpha-adrenoceptor @/GENETgt$ antagonists in vas deferens only slightly .	6 3 1 6 6 6 11 11 11 11 6 15 15 15 11 15 22 22 20 22 22 15 26 26 26 15 6 31 31 31 6 33 31 35 33|34 33 33|34 39 39 33 31 31 43 41 48 48 48|44 48 48|44 43 51 51 43 53 41 6	None-BC7
7911719	CHEMICAL	GENE	T21	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ Ca2+ @/CHEMICALSrc$ and @GENETgt$ voltage-operated channels @/GENETgt$ ? [SEP] Following inactivation of alpha 1B-adrenoceptors by chloroethylclonidine treatment , alpha lA-adrenoceptors can fully compensate and mediate inotropic effects by promoting influx of extracellular @CHEMICALSrc$ Ca2 + @/CHEMICALSrc$ at least partly via @GENETgt$ voltage-operated channels @/GENETgt$ .	2 14 5 5 2 8 8 2 14 11 14 14 14 14 14 14 18 16 20 16 20 24 24 21|23 21|23 21 21|23 28 29 21 31 28|20|31 28|20|31 20|31 28|20|31 14	SUBSTRATE
7911719	CHEMICAL	GENE	T22	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ beta-adrenoceptor @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ did not affect the maximal @GENETgt$ beta-adrenoceptor-mediated @/GENETgt$ inotropic effects in rat right ventricle or the maximal alpha 1A-adrenoceptor-mediated contractile effects in rat vas deferens ; it did not alter the potency of isoprenaline in the ventricle and reduced the potency of the alpha-adrenoceptor antagonists in vas deferens only slightly .	7 3 1|2 1 1|2 7 7 7 13 13 8|13 13 8|13 13 7 17 17 17 13 17 24 24 22 24 24 17 28 28 28 17 7 33 33 33 7 35 33 37 35 40 40 35 33 33 44 42 48 48 48 44 51 51 44 53 42 7	None-BC7
7911719	CHEMICAL	GENE	T1	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the @GENETgt$ alpha 1A-adrenoceptor-selective @/GENETgt$ antagonists , @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and (+/-)-tamsulosin , demonstrated that adrenaline causes its inotropic effects mainly via the alpha 1B-adrenoceptor subtype .	1 1 4 20 7 7 4 13 13 9|13 9|13 13 9|13 7 13 12|13 13 12|13 15 15 20 20 23 23 20 26 26 23 23 32 32 32 32 23 20	ANTAGONIST
7911719	CHEMICAL	GENE	T28	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Inactivation of cardiac @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ by treatment with chloroethylclonidine slightly enhanced the maximal inotropic effects of the full agonist , @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and of several partial agonists .	12 4 4 1|3|4 1|3|4 1|4 1|3|4 8 1 10 8 12 12 16 16 16 12 20 20 20 16 20 19|20 20 19|20 20 28 28 28 20 12	AGONIST-ACTIVATOR
7911719	CHEMICAL	GENE	T21	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ Ca2+ @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Following inactivation of @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ by chloroethylclonidine treatment , alpha lA-adrenoceptors can fully compensate and mediate inotropic effects by promoting influx of extracellular @CHEMICALSrc$ Ca2 + @/CHEMICALSrc$ at least partly via voltage-operated channels .	2 15 4 2|3|4 2|3|4 2|4 2|3|4 9 9 2 15 12 15 15 15 15 15 15 19 17 21 17 21 25 25 22 22 22 22 29 30 22 33 33 21 15	None-BC7
7911719	CHEMICAL	GENE	T3	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the alpha 1A-adrenoceptor-selective antagonists , 5-methyl-urapidil and (+/-)-tamsulosin , demonstrated that @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ causes its inotropic effects mainly via the @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ subtype .	1 1 4 18 7 7 4 12 12 12 12 7 12 12 14 14 18 18 22 19|22 22 19|22 18 25 25 22 22 32 32 32|27 32|27 32 32|27 22 18	None-BC7
7911719	CHEMICAL	GENE	T6	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of 5-methyl-urapidil inhibition experiments in @CHEMICALSrc$ chloroethylclonidine-treated @/CHEMICALSrc$ ventricles indicated that only @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ mediate the inotropic effects of adrenaline following inactivation of the alpha 1B-adrenoceptors .	2 11 6 6 6 2 10 10|7 10 10|7 6 11 17 14 17|12|14 17|12|14 17|14 17|12|14 11 20 20 17 22 20 24 20 28 28 28 24 11	None-BC7
7911719	CHEMICAL	GENE	T5	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ inhibition experiments in chloroethylclonidine-treated ventricles indicated that only alpha 1A-adrenoceptors mediate the inotropic effects of adrenaline following inactivation of the @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ .	2 11 7 3|7 7 3|7 7 2 10 10 7 11 16 15 15 16 11 19 19 16 21 19 23 19 26 26 24|26|23 24|26|23 26|23 24|26|23 11	None-BC7
7911719	CHEMICAL	GENE	T22	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha-adrenoceptor @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ did not affect the maximal beta-adrenoceptor-mediated inotropic effects in rat right ventricle or the maximal alpha 1A-adrenoceptor-mediated contractile effects in rat vas deferens ; it did not alter the potency of isoprenaline in the ventricle and reduced the potency of the @GENETgt$ alpha-adrenoceptor @/GENETgt$ antagonists in vas deferens only slightly .	7 3 1|2 1 1|2 7 7 7 12 12 12 12 7 16 16 16 12 16 23 23 21 23 23 16 27 27 27 16 7 32 32 32 7 34 32 36 34 39 39 34 32 32 43 41 48 48 48|44 48 48|44 43 51 51 43 53 41 7	None-BC7
7911719	CHEMICAL	GENE	T7	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of 5-methyl-urapidil inhibition experiments in chloroethylclonidine-treated ventricles indicated that only alpha 1A-adrenoceptors mediate the inotropic effects of @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ following inactivation of the @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ .	2 10 6 6 6 2 9 9 6 10 15 14 14 15 10 18 18 15 20 18|19 18 18|19 23 18 26 26 24|26|23 24|26|23 26|23 24|26|23 10	None-BC7
7911719	CHEMICAL	GENE	T19	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Ca2+ @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] 6 . We conclude that inotropic effects of adrenaline in rat heart are mediated mainly by @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ via release of @CHEMICALSrc$ Ca2 + @/CHEMICALSrc$ from an intracellular pool .	1 1 4 4 14 7 14 9 7 12 12 7 14 4 14 17 16|17|14 16|17|14 17|14 16|17|14 21 14 23 20|21 20|21 21 20|21 29 29 29 21 4	None-BC7
7911719	CHEMICAL	GENE	T4	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ Ca2+ @/CHEMICALSrc$ and @GENETgt$ alpha 1-adrenoceptor @/GENETgt$ ? [SEP] 1 . We have studied the @GENETgt$ alpha 1-adrenoceptor @/GENETgt$ subtypes mediating inotropic effects of adrenaline in rat right ventricle and the @CHEMICALSrc$ Ca2 + @/CHEMICALSrc$ sources used to elicit these effects .	5 1 5 5 5 10 10|6 10|6 10 10|6 5 10 13 11 15 13 19 19 19 13 13 22 19|13|22 19|13|22 13|22 19|13|22 22 5 28 26 30 28 5	None-BC7
7911719	CHEMICAL	GENE	T21	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Ca2+ @/CHEMICALSrc$ and @GENETgt$ alpha lA-adrenoceptors @/GENETgt$ ? [SEP] Following inactivation of alpha 1B-adrenoceptors by chloroethylclonidine treatment , @GENETgt$ alpha lA-adrenoceptors @/GENETgt$ can fully compensate and mediate inotropic effects by promoting influx of extracellular @CHEMICALSrc$ Ca2 + @/CHEMICALSrc$ at least partly via voltage-operated channels .	2 15 5 5 2 8 8 2 15 9|10|15 9|10|15 10|15 9|10|15 15 15 15 15 15 19 17 21 17 21 25 25 22 22 22 22 29 30 22 33 33 21 15	None-BC7
7911719	CHEMICAL	GENE	T2	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ (+/-)-tamsulosin @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the @GENETgt$ alpha 1A-adrenoceptor-selective @/GENETgt$ antagonists , 5-methyl-urapidil and @CHEMICALSrc$ (+/-)-tamsulosin @/CHEMICALSrc$ , demonstrated that adrenaline causes its inotropic effects mainly via the alpha 1B-adrenoceptor subtype .	1 1 4 20 7 7 4 13 13 9|13 9|13 13 9|13 7 13 13 15 14|15 15 14|15 20 20 23 23 20 26 26 23 23 32 32 32 32 23 20	ANTAGONIST
7911719	CHEMICAL	GENE	T23	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptor @/GENETgt$ ? [SEP] Treatment with chloroethylclonidine did not affect the maximal beta-adrenoceptor-mediated inotropic effects in rat right ventricle or the maximal @GENETgt$ alpha 1A-adrenoceptor-mediated @/GENETgt$ contractile effects in rat vas deferens ; it did not alter the potency of @CHEMICALSrc$ isoprenaline @/CHEMICALSrc$ in the ventricle and reduced the potency of the alpha-adrenoceptor antagonists in vas deferens only slightly .	6 3 1 6 6 6 11 11 11 11 6 15 15 15 11 15 23 23 18|19|23 18|19|23 19|23 18|19|23 23 15 27 27 27 15 6 32 32 32 6 34 32 36 33|34 34 33|34 40 40 34 32 32 44 42 48 48 48 44 51 51 44 53 42 6	None-BC7
7911719	CHEMICAL	GENE	T5	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ ? [SEP] Schild analysis of @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ inhibition experiments in chloroethylclonidine-treated ventricles indicated that only @GENETgt$ alpha 1A-adrenoceptors @/GENETgt$ mediate the inotropic effects of adrenaline following inactivation of the alpha 1B-adrenoceptors .	2 11 7 3|7 7 3|7 7 2 10 10 7 11 17 14 17|12|14 17|12|14 17|14 17|12|14 11 20 20 17 22 20 24 20 28 28 28 24 11	INHIBITOR
7911719	CHEMICAL	GENE	T27	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ ? [SEP] Inactivation of cardiac @GENETgt$ alpha 1B-adrenoceptors @/GENETgt$ by treatment with @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ slightly enhanced the maximal inotropic effects of the full agonist , adrenaline and of several partial agonists .	13 4 4 1|3|4 1|3|4 1|4 1|3|4 8 1 10 8|7 8 8|7 13 13 17 17 17 13 21 21 21 17 21 21 21 28 28 28 21 13	INHIBITOR
7911719	CHEMICAL	GENE	T20	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ and @GENETgt$ voltage-operated channels @/GENETgt$ ? [SEP] Following inactivation of alpha 1B-adrenoceptors by @CHEMICALSrc$ chloroethylclonidine @/CHEMICALSrc$ treatment , alpha lA-adrenoceptors can fully compensate and mediate inotropic effects by promoting influx of extracellular Ca2 + at least partly via @GENETgt$ voltage-operated channels @/GENETgt$ .	2 15 5 5 2 9 9|6 9 9|6 2 15 12 15 15 15 15 15 15 19 17 21 17 21 25 25 22 22 28 29 22 31 21|29|31 21|29|31 21|31 21|29|31 15	None-BC7
7911719	CHEMICAL	GENE	T3	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1A-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the @GENETgt$ alpha 1A-adrenoceptor-selective @/GENETgt$ antagonists , 5-methyl-urapidil and (+/-)-tamsulosin , demonstrated that @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ causes its inotropic effects mainly via the alpha 1B-adrenoceptor subtype .	1 1 4 19 7 7 4 13 13 9|13 9|13 13 9|13 7 13 13 15 15 19 19 23 18|23 23 18|23 19 26 26 23 23 32 32 32 32 23 19	None-BC7
7911719	CHEMICAL	GENE	T2	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ (+/-)-tamsulosin @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the alpha 1A-adrenoceptor-selective antagonists , 5-methyl-urapidil and @CHEMICALSrc$ (+/-)-tamsulosin @/CHEMICALSrc$ , demonstrated that adrenaline causes its inotropic effects mainly via the @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ subtype .	1 1 4 19 7 7 4 12 12 12 12 7 12 12 14 14|15 14 14|15 19 19 22 22 19 25 25 22 22 32 32 32|27 32|27 32 32|27 22 19	None-BC7
7911719	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ ? [SEP] 4 . Schild analysis of inhibition experiments with the alpha 1A-adrenoceptor-selective antagonists , @CHEMICALSrc$ 5-methyl-urapidil @/CHEMICALSrc$ and (+/-)-tamsulosin , demonstrated that adrenaline causes its inotropic effects mainly via the @GENETgt$ alpha 1B-adrenoceptor @/GENETgt$ subtype .	1 1 4 19 7 7 4 12 12 12 12 7 12 12|13 12 12|13 14 14 19 19 22 22 19 25 25 22 22 32 32 32|27 32|27 32 32|27 22 19	None-BC7
7911719	CHEMICAL	GENE	T26	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ and @GENETgt$ alpha 1-adrenoceptor @/GENETgt$ ? [SEP] 1 . We have studied the @GENETgt$ alpha 1-adrenoceptor @/GENETgt$ subtypes mediating inotropic effects of @CHEMICALSrc$ adrenaline @/CHEMICALSrc$ in rat right ventricle and the Ca2 + sources used to elicit these effects .	5 1 5 5 5 10 10|6 10|6 10 10|6 5 10 13 11 15 12|13 13 12|13 20 20 20 13 13 23 13 23 23 5 28 26 30 28 5	None-BC7
17372252	CHEMICAL	GENE	T2	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ NQO1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , @GENETgt$ NQO1 @/GENETgt$ , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9|12 9 9|12 9 9 9 9 9 9 9 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T1	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ and @GENETgt$ GSTM3 @/GENETgt$ ? [SEP] BACKGROUND : @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ transferases ( GST ) detoxify environmental and endogenous compounds and levels of two polymorphic GST proteins , @GENETgt$ GSTM3 @/GENETgt$ and GSTP1 , are high in the brain .	28 1 2|5 5 2|5 9 7 5 7 1 9 10 10 10 10 10 20 20 20 20 10 20 20 20 20 22 22 1 28 28 31 31 28 28	None-BC7
17372252	CHEMICAL	GENE	T2	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTP1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) @GENETgt$ GSTP1 @/GENETgt$ 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 25 9 9 30 30 30 6 34 34 34 30 45 45 45 39 45|38 45 45|38 45 40|45 45 40|45 45 34 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	PART-OF
17372252	CHEMICAL	GENE	T2	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ CYP1A1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , @GENETgt$ CYP1A1 @/GENETgt$ , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9|14 9 9|14 9 9 9 9 9 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] BACKGROUND : @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ transferases ( @GENETgt$ GST @/GENETgt$ ) detoxify environmental and endogenous compounds and levels of two polymorphic GST proteins , GSTM3 and GSTP1 , are high in the brain .	28 1 2|5 5 2|5 10 7 5 5 5 7 1 10 11 11 11 11 11 21 21 21 21 11 21 21 23 23 1 28 28 31 31 28 28	None-BC7
17372252	CHEMICAL	GENE	T2	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTM3 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the @GENETgt$ GSTM3 @/GENETgt$ , GSTP1 , NQO1 , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 8|6 6 8|6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTM1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , CYP1A1 , @GENETgt$ GSTM1 @/GENETgt$ , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9 9 16|9 9 16|9 9 9 9 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T1	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ and @GENETgt$ GSTP1 @/GENETgt$ ? [SEP] BACKGROUND : @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ transferases ( GST ) detoxify environmental and endogenous compounds and levels of two polymorphic GST proteins , GSTM3 and @GENETgt$ GSTP1 @/GENETgt$ , are high in the brain .	28 1 2|5 5 2|5 9 7 5 7 1 9 10 10 10 10 10 20 20 20 20 10 20 20 22 22 22 22 1 28 28 31 31 28 28	None-BC7
17372252	CHEMICAL	GENE	T2	T5	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTP1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , @GENETgt$ GSTP1 @/GENETgt$ , NQO1 , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9|10 9 9|10 9 9 9 9 9 9 9 9 9 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T2	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTT1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , CYP1A1 , GSTM1 , or @GENETgt$ GSTT1 @/GENETgt$ polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9 9 9 9 9 9|19 9 9|19 9 9 9 26 9 9 31 31 31 6 35 35 35 31 45 45 45 40 45|38 45 45|38 45 45 45 35 45 45 50 50 45 52 50 52 50 4 55 60 60 60 55 64 63 64 60 64 60 69 67 60 60 4 4 76 73 76 4 79 79 76 82 82 79 82 82 82 82 82 82 4	None-BC7
17372252	CHEMICAL	GENE	T1	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] BACKGROUND : @CHEMICALSrc$ Glutathione @/CHEMICALSrc$ transferases ( GST ) detoxify environmental and endogenous compounds and levels of two polymorphic @GENETgt$ GST @/GENETgt$ proteins , GSTM3 and GSTP1 , are high in the brain .	28 1 2|5 5 2|5 9 7 5 7 1 9 10 10 10 10 10 21 21 21 17|21 21 17|21 10 21 21 23 23 1 28 28 31 31 28 28	None-BC7
17372252	CHEMICAL	GENE	T2	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTP1 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the GSTM3 or @GENETgt$ GSTP1 @/GENETgt$ polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 25 9 9 30 30 30 6 34 34 34 30 44 44 44 39 44|38 44 44|38 44 44 44 34 44 44 49 49 44 51 49 51 49 4 54 59 59 59 54 63 62 63 59 63 59 68 66 59 59 4 4 75 72 75 4 78 78 75 81 81 78 81 81 81 81 81 81 81 81 4	None-BC7
17372252	CHEMICAL	GENE	T2	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ and @GENETgt$ GSTM3 @/GENETgt$ ? [SEP] RESULTS : We found no associations between the GSTM3 , GSTP1 , NQO1 , CYP1A1 , GSTM1 , or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C ( @CHEMICALSrc$ Val-Ala @/CHEMICALSrc$ ) GSTP1 105/114 haplotype and glioma [ odds ratio ( OR ) , 0.73 ; 95 % confidence interval ( 95 % CI ) , 0.54 , 0.99 ] , nor was there an interaction between the effects of the @GENETgt$ GSTM3 @/GENETgt$ or GSTP1 polymorphisms and cigarette smoking .	1 1 4 1 6 4 9 9 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 25 9 9 30 30 30 6 34 34 34 30 44 44 44 39 44|38 44 44|38 44 44 44 34 44 44 49 49 44 51 49 51 49 4 54 59 59 59 54 63 62 63 59 63 59 68 66 59 59 4 4 75 72 75 4 78 78 75 81 81 78|79 78 78|79 81 81 81 81 81 81 4	None-BC7
23086035	CHEMICAL	GENE	T1	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ PGC-1α @/GENETgt$ ? [SEP] We show that elevated @GENETgt$ PGC-1α @/GENETgt$ in combination with exercise preferentially improves @CHEMICALSrc$ glucose @/CHEMICALSrc$ homeostasis , increases Krebs cycle activity , and reduces the levels of acylcarnitines and sphingosine .	2 2 12 5 4|12 12 4|12 8 5 10 8 12 2 11|15 15 11|15 12 17 2 20 20 17 17 17 17 25 23 27 25 27 27 2	None-BC7
23086035	CHEMICAL	GENE	T3	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ sphingosine @/CHEMICALSrc$ and @GENETgt$ PGC-1α @/GENETgt$ ? [SEP] We show that elevated @GENETgt$ PGC-1α @/GENETgt$ in combination with exercise preferentially improves glucose homeostasis , increases Krebs cycle activity , and reduces the levels of acylcarnitines and @CHEMICALSrc$ sphingosine @/CHEMICALSrc$ .	2 2 12 5 4|12 12 4|12 8 5 10 8 12 2 14 12 16 2 19 19 16 16 16 16 24 22 26 24 26 26 26 26 2	None-BC7
23086035	CHEMICAL	GENE	T4	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ PGC-1α @/GENETgt$ ? [SEP] @GENETgt$ PGC-1α @/GENETgt$ improves @CHEMICALSrc$ glucose @/CHEMICALSrc$ homeostasis in skeletal muscle in an activity-dependent manner .	0|3 3 0|3 3 2|6 6 2|6 3 9 9 3 13 13 13 3 3	None-BC7
23086035	CHEMICAL	GENE	T2	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ acylcarnitines @/CHEMICALSrc$ and @GENETgt$ PGC-1α @/GENETgt$ ? [SEP] We show that elevated @GENETgt$ PGC-1α @/GENETgt$ in combination with exercise preferentially improves glucose homeostasis , increases Krebs cycle activity , and reduces the levels of @CHEMICALSrc$ acylcarnitines @/CHEMICALSrc$ and sphingosine .	2 2 12 5 4|12 12 4|12 8 5 10 8 12 2 14 12 16 2 19 19 16 16 16 16 24 22 26 24 24 24 26 26 2	None-BC7
22424117	CHEMICAL	GENE	T8	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and @GENETgt$ butyrylcholinesterase @/GENETgt$ ? [SEP] Moreover , their inhibitory potential was also screened against three enzymes , namely @CHEMICALSrc$ acetyl @/CHEMICALSrc$ cholinesterase , @GENETgt$ butyrylcholinesterase @/GENETgt$ and lipoxygenase .	8 8 5 5 8 8 8 8 11 11 8 11 16 16|13 16 16|13 11 16 16 16 16 18 18 8	None-BC7
22424117	CHEMICAL	GENE	T9	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ and @GENETgt$ lipoxygenase @/GENETgt$ ? [SEP] These @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ were found to be inactive against acetyl and butyrylcholinesterases but active against @GENETgt$ lipoxygenase @/GENETgt$ .	2 1|2|6 1|2|6 2|6 1|2|6 6 6 9 9 6 11 9 11 11 9 9 17 14|15 15 14|15 6	None-BC7
22424117	CHEMICAL	GENE	T10	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and @GENETgt$ butyrylcholinesterases @/GENETgt$ ? [SEP] These iridoid glucosides were found to be inactive against @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and @GENETgt$ butyrylcholinesterases @/GENETgt$ but active against lipoxygenase .	3 3 5 5 5 8 8 5 10 8|9 8 8|9 10 10|11 10 10|11 8 8 18 16 5	None-BC7
22424117	CHEMICAL	GENE	T11	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ and @GENETgt$ lipoxygenase @/GENETgt$ ? [SEP] Antioxidant and @GENETgt$ lipoxygenase @/GENETgt$ inhibiting new @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ from Caryopteris odorata .	1 1 1|2 1 1|2 1 7 5|7 5|7 5|7 5|7 12 12 5 1	None-BC7
22424117	CHEMICAL	GENE	T9	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ and @GENETgt$ butyrylcholinesterases @/GENETgt$ ? [SEP] These @CHEMICALSrc$ iridoid glucosides @/CHEMICALSrc$ were found to be inactive against acetyl and @GENETgt$ butyrylcholinesterases @/GENETgt$ but active against lipoxygenase .	2 1|2|6 1|2|6 2|6 1|2|6 6 6 9 9 6 11 9 11 10|11 11 10|11 9 9 18 16 6	None-BC7
22424117	CHEMICAL	GENE	T8	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and @GENETgt$ lipoxygenase @/GENETgt$ ? [SEP] Moreover , their inhibitory potential was also screened against three enzymes , namely @CHEMICALSrc$ acetyl @/CHEMICALSrc$ cholinesterase , butyrylcholinesterase and @GENETgt$ lipoxygenase @/GENETgt$ .	8 8 5 5 8 8 8 8 11 11 8 11 16 16|13 16 16|13 11 16 16 18 18 18 18 8	None-BC7
22424117	CHEMICAL	GENE	T10	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and @GENETgt$ lipoxygenase @/GENETgt$ ? [SEP] These iridoid glucosides were found to be inactive against @CHEMICALSrc$ acetyl @/CHEMICALSrc$ and butyrylcholinesterases but active against @GENETgt$ lipoxygenase @/GENETgt$ .	3 3 5 5 5 8 8 5 10 8|9 8 8|9 10 10 8 8 17 15 15 15 5	None-BC7
3917545	CHEMICAL	GENE	T6	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12 12 6 21 21 21 21 6 24 24 21 27 27 21 29 34 29 29 29 34 6 38 38 38 34 40 38 42 41|42|38 41|42|38 42|38 41|42|38 38 47 38 47 34 34 53 53 50 56 56 53 58 56|58|55 56|58|55 56|58 56|58|55 6	None-BC7
3917545	CHEMICAL	GENE	T27	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of @GENETgt$ PHS @/GENETgt$ is markedly increased in the presence of 100 microM @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ .	2 13 5 5 2 9 9 9 5 12 12 5 13 22 16 22 18 16|17 16 16|17 22 22 13 25 25 22 29 28 29 25|27 25 25|27 13	INHIBITOR
3917545	CHEMICAL	GENE	T2	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at @CHEMICALSrc$ PB @/CHEMICALSrc$ concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 26 26|21 26 26|21 22 29 29 22 31 36 31 31 31 36 7 40 40 40 36 42 40 45 45 40 40 48 40 48 36 36 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T5	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ PGH2 @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether @CHEMICALSrc$ PGH2 @/CHEMICALSrc$ is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 35 30 30 30 35 7 40 40|34 40 40|34 40 35 42 40 45 45 40 40 48 40 48 35 35 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T9	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As @CHEMICALSrc$ PB @/CHEMICALSrc$ undergoes peroxide-dependent co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase .	4 1|4 4 1|4 12 6 4 6 9 7 12 12 12 18 18 18 18 18 12 20 18 20 18 22 26 26 18 26 30 30 26 33 33 30 35 33 33 33 35 39 35 12	None-BC7
3917545	CHEMICAL	GENE	T30	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined @CHEMICALSrc$ PB @/CHEMICALSrc$ and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9|10 9 9|10 13 13 13 7 23 23 23 23 7 26 26 23 29 29 23 31 36 31 31 31 36 7 40 40 40 36 42 40 45 45 40 40 48 40 48 36 36 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T8	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ prostaglandin H @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Phenylbutazone ( PB ) , a nonsteroidal anti-inflammatory drug , is an efficient reducing cofactor for the peroxidase activity of @CHEMICALSrc$ prostaglandin H @/CHEMICALSrc$ synthase ( @GENETgt$ PHS @/GENETgt$ ) .	15 3 1 3 1 9 9 9 1 1 15 15 15 15 15 19 19 19 15 24 24|20 24|20 24 24|20 19 26 24|23 24 24|23 26 15	None-BC7
3917545	CHEMICAL	GENE	T23	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Using ram seminal vesicle microsomes as a source of PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ , we have examined the interaction of @CHEMICALSrc$ PB @/CHEMICALSrc$ and exogenous hydroperoxides .	18 5 5 5 1 8 8 1 10 8 10 10|11|12 10|11|12 10|12 10|11|12 18 18 18 18 20 18 22 19|20 20 19|20 22 26 22 18	None-BC7
3917545	CHEMICAL	GENE	T6	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 35 30 30 30 35 7 39 39 39 35 41 39 43 40|43|39 40|43|39 43|39 40|43|39 39 48 39 48 35 35 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T17	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Phenylbutazone ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , a nonsteroidal anti-inflammatory drug , is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ( @GENETgt$ PHS @/GENETgt$ ) .	16 3 1|2 1 1|2 3 1 10 10 10 1 1 16 16 16 16 16 20 20 20 16 24 24 24 20 26 24 24 24 26 16	None-BC7
3917545	CHEMICAL	GENE	T32	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ prostaglandin H @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Inactivation of @CHEMICALSrc$ prostaglandin H @/CHEMICALSrc$ synthase and @GENETgt$ prostacyclin synthase @/GENETgt$ by phenylbutazone .	1 6 2|6 2|6 6 2|6 1 6 8|5|6 8|5|6 8|6 8|5|6 12 1 1	None-BC7
3917545	CHEMICAL	GENE	T24	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Using ram seminal vesicle microsomes as a source of PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ , we have examined the interaction of PB and exogenous @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ .	18 5 5 5 1 8 8 1 10 8 10 10|11|12 10|11|12 10|12 10|11|12 18 18 18 18 20 18 22 20 22 25 22 22 22 18	None-BC7
3917545	CHEMICAL	GENE	T3	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This @CHEMICALSrc$ PB- @/CHEMICALSrc$ and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12 12 6 21 21 21 21 6 24 24 21 27 27 21 29 35|28 35 35|28 29 29 29 35 6 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T9	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As @CHEMICALSrc$ PB @/CHEMICALSrc$ undergoes peroxide-dependent co-oxygenation catalyzed by @GENETgt$ PHS @/GENETgt$ , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of PHS and prostacyclin synthase .	4 1|4 4 1|4 13 6 4 6 9 7 7 7 13 13 13 19 19 19 19 19 13 21 19 21 19 23 27 27 19 27 31 31 27 34 34 31 36 34 36 39 36 13	None-BC7
3917545	CHEMICAL	GENE	T31	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 12|13 13 12|13 13 7 23 23 23 23 7 26 26 23 29 29 23 31 36 31 31 31 36 7 40 40 40 36 42 40 45 45 40 40 48 40 48 36 36 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T23	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Using ram seminal vesicle microsomes as a source of @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase , we have examined the interaction of @CHEMICALSrc$ PB @/CHEMICALSrc$ and exogenous hydroperoxides .	18 5 5 5 1 8 8 1 10 8|9 8 8|9 10 14 10 18 18 18 18 20 18 22 20 20 20 22 26 22 18	None-BC7
3917545	CHEMICAL	GENE	T10	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ peroxide @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes @CHEMICALSrc$ peroxide-dependent @/CHEMICALSrc$ co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase .	3 3 12 3|6 6 3|6 3 6 9 7 12 12 12 18 18 18 18 18 12 20 18 20 18 22 26 26 18 26 30 30 26 33 33 30 35 33 33 33 35 39 35 12	None-BC7
3917545	CHEMICAL	GENE	T7	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 35 30 30 30 35 7 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 60 60|55 60 60|55 56 7	None-BC7
3917545	CHEMICAL	GENE	T34	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutazone @/CHEMICALSrc$ and @GENETgt$ prostaglandin H synthase @/GENETgt$ ? [SEP] Inactivation of @GENETgt$ prostaglandin H synthase @/GENETgt$ and prostacyclin synthase by @CHEMICALSrc$ phenylbutazone @/CHEMICALSrc$ .	1 3 1|2|3 1|2|3 1|2|3 1|3 1|2|3 3 9 3 11 1|7 1 1|7 1	INHIBITOR
3917545	CHEMICAL	GENE	T10	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ peroxide @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes @CHEMICALSrc$ peroxide-dependent @/CHEMICALSrc$ co-oxygenation catalyzed by @GENETgt$ PHS @/GENETgt$ , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of PHS and prostacyclin synthase .	3 3 13 3|6 6 3|6 3 6 9 7 7 7 13 13 13 19 19 19 19 19 13 21 19 21 19 23 27 27 19 27 31 31 27 34 34 31 36 34 36 39 36 13	None-BC7
3917545	CHEMICAL	GENE	T4	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and @CHEMICALSrc$ H2O2-dependent @/CHEMICALSrc$ inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 36 30 29|30 30 29|30 30 36 7 40 40 40 36 42 40 45 45 40 40 48 40 48 36 36 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T3	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ Prostacyclin synthase @/GENETgt$ ? [SEP] @GENETgt$ Prostacyclin synthase @/GENETgt$ is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This @CHEMICALSrc$ PB- @/CHEMICALSrc$ and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on prostacyclin synthase .	0|1|7 0|1|7 1|7 0|1|7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 27|36 36 27|36 30 30 30 36 7 40 40 40 36 42 40 45 45 40 40 48 40 48 36 36 54 54 51 57 57 54 60 60 57 7	None-BC7
3917545	CHEMICAL	GENE	T31	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12|13 12 12|13 12 6 22 22 22 22 6 25 25 22 28 28 22 30 35 30 30 30 35 6 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T29	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ Prostacyclin @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Prostacyclin @/CHEMICALSrc$ synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	0|3 3 0|3 7 7 6 7 7 9 7 13 13 13 9 13 13 13 7 22 22 22 22 7 25 25 22 28 28 22 30 35 30 30 30 35 7 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 7	None-BC7
3917545	CHEMICAL	GENE	T19	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Most reducing cofactors for the peroxidase protect PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ from inactivation by @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ .	2 7 7 6 6 3 7 7 8 8|9|10 8|9|10 8|10 8|9|10 14 7 16 13|14 14 13|14 7	INHIBITOR
3917545	CHEMICAL	GENE	T12	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of @GENETgt$ PHS @/GENETgt$ and @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase .	3 3 11 5 3 5 8 6 11 11 11 17 17 17 17 17 11 19 17 19 17 21 25 25 17 25 29 29 25 32 32 29 34 32|33 32 32|33 34 35|39 39 35|39 34 11	None-BC7
3917545	CHEMICAL	GENE	T33	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ prostaglandin H synthase @/GENETgt$ ? [SEP] Inactivation of @GENETgt$ prostaglandin H synthase @/GENETgt$ and @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase by phenylbutazone .	1 3 1|2|3 1|2|3 1|2|3 1|3 1|2|3 3 10|4 10 10|4 3 12 1 1	None-BC7
3917545	CHEMICAL	GENE	T11	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of @CHEMICALSrc$ PB @/CHEMICALSrc$ , rather than the parent compound , which is responsible for the inactivation of PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ .	3 3 11 5 3 5 8 6 11 11 11 17 17 17 17 17 11 19 17|18 17 17|18 19 17 22 26 26 17 26 30 30 26 33 33 30 35 33 35 35|37 35|37 35|37 35|37 11	None-BC7
3917545	CHEMICAL	GENE	T10	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ peroxide @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] As PB undergoes @CHEMICALSrc$ peroxide-dependent @/CHEMICALSrc$ co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ .	3 3 12 3|6 6 3|6 3 6 9 7 12 12 12 18 18 18 18 18 12 20 18 20 18 22 26 26 18 26 30 30 26 33 33 30 35 33 35 35|37 35|37 35|37 35|37 12	None-BC7
3917545	CHEMICAL	GENE	T24	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Using ram seminal vesicle microsomes as a source of @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase , we have examined the interaction of PB and exogenous @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ .	18 5 5 5 1 8 8 1 10 8|9 8 8|9 10 14 10 18 18 18 18 20 18 22 20 22 25 22|23 22 22|23 18	None-BC7
3917545	CHEMICAL	GENE	T22	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Using ram seminal vesicle microsomes as a source of @GENETgt$ PHS @/GENETgt$ and @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase , we have examined the interaction of PB and exogenous hydroperoxides .	19 5 5 5 1 8 8 1 10 8|9 8 8|9 10 11|15 15 11|15 10 19 19 19 19 21 19 23 21 23 26 23 19	None-BC7
3917545	CHEMICAL	GENE	T25	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ 14C-labeled arachidonic acid @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Chromatographic analysis of the metabolism of @CHEMICALSrc$ 14C-labeled arachidonic acid @/CHEMICALSrc$ in this system revealed that PB-dependent inactivation of @GENETgt$ PHS @/GENETgt$ is markedly increased in the presence of 100 microM H2O2 .	2 14 5 5 2 7 5|6|7 5|6|7 5|6|7 5|7 5|6|7 13 13 5 14 23 17 23 19 17|15 17 17|15 23 23 14 26 26 23 30 29 30 26 14	SUBSTRATE
3917545	CHEMICAL	GENE	T34	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutazone @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Inactivation of prostaglandin H synthase and @GENETgt$ prostacyclin synthase @/GENETgt$ by @CHEMICALSrc$ phenylbutazone @/CHEMICALSrc$ .	1 5 5 5 1 5 5|6|7 5|6|7 5|7 5|6|7 11 8|1 1 8|1 1	INHIBITOR
3917545	CHEMICAL	GENE	T1	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ Phenylbutazone @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] @CHEMICALSrc$ Phenylbutazone @/CHEMICALSrc$ ( PB ) , a nonsteroidal anti-inflammatory drug , is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ( @GENETgt$ PHS @/GENETgt$ ) .	0|16 16 0|16 4 1 4 1 10 10 10 1 1 16 16 16 16 16 20 20 20 16 24 24 24 20 26 24 24 24 26 16	None-BC7
3917545	CHEMICAL	GENE	T11	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of @CHEMICALSrc$ PB @/CHEMICALSrc$ , rather than the parent compound , which is responsible for the inactivation of @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase .	3 3 11 5 3 5 8 6 11 11 11 17 17 17 17 17 11 19 17|18 17 17|18 19 17 22 26 26 17 26 30 30 26 33 33 30 35 33 33 33 35 39 35 11	None-BC7
3917545	CHEMICAL	GENE	T12	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes peroxide-dependent co-oxygenation catalyzed by @GENETgt$ PHS @/GENETgt$ , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of PHS and @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase .	3 3 12 5 3 5 8 6|7 6 6|7 12 12 12 18 18 18 18 18 12 20 18 20 18 22 26 26 18 26 30 30 26 33 33 30 35 33 35 35|39 39 35|39 35 12	None-BC7
3917545	CHEMICAL	GENE	T19	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Most reducing cofactors for the peroxidase protect @GENETgt$ PHS @/GENETgt$ and prostacyclin synthase from inactivation by @CHEMICALSrc$ hydroperoxides @/CHEMICALSrc$ .	2 7 7 6 6 3 7 7 7 7 8 12 8 14 7 16 14 14 14 7	INHIBITOR
3917545	CHEMICAL	GENE	T18	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Most reducing cofactors for the peroxidase protect @GENETgt$ PHS @/GENETgt$ and @CHEMICALSrc$ prostacyclin @/CHEMICALSrc$ synthase from inactivation by hydroperoxides .	2 7 7 6 6 3 7 7 7 7 8 9|13 13 9|13 8 15 7 17 15 7	None-BC7
3917545	CHEMICAL	GENE	T26	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that @CHEMICALSrc$ PB-dependent @/CHEMICALSrc$ inactivation of @GENETgt$ PHS @/GENETgt$ is markedly increased in the presence of 100 microM H2O2 .	2 13 5 5 2 9 9 9 5 12 12 5 13 23 17|14 17 17|14 23 19 17 17 17 23 23 13 26 26 23 30 29 30 26 13	None-BC7
3917545	CHEMICAL	GENE	T1	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Phenylbutazone @/CHEMICALSrc$ and @GENETgt$ prostaglandin H synthase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Phenylbutazone @/CHEMICALSrc$ ( PB ) , a nonsteroidal anti-inflammatory drug , is an efficient reducing cofactor for the peroxidase activity of @GENETgt$ prostaglandin H synthase @/GENETgt$ ( PHS ) .	0|16 16 0|16 4 1 4 1 10 10 10 1 1 16 16 16 16 16 20 20 20 16 22 20|22 20|22 20|22 20|22 20|22 27 22 27 16	None-BC7
3917545	CHEMICAL	GENE	T4	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ H2O2 @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and @CHEMICALSrc$ H2O2-dependent @/CHEMICALSrc$ inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12 12 6 21 21 21 21 6 24 24 21 27 27 21 29 35 29 29|30 29 29|30 29 35 6 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T30	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined @CHEMICALSrc$ PB @/CHEMICALSrc$ and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8|11 8 8|11 12 12 12 6 22 22 22 22 6 25 25 22 28 28 22 30 35 30 30 30 35 6 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T9	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] As @CHEMICALSrc$ PB @/CHEMICALSrc$ undergoes peroxide-dependent co-oxygenation catalyzed by PHS , we propose that it is an oxygenated derivative of PB , rather than the parent compound , which is responsible for the inactivation of PHS and @GENETgt$ prostacyclin synthase @/GENETgt$ .	4 1|4 4 1|4 12 6 4 6 9 7 12 12 12 18 18 18 18 18 12 20 18 20 18 22 26 26 18 26 30 30 26 33 33 30 35 33 35 35|37 35|37 35|37 35|37 12	None-BC7
3917545	CHEMICAL	GENE	T5	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ PGH2 @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at PB concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether @CHEMICALSrc$ PGH2 @/CHEMICALSrc$ is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12 12 6 21 21 21 21 6 24 24 21 27 27 21 29 34 29 29 29 34 6 39 35|39 39 35|39 39 34 41 39 44 44 39 39 47 39 47 34 34 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T11	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ PHS @/GENETgt$ ? [SEP] As PB undergoes peroxide-dependent co-oxygenation catalyzed by @GENETgt$ PHS @/GENETgt$ , we propose that it is an oxygenated derivative of @CHEMICALSrc$ PB @/CHEMICALSrc$ , rather than the parent compound , which is responsible for the inactivation of PHS and prostacyclin synthase .	3 3 12 5 3 5 8 6|7 6 6|7 12 12 12 18 18 18 18 18 12 20 18 18 18 20 18 23 27 27 18 27 31 31 27 34 34 31 36 34 36 39 36 12	None-BC7
3917545	CHEMICAL	GENE	T2	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostacyclin synthase @/GENETgt$ ? [SEP] Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment , with a corresponding half-maximal effect at @CHEMICALSrc$ PB @/CHEMICALSrc$ concentrations near 25 microM. This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously , supporting a direct effect of the treatment on @GENETgt$ prostacyclin synthase @/GENETgt$ .	2 6 6 5 6 6 8 6 12 12 12 8 12 12 12 6 21 21 21 21 6 25 25|22 25 25|22 21 28 28 21 30 35 30 30 30 35 6 39 39 39 35 41 39 44 44 39 39 47 39 47 35 35 53 53 50 56 56 53 58 56|58 56|58 56|58 56|58 6	None-BC7
3917545	CHEMICAL	GENE	T17	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ prostaglandin H synthase @/GENETgt$ ? [SEP] Phenylbutazone ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , a nonsteroidal anti-inflammatory drug , is an efficient reducing cofactor for the peroxidase activity of @GENETgt$ prostaglandin H synthase @/GENETgt$ ( PHS ) .	16 3 1|2 1 1|2 3 1 10 10 10 1 1 16 16 16 16 16 20 20 20 16 22 20|22 20|22 20|22 20|22 20|22 27 22 27 16	None-BC7
7832763	CHEMICAL	GENE	T10	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ inhibited both hCOX-1 and hCOX-2 , whereas NS-398 and Dup-697 selectively inhibited @GENETgt$ hCOX-2 @/GENETgt$ .	0|3 3 0|3 3 5 3 5 5 3 3 14 10 10 14 3 13|14 14 13|14 3	None-BC7
7832763	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Indomethacin inhibited both hCOX-1 and hCOX-2 , whereas NS-398 and @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ selectively inhibited @GENETgt$ hCOX-2 @/GENETgt$ .	2 2 4 2 4 4 2 2 14 9 9|10 9 9|10 14 2 13|14 14 13|14 2	INHIBITOR
7832763	CHEMICAL	GENE	T14	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Both NS-398 and @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ exhibited time-dependent inactivation of @GENETgt$ hCOX-2 @/GENETgt$ , as did indomethacin on both enzymes .	2 6 2 2|3 2 2|3 6 8 6 10 8 8 8 6 14 6 14 18 18 14 6	INHIBITOR
7832763	CHEMICAL	GENE	T7	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ O2 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] of 1500 nmol of O2/nmol of enzyme , whereas @GENETgt$ hCOX-2 @/GENETgt$ had a specific activity of 12.2 mumol of @CHEMICALSrc$ O2/mg @/CHEMICALSrc$ with a Km of 8.7 microM for arachidonate and a Vmax .	3 3 3 5 3 7 5 3 3 9|12 12 9|12 3 15 15 12 18 18 15 20 18 18 18 24 24 12 27 27 24 29 24 29 32 29 12	None-BC7
7832763	CHEMICAL	GENE	T12	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] Indomethacin inhibited both @GENETgt$ hCOX-1 @/GENETgt$ and hCOX-2 , whereas NS-398 and @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ selectively inhibited hCOX-2 .	2 2 4 2|3 2 2|3 4 4 2 2 15 10 10 10 10 15 2 15 2	None-BC7
7832763	CHEMICAL	GENE	T12	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Indomethacin inhibited both hCOX-1 and @GENETgt$ hCOX-2 @/GENETgt$ , whereas NS-398 and @CHEMICALSrc$ Dup-697 @/CHEMICALSrc$ selectively inhibited hCOX-2 .	2 2 4 2 4 4|5 4 4|5 2 2 15 10 10 10 10 15 2 15 2	None-BC7
7832763	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ arachidonate @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] of 1500 nmol of O2/nmol of enzyme , whereas @GENETgt$ hCOX-2 @/GENETgt$ had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for @CHEMICALSrc$ arachidonate @/CHEMICALSrc$ and a Vmax .	3 3 3 5 3 7 5 3 3 9|12 12 9|12 3 15 15 12 18 18 15 20 18 23 23 12 26 26 23 28 26|23 23 26|23 28 32 28 12	SUBSTRATE
7832763	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ inhibited both @GENETgt$ hCOX-1 @/GENETgt$ and hCOX-2 , whereas NS-398 and Dup-697 selectively inhibited hCOX-2 .	0|3 3 0|3 3 5 3 3 3 5 5 3 3 15 11 11 15 3 15 3	INHIBITOR
7832763	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Indomethacin @/CHEMICALSrc$ inhibited both hCOX-1 and @GENETgt$ hCOX-2 @/GENETgt$ , whereas NS-398 and Dup-697 selectively inhibited hCOX-2 .	0|3 3 0|3 3 5 3 5 5 5 5 3 3 15 11 11 15 3 15 3	INHIBITOR
7832763	CHEMICAL	GENE	T11	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Indomethacin inhibited both hCOX-1 and hCOX-2 , whereas @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and Dup-697 selectively inhibited @GENETgt$ hCOX-2 @/GENETgt$ .	2 2 4 2 4 4 2 2 8|14 14 8|14 9 9 14 2 13|14 14 13|14 2	INHIBITOR
7832763	CHEMICAL	GENE	T2	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ mefenamic acid @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] The competitive inhibitor of hCOX-1 , @CHEMICALSrc$ mefenamic acid @/CHEMICALSrc$ , also displayed competitive inhibition of @GENETgt$ hCOX-2 @/GENETgt$ .	3 3 12 5 3 5 5|6|7 5|6|7 5|7 5|6|7 12 12 12 14 12 16 13|14 14 13|14 12	INHIBITOR
7832763	CHEMICAL	GENE	T15	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ indomethacin @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Both NS-398 and Dup-697 exhibited time-dependent inactivation of @GENETgt$ hCOX-2 @/GENETgt$ , as did @CHEMICALSrc$ indomethacin @/CHEMICALSrc$ on both enzymes .	2 5 2 2 5 7 5 9 8|7 7 8|7 5 13 5 12|13 13 12|13 18 18 13 5	INHIBITOR
7832763	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ prostaglandins @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The enzyme @GENETgt$ cyclo-oxygenase @/GENETgt$ catalyses the oxygenation of arachidonic acid , leading to the formation of @CHEMICALSrc$ prostaglandins @/CHEMICALSrc$ .	3 3 2|5 5 2|5 5 7 5 10 10 7 5 5 15 15 12 17 15 15 15 5	PRODUCT-OF
7832763	CHEMICAL	GENE	T6	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ arachidonate @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] @GENETgt$ hCOX-1 @/GENETgt$ had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for @CHEMICALSrc$ arachidonate @/CHEMICALSrc$ and Vmax .	0|3 3 0|3 3 6 6 3 9 9 6 11 9 14 14 6 17 17 14 19 17|14 14 17|14 19 19 3	SUBSTRATE
7832763	CHEMICAL	GENE	T11	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] Indomethacin inhibited both @GENETgt$ hCOX-1 @/GENETgt$ and hCOX-2 , whereas @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and Dup-697 selectively inhibited hCOX-2 .	2 2 4 2|3 2 2|3 4 4 2 2 8|15 15 8|15 10 10 15 2 15 2	None-BC7
7832763	CHEMICAL	GENE	T5	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The enzyme @GENETgt$ cyclo-oxygenase @/GENETgt$ catalyses the oxygenation of @CHEMICALSrc$ arachidonic acid @/CHEMICALSrc$ , leading to the formation of prostaglandins .	3 3 2|5 5 2|5 5 7 5 9 9|7 9|7 9|7 9|7 5 5 16 16 13 18 16 5	SUBSTRATE
7832763	CHEMICAL	GENE	T4	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ O2 @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] @GENETgt$ hCOX-1 @/GENETgt$ had a specific activity of 18.8 mumol of @CHEMICALSrc$ O2/mg @/CHEMICALSrc$ with a Km of 13.8 microM for arachidonate and Vmax .	0|3 3 0|3 3 6 6 3 9 9 6 11 9 9 9 15 15 6 18 18 15 20 15 20 20 3	None-BC7
7832763	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Indomethacin inhibited both hCOX-1 and @GENETgt$ hCOX-2 @/GENETgt$ , whereas @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and Dup-697 selectively inhibited hCOX-2 .	2 2 4 2 4 4|5 4 4|5 2 2 8|15 15 8|15 10 10 15 2 15 2	None-BC7
7832763	CHEMICAL	GENE	T13	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and @GENETgt$ hCOX-2 @/GENETgt$ ? [SEP] Both @CHEMICALSrc$ NS-398 @/CHEMICALSrc$ and Dup-697 exhibited time-dependent inactivation of @GENETgt$ hCOX-2 @/GENETgt$ , as did indomethacin on both enzymes .	2 1|6 6 1|6 2 2 6 8 6 10 8 8 8 6 14 6 14 18 18 14 6	INHIBITOR
7832763	CHEMICAL	GENE	T2	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ mefenamic acid @/CHEMICALSrc$ and @GENETgt$ hCOX-1 @/GENETgt$ ? [SEP] The competitive inhibitor of @GENETgt$ hCOX-1 @/GENETgt$ , @CHEMICALSrc$ mefenamic acid @/CHEMICALSrc$ , also displayed competitive inhibition of hCOX-2 .	3 3 13 5 3|4 3 3|4 5 8|5|6 8|5|6 8|5 8|5|6 13 13 13 15 13 17 15 13	INHIBITOR
23386616	CHEMICAL	GENE	T1	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ NADPH @/CHEMICALSrc$ and @GENETgt$ Nox2 @/GENETgt$ ? [SEP] We have previously reported that @CHEMICALSrc$ NADPH @/CHEMICALSrc$ oxidase 2 ( @GENETgt$ Nox2 @/GENETgt$ ) is up-regulated in spinal cord microglia after spinal nerve injury , demonstrating that it is critical for microglia activation and subsequent pain hypersensitivity .	4 4 4 4 15 8|5 8 8|5 15 8 11 8|9 8 8|9 11 15 4 19 19 19 15 23 23 23 15 15 15 29 29 29 25 32 32 29 32 36 36 32 4	None-BC7
23386616	CHEMICAL	GENE	T2	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ oxygen @/CHEMICALSrc$ and @GENETgt$ Nox2 @/GENETgt$ ? [SEP] Similarly , lipoteichoic acid stimulation induced @GENETgt$ Nox2 @/GENETgt$ expression and reactive @CHEMICALSrc$ oxygen @/CHEMICALSrc$ species production in primary spinal cord glial cells in vitro .	6 6 5 5 6 6 9|6 9 9|6 6 9 15 10|15 15 10|15 15 9 21 21 21 21 21 9 23 6 6	None-BC7
23386616	CHEMICAL	GENE	T3	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ NADPH @/CHEMICALSrc$ and @GENETgt$ Toll-like receptor 2 @/GENETgt$ ? [SEP] @GENETgt$ Toll-like receptor 2 @/GENETgt$ mediates peripheral nerve injury-induced @CHEMICALSrc$ NADPH @/CHEMICALSrc$ oxidase 2 expression in spinal cord microglia .	0|1|5 0|1|5 0|1|5 1|5 0|1|5 5 8 8 13 13|5 13 13|5 13 13 5 17 17 17 13 5	None-BC7
17590520	CHEMICAL	GENE	T1	T5	True	0	What is [Drugprot] between @CHEMICALSrc$ thymine @/CHEMICALSrc$ and @GENETgt$ Ser543Ser @/GENETgt$ ? [SEP] The same sense @CHEMICALSrc$ thymine-to-cytosine @/CHEMICALSrc$ polymorphism ( c.1629T-C ; @GENETgt$ Ser543Ser @/GENETgt$ ) was shown to preferentially modulate early components in both modalities .	3 3 14 3|6 6 3|6 14 8 6 10 8 8 8 8 14 14 17 17 14 19 17 22 22 17 14	None-BC7
17590520	CHEMICAL	GENE	T2	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ cytosine @/CHEMICALSrc$ and @GENETgt$ 1629T-C @/GENETgt$ ? [SEP] The same sense @CHEMICALSrc$ thymine-to-cytosine @/CHEMICALSrc$ polymorphism ( @GENETgt$ c.1629T-C @/GENETgt$ ; Ser543Ser ) was shown to preferentially modulate early components in both modalities .	3 3 14 3|6 6 3|6 14 8 6 6 6 11 8 8 14 14 17 17 14 19 17 22 22 17 14	None-BC7
17590520	CHEMICAL	GENE	T1	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ thymine @/CHEMICALSrc$ and @GENETgt$ 1629T-C @/GENETgt$ ? [SEP] The same sense @CHEMICALSrc$ thymine-to-cytosine @/CHEMICALSrc$ polymorphism ( @GENETgt$ c.1629T-C @/GENETgt$ ; Ser543Ser ) was shown to preferentially modulate early components in both modalities .	3 3 14 3|6 6 3|6 14 8 6 6 6 11 8 8 14 14 17 17 14 19 17 22 22 17 14	None-BC7
17590520	CHEMICAL	GENE	T2	T5	True	0	What is [Drugprot] between @CHEMICALSrc$ cytosine @/CHEMICALSrc$ and @GENETgt$ Ser543Ser @/GENETgt$ ? [SEP] The same sense @CHEMICALSrc$ thymine-to-cytosine @/CHEMICALSrc$ polymorphism ( c.1629T-C ; @GENETgt$ Ser543Ser @/GENETgt$ ) was shown to preferentially modulate early components in both modalities .	3 3 14 3|6 6 3|6 14 8 6 10 8 8 8 8 14 14 17 17 14 19 17 22 22 17 14	None-BC7
17590520	CHEMICAL	GENE	T3	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ Nicotine @/CHEMICALSrc$ and @GENETgt$ CHRNA4 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Nicotine @/CHEMICALSrc$ receptor gene @GENETgt$ CHRNA4 @/GENETgt$ modulates early event-related potentials in auditory and visual oddball target detection tasks .	0|5 5 0|5 5 5 3|7 7 3|7 7 10 8 7 12 18 12 12 18 18 18 10 7	None-BC7
23416191	CHEMICAL	GENE	T1	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ and @GENETgt$ STAT3 @/GENETgt$ ? [SEP] The most potent compound 5 ( @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ ) has demonstrated to inhibit STAT3 promoter activity , downregulate phosphorylation of @GENETgt$ STAT3 @/GENETgt$ , increase the expression of cleaved caspase-3 , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values .	4 3 4 11 4 7 4|6 4 4|6 7 11 11 13 11 16 16 13 13 11 18 21 19 19 19 11 11 26 24 29 29 26 24 24 34 34 31 31 31 36 39 37 39 39 43 39 46 46 36 50 50 50 46 11	INHIBITOR
23416191	CHEMICAL	GENE	T1	T5	True	0	What is [Drugprot] between @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ and @GENETgt$ STAT3 promoter @/GENETgt$ ? [SEP] The most potent compound 5 ( @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ ) has demonstrated to inhibit @GENETgt$ STAT3 promoter @/GENETgt$ activity , downregulate phosphorylation of STAT3 , increase the expression of cleaved caspase-3 , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values .	4 3 4 11 4 7 4|6 4 4|6 7 11 11 13 11 17|12 17|12 17 17|12 13 13 11 19 22 20 11 11 26 24 29 29 26 24 24 34 34 31 31 31 36 39 37 39 39 43 39 46 46 36 50 50 50 46 11	INHIBITOR
23416191	CHEMICAL	GENE	T3	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ and @GENETgt$ STAT3 @/GENETgt$ ? [SEP] Fragment-based drug design and identification of @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ , a novel orally bioavailable @GENETgt$ STAT3 @/GENETgt$ inhibitor for cancer therapy .	3 3 3 3 3 7 5|6 5 5|6 7 16 16 13 16 16|12 16 16|12 7 19 19 16 3	INHIBITOR
23416191	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ estrogen @/CHEMICALSrc$ and @GENETgt$ ER @/GENETgt$ ? [SEP] Furthermore , compound 5 significantly suppressed @CHEMICALSrc$ estrogen @/CHEMICALSrc$ receptor @GENETgt$ (ER)-negative @/GENETgt$ breast cancer MDA-MB-231 xenograft tumor growth in vivo ( p.o . ) , indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy .	6 6 6 3 6 6 17|6 17 17|6 17 8|17 17 8|17 17 17 17 17 17 6 19 21 21 17 21 21 6 6 28 28 25 36 36 36 31 34 31 36 28 40 40 40 36 6	None-BC7
23416191	CHEMICAL	GENE	T1	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ and @GENETgt$ caspase-3 @/GENETgt$ ? [SEP] The most potent compound 5 ( @CHEMICALSrc$ HJC0123 @/CHEMICALSrc$ ) has demonstrated to inhibit STAT3 promoter activity , downregulate phosphorylation of STAT3 , increase the expression of cleaved @GENETgt$ caspase-3 @/GENETgt$ , inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values .	4 3 4 11 4 7 4|6 4 4|6 7 11 11 13 11 16 16 13 13 11 18 21 19 11 11 25 23 28 28 25|26 25 25|26 23 23 34 34 31 31 31 36 39 37 39 39 43 39 46 46 36 50 50 50 46 11	INDIRECT-UPREGULATOR
17069932	CHEMICAL	GENE	T11	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] Tiagabine ( 0.1 microM ) , an antiepileptic drug that specifically inhibits the @GENETgt$ GAT-1 @/GENETgt$ @CHEMICALSrc$ GABA @/CHEMICALSrc$ transporter inhibited GABA uptake 50 % in temporal cortex and 60 - 68 % in white structures .	19 4 4 1 4 1 9 9 1 12 12 9 18 18|13 18 18|13 18|14 18 18|14 12 19 21 19 23 19 26 26 23 26 30 30 31 26 34 34 26 19	None-BC7
17069932	CHEMICAL	GENE	T3	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ tricarboxylic acid @/CHEMICALSrc$ and @GENETgt$ GAD @/GENETgt$ ? [SEP] Since white matter activity of citrate synthase of the @CHEMICALSrc$ tricarboxylic acid @/CHEMICALSrc$ cycle was approximately 25 % of neocortical values ( approximately 0.4 nmol/mg tissue x min(-1 ) versus approximately 1.5 nmol/mg tissue x min(-1 ) ) , the low @GENETgt$ GAD @/GENETgt$ activity suggests a slower metabolic turnover of GABA in white than in gray matter .	4 3 4 17 7 7 4 13 13 9|13 9|13 13 9|13 7 17 16 17 17 20 20 17 27 23 27 27 27 27 20 27 20 31 35 35 35 35 20 20 17 44 43 43 43|38 43 43|38 44 17 48 48 48 44 50 48 52 48 56 56 56 44 44	None-BC7
17069932	CHEMICAL	GENE	T4	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GAD @/GENETgt$ ? [SEP] Since white matter activity of citrate synthase of the tricarboxylic acid cycle was approximately 25 % of neocortical values ( approximately 0.4 nmol/mg tissue x min(-1 ) versus approximately 1.5 nmol/mg tissue x min(-1 ) ) , the low @GENETgt$ GAD @/GENETgt$ activity suggests a slower metabolic turnover of @CHEMICALSrc$ GABA @/CHEMICALSrc$ in white than in gray matter .	4 3 4 16 7 7 4 12 12 12 12 7 16 15 16 16 19 19 16 26 22 26 26 26 26 19 26 19 30 34 34 34 34 19 19 16 43 42 42 42|39 42 42|39 43 16 47 47 47 43 49 47 47 47 52 47 56 56 56 43 43	PRODUCT-OF
17069932	CHEMICAL	GENE	T15	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ tiagabine @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] This finding indicates that @GENETgt$ GAT-1 @/GENETgt$ is an important GABA transporter in white matter and suggests that white matter GABA uptake is inhibited during @CHEMICALSrc$ tiagabine @/CHEMICALSrc$ therapy .	2 3 3 11 11|4 11 11|4 11 11 11 11 3 14 14 11 3 3 23 19 21 21 23 23 16 27 27|23 27 27|23 23 3	INHIBITOR
17069932	CHEMICAL	GENE	T15	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ tiagabine @/CHEMICALSrc$ and @GENETgt$ GABA transporter @/GENETgt$ ? [SEP] This finding indicates that GAT-1 is an important @GENETgt$ GABA transporter @/GENETgt$ in white matter and suggests that white matter GABA uptake is inhibited during @CHEMICALSrc$ tiagabine @/CHEMICALSrc$ therapy .	2 3 3 9 9 9 9 9 8|9|3 8|9|3 9|3 8|9|3 14 14 9 3 3 23 19 21 21 23 23 16 27 27|22 27 27|22 23 3	INHIBITOR
17069932	CHEMICAL	GENE	T17	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutamate @/CHEMICALSrc$ and @GENETgt$ GAD @/GENETgt$ ? [SEP] @CHEMICALSrc$ Glutamate @/CHEMICALSrc$ decarboxylase ( @GENETgt$ GAD @/GENETgt$ ) activity in white structures was only 4 % of that in neocortex ( 7 - 12 pmol/mg tissue x min(-1 ) versus approximately 200 pmol/mg tissue x min(-1 ) ) .	0|3 3 0|3 8 5 3 3 3 5 15 11 11 8 15 14 15 15 17 15 25 25 25 23 21 24 25 17 25 25 25 15 31 32 35 35 35 15 15 15 15	None-BC7
17069932	CHEMICAL	GENE	T13	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] This finding indicates that @GENETgt$ GAT-1 @/GENETgt$ is an important @CHEMICALSrc$ GABA @/CHEMICALSrc$ transporter in white matter and suggests that white matter GABA uptake is inhibited during tiagabine therapy .	2 3 3 12 4|12 12 4|12 12 12 12 8|12 12 8|12 3 15 15 12 3 3 24 20 22 22 24 24 17 27 27 24 3	None-BC7
17069932	CHEMICAL	GENE	T12	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GABA transporter @/GENETgt$ ? [SEP] Tiagabine ( 0.1 microM ) , an antiepileptic drug that specifically inhibits the GAT-1 @GENETgt$ GABA transporter @/GENETgt$ inhibited @CHEMICALSrc$ GABA @/CHEMICALSrc$ uptake 50 % in temporal cortex and 60 - 68 % in white structures .	18 4 4 1 4 1 9 9 1 12 12 9 15 15 12|14|15 12|14|15 12|15 12|14|15 18 16|21 21 16|21 18 23 18 26 26 23 26 30 30 31 26 34 34 26 18	SUBSTRATE
17069932	CHEMICAL	GENE	T12	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] Tiagabine ( 0.1 microM ) , an antiepileptic drug that specifically inhibits the @GENETgt$ GAT-1 @/GENETgt$ GABA transporter inhibited @CHEMICALSrc$ GABA @/CHEMICALSrc$ uptake 50 % in temporal cortex and 60 - 68 % in white structures .	18 4 4 1 4 1 9 9 1 12 12 9 17 17|13 17 17|13 17 12 18 17|21 21 17|21 18 23 18 26 26 23 26 30 30 31 26 34 34 26 18	SUBSTRATE
17069932	CHEMICAL	GENE	T14	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GABA transporter @/GENETgt$ ? [SEP] This finding indicates that GAT-1 is an important @GENETgt$ GABA transporter @/GENETgt$ in white matter and suggests that white matter @CHEMICALSrc$ GABA @/CHEMICALSrc$ uptake is inhibited during tiagabine therapy .	2 3 3 9 9 9 9 9 8|9|3 8|9|3 9|3 8|9|3 14 14 9 3 3 24 19 22 17|22 22 17|22 24 24 16 27 27 24 3	SUBSTRATE
17069932	CHEMICAL	GENE	T10	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiagabine @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiagabine @/CHEMICALSrc$ ( 0.1 microM ) , an antiepileptic drug that specifically inhibits the @GENETgt$ GAT-1 @/GENETgt$ GABA transporter inhibited GABA uptake 50 % in temporal cortex and 60 - 68 % in white structures .	0|19 19 0|19 5 5 1 5 1 10 10 1 13 13 10 18 18|13 18 18|13 18 13 19 21 19 23 19 26 26 23 26 30 30 31 26 34 34 26 19	INHIBITOR
17069932	CHEMICAL	GENE	T10	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiagabine @/CHEMICALSrc$ and @GENETgt$ GABA transporter @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiagabine @/CHEMICALSrc$ ( 0.1 microM ) , an antiepileptic drug that specifically inhibits the GAT-1 @GENETgt$ GABA transporter @/GENETgt$ inhibited GABA uptake 50 % in temporal cortex and 60 - 68 % in white structures .	0|19 19 0|19 5 5 1 5 1 10 10 1 13 13 10 16 16 16|13|14 16|13|14 16|13 16|13|14 19 21 19 23 19 26 26 23 26 30 30 31 26 34 34 26 19	INHIBITOR
17069932	CHEMICAL	GENE	T14	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ GABA @/CHEMICALSrc$ and @GENETgt$ GAT-1 @/GENETgt$ ? [SEP] This finding indicates that @GENETgt$ GAT-1 @/GENETgt$ is an important GABA transporter in white matter and suggests that white matter @CHEMICALSrc$ GABA @/CHEMICALSrc$ uptake is inhibited during tiagabine therapy .	2 3 3 11 11|4 11 11|4 11 11 11 11 3 14 14 11 3 3 24 19 22 18|22 22 18|22 24 24 16 27 27 24 3	SUBSTRATE
17069932	CHEMICAL	GENE	T2	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ citrate @/CHEMICALSrc$ and @GENETgt$ GAD @/GENETgt$ ? [SEP] Since white matter activity of @CHEMICALSrc$ citrate @/CHEMICALSrc$ synthase of the tricarboxylic acid cycle was approximately 25 % of neocortical values ( approximately 0.4 nmol/mg tissue x min(-1 ) versus approximately 1.5 nmol/mg tissue x min(-1 ) ) , the low @GENETgt$ GAD @/GENETgt$ activity suggests a slower metabolic turnover of GABA in white than in gray matter .	4 3 4 17 8 8|5 8 8|5 4 13 13 13 13 8 17 16 17 17 20 20 17 27 23 27 27 27 27 20 27 20 31 35 35 35 35 20 20 17 44 43 43 43|39 43 43|39 44 17 48 48 48 44 50 48 52 48 56 56 56 44 44	None-BC7
14753499	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ forskolin @/CHEMICALSrc$ and @GENETgt$ AQP1 @/GENETgt$ ? [SEP] CSF production in wildtype mice was ( in microl/min ) 0.37 + /- 0.04 microl/min ( control ) , 0.16 + /- 0.03 microl/min ( acetazolamide-treated ) and 1.14 + /- 0.15 microl/min ( @CHEMICALSrc$ forskolin-treated @/CHEMICALSrc$ ) , and reduced by up to 25 % in @GENETgt$ AQP1 @/GENETgt$ null mice .	2 9 5 5 2 9 9 9 9 11 9 11 26 15 26 17 15 17 15 15 20 26 24 26 26 9 26 9 9 29 29 33 29 35 33|34 33 33|34 35 9 9 9 45 44 44 45 40 50 50|45 50 50|45 50 45 9	None-BC7
14753499	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ acetazolamide @/CHEMICALSrc$ and @GENETgt$ AQP1 @/GENETgt$ ? [SEP] CSF production in wildtype mice was ( in microl/min ) 0.37 + /- 0.04 microl/min ( control ) , 0.16 + /- 0.03 microl/min ( @CHEMICALSrc$ acetazolamide-treated @/CHEMICALSrc$ ) and 1.14 + /- 0.15 microl/min ( forskolin-treated ) , and reduced by up to 25 % in @GENETgt$ AQP1 @/GENETgt$ null mice .	2 9 5 5 2 9 9 9 9 11 9 11 26 15 26 17 15 17 15 15 20 26 24 26 26 25|9 9 25|9 26 9 9 30 30 34 30 36 34 36 9 9 9 45 44 44 45 40 50 50|45 50 50|45 50 45 9	None-BC7
17065073	CHEMICAL	GENE	T7	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ adenosine @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead ATP , according to the reaction : adenosine + ADP -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate @CHEMICALSrc$ adenosine @/CHEMICALSrc$ , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22 4 29 26 29 4 29 29 31 31 36 36 31 36 29 40 38 42 40|41 40 40|41 45 40 44|45 45 44|45 29 50 29 52 50 4	SUBSTRATE
17065073	CHEMICAL	GENE	T8	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead ATP , according to the reaction : adenosine + ADP -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from @CHEMICALSrc$ ADP @/CHEMICALSrc$ .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22 4 29 26 29 4 29 29 31 31 36 36 31 36 29 40 38 42 40|41 40 40|41 45 40 45 29 49 29 51 49 49 49 4	None-BC7
17065073	CHEMICAL	GENE	T6	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ 2AMP @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead ATP , according to the reaction : adenosine + ADP -- > @CHEMICALSrc$ 2AMP @/CHEMICALSrc$ ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22 4 29 26 29 4 29 29 31 31 36 36 35|31 31 35|31 36 29 41 39 43 41 41 41 46 41 46 29 50 29 52 50 4	None-BC7
17065073	CHEMICAL	GENE	T4	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ adenosine @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead ATP , according to the reaction : @CHEMICALSrc$ adenosine @/CHEMICALSrc$ + ADP -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22 4 29 26 29 4 29 29|30 29 29|30 31 31 37 37 31 37 29 41 39 43 41 41 41 46 41 46 29 50 29 52 50 4	None-BC7
17065073	CHEMICAL	GENE	T12	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ AMP @/CHEMICALSrc$ and @GENETgt$ Adenosine kinase @/GENETgt$ ? [SEP] @GENETgt$ Adenosine kinase @/GENETgt$ is a well-known enzyme which catalyzes the phosphorylation of adenosine to @CHEMICALSrc$ AMP @/CHEMICALSrc$ : Its metabolic and kinetic properties are well studied .	0|1|7 0|1|7 1|7 0|1|7 7 7 7 7 9 7 11 9 13 11 15 11|12 11 11|12 7 19 25 19 19 19 25 25 7 7	PRODUCT-OF
17065073	CHEMICAL	GENE	T3	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead @CHEMICALSrc$ ATP @/CHEMICALSrc$ , according to the reaction : adenosine + ADP -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22|23 22 22|23 4 30 27 30 4 30 30 32 32 37 37 32 37 30 41 39 43 41 41 41 46 41 46 30 50 30 52 50 4	None-BC7
17065073	CHEMICAL	GENE	T11	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ adenosine @/CHEMICALSrc$ and @GENETgt$ Adenosine kinase @/GENETgt$ ? [SEP] @GENETgt$ Adenosine kinase @/GENETgt$ is a well-known enzyme which catalyzes the phosphorylation of @CHEMICALSrc$ adenosine @/CHEMICALSrc$ to AMP : Its metabolic and kinetic properties are well studied .	0|1|7 0|1|7 1|7 0|1|7 7 7 7 7 9 7 11 9 13 10|11 11 10|11 16 11 7 19 25 19 19 19 25 25 7 7	SUBSTRATE
17065073	CHEMICAL	GENE	T5	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : ADP can be a phosphate donor instead ATP , according to the reaction : adenosine + @CHEMICALSrc$ ADP @/CHEMICALSrc$ -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 22 22 22 22 22 22 4 24 22 4 29 26 29 4 29 29 31 32|31 31 32|31 37 37 31 37 29 41 39 43 41 41 41 46 41 46 29 50 29 52 50 4	None-BC7
17065073	CHEMICAL	GENE	T2	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ ADP @/CHEMICALSrc$ and @GENETgt$ AdK @/GENETgt$ ? [SEP] Here , we report new properties of rat liver enzyme , demonstrating a new reaction : @CHEMICALSrc$ ADP @/CHEMICALSrc$ can be a phosphate donor instead ATP , according to the reaction : adenosine + ADP -- > 2AMP ) demonstrating the efficiency of @GENETgt$ AdK @/GENETgt$ to phosphorylate adenosine , also starting from ADP .	4 4 4 4 6 4 10 10 10 6 4 4 15 15 12 23 16|23 23 16|23 23 23 23 23 4 25 23 4 30 27 30 4 30 30 32 32 37 37 32 37 30 41 39 43 41 41 41 46 41 46 30 50 30 52 50 4	None-BC7
20517484	CHEMICAL	GENE	T1	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ and @GENETgt$ monoamine oxidase type B @/GENETgt$ ? [SEP] @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ is a novel , potent , and irreversible @GENETgt$ monoamine oxidase type B @/GENETgt$ ( MAO-B ) inhibitor which has been approved for treatment of PD .	0|19 19 0|19 19 19 19 5 5 5 5 5 9|19 9|19 9|19 9|19 19 9|19 19 19 19 19 23 23 23 19 25 23 27 25 19	INHIBITOR
20517484	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ and @GENETgt$ MAO-B @/GENETgt$ ? [SEP] @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ is a novel , potent , and irreversible monoamine oxidase type B ( @GENETgt$ MAO-B @/GENETgt$ ) inhibitor which has been approved for treatment of PD .	0|19 19 0|19 19 19 19 5 5 5 5 5 19 19 19 19 19 19|14 19 19|14 19 19 23 23 23 19 25 23 27 25 19	INHIBITOR
20517484	CHEMICAL	GENE	T3	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ and @GENETgt$ MAO-B @/GENETgt$ ? [SEP] @CHEMICALSrc$ Rasagiline @/CHEMICALSrc$ inhibits @GENETgt$ MAO-B @/GENETgt$ more potently than selegiline and has the advantage of once-daily dosing .	0|3 3 0|3 3 2|3 3 2|3 7 3 9 7 3 3 13 11 16 16 13 3	INHIBITOR
20517484	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ monoamine @/CHEMICALSrc$ and @GENETgt$ MAO-B @/GENETgt$ ? [SEP] Rasagiline is a novel , potent , and irreversible @CHEMICALSrc$ monoamine @/CHEMICALSrc$ oxidase type B ( @GENETgt$ MAO-B @/GENETgt$ ) inhibitor which has been approved for treatment of PD .	19 19 19 19 4 4 4 4 4 9|19 19 9|19 19 19 19 19 19|14 19 19|14 19 19 23 23 23 19 25 23 27 25 19	None-BC7
23216335	CHEMICAL	GENE	T1	T2	True	0	What is [Drugprot] between @CHEMICALSrc$ androgens @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] Circulating @CHEMICALSrc$ androgens @/CHEMICALSrc$ and markers of @GENETgt$ insulin @/GENETgt$ resistance ( IR ) were higher in women with PCOS than in controls .	2 1|14 14 1|14 2 2 9 9|5 9 9|5 2 11 9 11 14 14 16 14 18 16 21 21 14 14	None-BC7
17327402	CHEMICAL	GENE	T3	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ gamma-carboxyglutamic acid @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to @CHEMICALSrc$ gamma-carboxyglutamic acid @/CHEMICALSrc$ ( Gla ) by the vitamin K-dependent gamma-glutamyl carboxylase ( @GENETgt$ gamma-carboxylase @/GENETgt$ ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 8 8|2|7 8|2|7 8|2 8|2|7 12 8 12 19 19 19 19 19 2 21 18|19 19 18|19 21 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	PRODUCT-OF
17327402	CHEMICAL	GENE	T3	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ gamma-carboxyglutamic acid @/CHEMICALSrc$ and @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to @CHEMICALSrc$ gamma-carboxyglutamic acid @/CHEMICALSrc$ ( Gla ) by the @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ( gamma-carboxylase ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 8 8|2|7 8|2|7 8|2 8|2|7 12 8 12 16 16 16|2|13 16|2|13 16|2|13 16|2|13 16|2 16|2|13 22 16 22 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	PRODUCT-OF
17327402	CHEMICAL	GENE	T4	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin K @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] Heterozygous mice carrying a null mutation at the @GENETgt$ gamma-carboxylase @/GENETgt$ ( Ggcx ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEMICALSrc$ vitamin K-dependent @/CHEMICALSrc$ clotting factors IX , X , and prothrombin .	2 15 2 6 6 3 14 14 8|14 14 8|14 14 14 14 6 15 17 15 17 17 22 22 15 24 22 24 28 28 24 35 35 35|29 35|29 35 35|29 35 24 35 36 36 36 36 36 15	None-BC7
17327402	CHEMICAL	GENE	T4	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin K @/CHEMICALSrc$ and @GENETgt$ Ggcx @/GENETgt$ ? [SEP] Heterozygous mice carrying a null mutation at the gamma-carboxylase ( @GENETgt$ Ggcx @/GENETgt$ ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEMICALSrc$ vitamin K-dependent @/CHEMICALSrc$ clotting factors IX , X , and prothrombin .	2 15 2 6 6 3 14 14 14 14 10|14 14 10|14 14 6 15 17 15 17 17 22 22 15 24 22 24 28 28 24 35 35 35|29 35|29 35 35|29 35 24 35 36 36 36 36 36 15	None-BC7
17327402	CHEMICAL	GENE	T6	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin K @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( Gla ) by the @CHEMICALSrc$ vitamin K-dependent @/CHEMICALSrc$ gamma-glutamyl carboxylase ( @GENETgt$ gamma-carboxylase @/GENETgt$ ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 9 9 2 11 9 11 19 19 19|14 19|14 19 19|14 19 2 21 18|19 19 18|19 21 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	None-BC7
17327402	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ gamma-glutamyl @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( Gla ) by the vitamin K-dependent @CHEMICALSrc$ gamma-glutamyl @/CHEMICALSrc$ carboxylase ( @GENETgt$ gamma-carboxylase @/GENETgt$ ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 9 9 2 11 9 11 19 19 19 19 16|19 19 16|19 2 21 19 19 19 21 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	None-BC7
17327402	CHEMICAL	GENE	T4	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin K @/CHEMICALSrc$ and @GENETgt$ prothrombin @/GENETgt$ ? [SEP] Heterozygous mice carrying a null mutation at the gamma-carboxylase ( Ggcx ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the @CHEMICALSrc$ vitamin K-dependent @/CHEMICALSrc$ clotting factors IX , X , and @GENETgt$ prothrombin @/GENETgt$ .	2 14 2 6 6 3 13 13 13 13 13 13 6 14 16 14 16 16 21 21 14 23 21 23 27 27 23 34 34 34|29 34|29 34 34|29 34 23 34 35 35 35 35 35|37 35 35|37 14	None-BC7
17327402	CHEMICAL	GENE	T1	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ gamma-glutamyl @/CHEMICALSrc$ and @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( Gla ) by the @GENETgt$ vitamin K-dependent @/GENETgt$ @CHEMICALSrc$ gamma-glutamyl carboxylase @/CHEMICALSrc$ ( gamma-carboxylase ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 9 9 2 11 9 11 18 18 18|14 18|14 18 18|14 2|18|15 2|18|15 2|18 2|18|15 22 18 22 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	None-BC7
17327402	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] The carboxylation of @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ residues to gamma-carboxyglutamic acid ( Gla ) by the vitamin K-dependent gamma-glutamyl carboxylase ( @GENETgt$ gamma-carboxylase @/GENETgt$ ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 7 3|7 3|7 7 3|7 2 10 10 2 12 10 12 19 19 19 19 19 2 21 18|19 19 18|19 21 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	SUBSTRATE
17327402	CHEMICAL	GENE	T2	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ? [SEP] The carboxylation of @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ residues to gamma-carboxyglutamic acid ( Gla ) by the @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ( gamma-carboxylase ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 7 3|7 3|7 7 3|7 2 10 10 2 12 10 12 16 16 16|2|13 16|2|13 16|2|13 16|2|13 16|2 16|2|13 22 16 22 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	SUBSTRATE
17327402	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ Gla @/CHEMICALSrc$ and @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( @CHEMICALSrc$ Gla @/CHEMICALSrc$ ) by the @GENETgt$ vitamin K-dependent gamma-glutamyl carboxylase @/GENETgt$ ( gamma-carboxylase ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 9 9 2 11 9|10 9 9|10 11 16 16 16|2|14 16|2|14 16|2|14 16|2|14 16|2 16|2|14 22 16 22 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	PRODUCT-OF
17327402	CHEMICAL	GENE	T5	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ Gla @/CHEMICALSrc$ and @GENETgt$ gamma-carboxylase @/GENETgt$ ? [SEP] The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid ( @CHEMICALSrc$ Gla @/CHEMICALSrc$ ) by the vitamin K-dependent gamma-glutamyl carboxylase ( @GENETgt$ gamma-carboxylase @/GENETgt$ ) is an essential posttranslational modification required for the biological activity of a number of proteins , including proteins involved in blood coagulation and its regulation .	2 28 6 6 6 2 9 9 2 11 9|10 9 9|10 11 19 19 19 19 19 2 21 19 19 19 21 28 28 28 28 28 28 33 33 33 29 36 36 33 38 36 38 41 38 41 45 45 42 41 48 41 28	PRODUCT-OF
23314046	CHEMICAL	GENE	T2	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidine triphosphate @/CHEMICALSrc$ and @GENETgt$ TMPK @/GENETgt$ ? [SEP] The thymidine monophosphate kinase ( @GENETgt$ TMPK @/GENETgt$ ) of Mycobacterium tuberculosis ( M. tuberculosis ) , which is an essential enzyme for the maintenance of the @CHEMICALSrc$ thymidine triphosphate @/CHEMICALSrc$ pools , is considered an attractive target for the development of effective antibiotics against tuberculosis .	4 4 4 33 6 4|5 4 4|5 6 11 11 4 14 14 11 14 4 21 21 21 21 4 24 24 21 30 30 25|30 25|30 30 25|30 24 4 33 33 36 36 33 39 39 36 42 42 39 44 42 33	PRODUCT-OF
23314046	CHEMICAL	GENE	T1	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidine monophosphate @/CHEMICALSrc$ and @GENETgt$ TMPK @/GENETgt$ ? [SEP] The @CHEMICALSrc$ thymidine monophosphate @/CHEMICALSrc$ kinase ( @GENETgt$ TMPK @/GENETgt$ ) of Mycobacterium tuberculosis ( M. tuberculosis ) , which is an essential enzyme for the maintenance of the thymidine triphosphate pools , is considered an attractive target for the development of effective antibiotics against tuberculosis .	5 1|5 1|5 5 1|5 33 7 4|5 5 4|5 7 12 12 5 15 15 12 15 5 22 22 22 22 5 25 25 22 30 30 30 30 25 5 33 33 36 36 33 39 39 36 42 42 39 44 42 33	None-BC7
23314046	CHEMICAL	GENE	T2	T3	True	0	What is [Drugprot] between @CHEMICALSrc$ thymidine triphosphate @/CHEMICALSrc$ and @GENETgt$ thymidine monophosphate kinase @/GENETgt$ ? [SEP] The @GENETgt$ thymidine monophosphate kinase @/GENETgt$ ( TMPK ) of Mycobacterium tuberculosis ( M. tuberculosis ) , which is an essential enzyme for the maintenance of the @CHEMICALSrc$ thymidine triphosphate @/CHEMICALSrc$ pools , is considered an attractive target for the development of effective antibiotics against tuberculosis .	2 1|2|33 1|2|33 1|2|33 33|2 1|2|33 7 2 7 11 11 2 14 14 11 14 2 21 21 21 21 2 24 24 21 30 30 30|23 30|23 30 30|23 24 2 33 33 36 36 33 39 39 36 42 42 39 44 42 33	PRODUCT-OF
23401472	CHEMICAL	GENE	T3	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The transfection of an HNF1α expression plasmid into the HK-2 cells resulted in an increase of UGT1A1 mRNA only in the presence of @CHEMICALSrc$ 5-Aza-dC. @/CHEMICALSrc$ In summary , we found that DNA hypermethylation along with histone hypoacetylation interferes with the binding of HNF1α , resulting in the defective expression of @GENETgt$ UGT1A1 @/GENETgt$ in the human kidney .	2 12 7 7 7 7 2 11 11 11 2 12 15 15 12 18 18 15 22 22 22 12 24 22|23 22 22|23 27 22 30 30 12 38 33 38 37 37 37 33 30 41 41 38 43 41 38 38 49 49 49 45 51 49 49 49 56 56 56 49 12	None-BC7
23401472	CHEMICAL	GENE	T5	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ SN-38 @/CHEMICALSrc$ and @GENETgt$ Human UDP-glucuronosyltransferase (UGT) 1A1 @/GENETgt$ ? [SEP] @GENETgt$ Human UDP-glucuronosyltransferase ( UGT ) 1A1 @/GENETgt$ catalyzes the metabolism of numerous clinically and pharmacologically important compounds such as bilirubin and @CHEMICALSrc$ SN-38 @/CHEMICALSrc$ .	0|1|8 0|1|8 0|1|8 0|1|8 0|1|8 0|1|8 8|1 0|1|8 8 10 8 13 13 10 13 16 13 13 20 18 17 20 20|15 20 20|15 8	SUBSTRATE
23401472	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ CpG @/CHEMICALSrc$ and @GENETgt$ UGT1A1 promoter @/GENETgt$ ? [SEP] Bisulfite sequence analysis revealed that the @CHEMICALSrc$ CpG-rich @/CHEMICALSrc$ region near the @GENETgt$ UGT1A1 promoter @/GENETgt$ ( -85 to + 40 ) was hypermethylated ( 83 % ) in the kidney , whereas it was hypomethylated ( 37 % ) in the liver .	3 3 4 4 22 9 9|6 9 9|6 22 12 12 9|10|12 9|10|12 9|12 9|10|12 16 12 16 17 16 16 22 4 25 25 22 25 29 29 22 22 22 34 34 22 37 37 34 37 41 41 34 4	PART-OF
23401472	CHEMICAL	GENE	T2	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] Treatment with 5-aza-2'-deoxycytidine ( @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ ) , an inhibitor of DNA methylation , resulted in an increase of @GENETgt$ UGT1A1 @/GENETgt$ mRNA expression in both cell types , but the increase was much larger in HK-2 cells than in HuH-7 cells .	15 3 1 5 3|4 3 3|4 5 3 10 3 13 13 10 3 15 18 18 15 23 18|23 23 18|23 23 18 27 27 27 18 15 15 31 34 34 34 15 37 37 34 41 41 41 34 15	INDIRECT-UPREGULATOR
23401472	CHEMICAL	GENE	T3	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ histone @/GENETgt$ ? [SEP] The transfection of an HNF1α expression plasmid into the HK-2 cells resulted in an increase of UGT1A1 mRNA only in the presence of @CHEMICALSrc$ 5-Aza-dC. @/CHEMICALSrc$ In summary , we found that DNA hypermethylation along with @GENETgt$ histone @/GENETgt$ hypoacetylation interferes with the binding of HNF1α , resulting in the defective expression of UGT1A1 in the human kidney .	2 12 7 7 7 7 2 11 11 11 2 12 15 15 12 18 18 15 22 22 22 12 24 22|23 22 22|23 27 22 30 30 12 39 33 39 38 38 34|38 38 34|38 33 30 42 42 39 44 42 39 39 50 50 50 46 52 50 56 56 56 50 12	None-BC7
23401472	CHEMICAL	GENE	T1	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-aza-2'-deoxycytidine @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ 5-aza-2'-deoxycytidine @/CHEMICALSrc$ ( 5-Aza-dC ) , an inhibitor of DNA methylation , resulted in an increase of @GENETgt$ UGT1A1 @/GENETgt$ mRNA expression in both cell types , but the increase was much larger in HK-2 cells than in HuH-7 cells .	15 3 1|2 1 1|2 6 3 6 3 10 3 13 13 10 3 15 18 18 15 23 18|23 23 18|23 23 18 27 27 27 18 15 15 31 34 34 34 15 37 37 34 41 41 41 34 15	INDIRECT-UPREGULATOR
23401472	CHEMICAL	GENE	T3	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ HNF1α @/GENETgt$ ? [SEP] The transfection of an HNF1α expression plasmid into the HK-2 cells resulted in an increase of UGT1A1 mRNA only in the presence of @CHEMICALSrc$ 5-Aza-dC. @/CHEMICALSrc$ In summary , we found that DNA hypermethylation along with histone hypoacetylation interferes with the binding of @GENETgt$ HNF1α @/GENETgt$ , resulting in the defective expression of UGT1A1 in the human kidney .	2 12 7 7 7 7 2 11 11 11 2 12 15 15 12 18 18 15 22 22 22 12 24 22|23 22 22|23 27 22 30 30 12 38 33 38 37 37 37 33 30 41 41 38 43 41 41 41 38 38 50 50 50 46 52 50 56 56 56 50 12	None-BC7
23401472	CHEMICAL	GENE	T3	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ HNF1α @/GENETgt$ ? [SEP] The transfection of an @GENETgt$ HNF1α @/GENETgt$ expression plasmid into the HK-2 cells resulted in an increase of UGT1A1 mRNA only in the presence of @CHEMICALSrc$ 5-Aza-dC. @/CHEMICALSrc$ In summary , we found that DNA hypermethylation along with histone hypoacetylation interferes with the binding of HNF1α , resulting in the defective expression of UGT1A1 in the human kidney .	2 13 8 8 8|4 8 8|4 8 2 12 12 12 2 13 16 16 13 19 19 16 23 23 23 13 25 23 23 23 28 23 31 31 13 39 34 39 38 38 38 34 31 42 42 39 44 42 39 39 50 50 50 46 52 50 56 56 56 50 13	None-BC7
23401472	CHEMICAL	GENE	T4	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ bilirubin @/CHEMICALSrc$ and @GENETgt$ Human UDP-glucuronosyltransferase (UGT) 1A1 @/GENETgt$ ? [SEP] @GENETgt$ Human UDP-glucuronosyltransferase ( UGT ) 1A1 @/GENETgt$ catalyzes the metabolism of numerous clinically and pharmacologically important compounds such as @CHEMICALSrc$ bilirubin @/CHEMICALSrc$ and SN-38 .	0|1|8 0|1|8 0|1|8 0|1|8 0|1|8 0|1|8 8|1 0|1|8 8 10 8 13 13 10 13 16 13 13 20 18 17|13 17 17|13 20 20 8	SUBSTRATE
23401472	CHEMICAL	GENE	T6	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ Bisulfite @/CHEMICALSrc$ and @GENETgt$ UGT1A1 promoter @/GENETgt$ ? [SEP] @CHEMICALSrc$ Bisulfite @/CHEMICALSrc$ sequence analysis revealed that the CpG-rich region near the @GENETgt$ UGT1A1 promoter @/GENETgt$ ( -85 to + 40 ) was hypermethylated ( 83 % ) in the kidney , whereas it was hypomethylated ( 37 % ) in the liver .	0|4 4 0|4 4 5 5 22 9 9 22 12 12 9|10|12 9|10|12 9|12 9|10|12 16 12 16 17 16 16 22 5 25 25 22 25 29 29 22 22 22 34 34 22 37 37 34 37 41 41 34 5	None-BC7
23401472	CHEMICAL	GENE	T8	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ Human UDP-glucuronosyltransferase (UGT) 1A1 @/GENETgt$ ? [SEP] @GENETgt$ Human @/GENETgt$ @CHEMICALSrc$ UDP-glucuronosyltransferase ( UGT ) 1A1 @/CHEMICALSrc$ catalyzes the metabolism of numerous clinically and pharmacologically important compounds such as bilirubin and SN-38 .	0|3 3 0|3 1|3|9 1|3|9 1|3|9 1|3|9 1|3|9 9|3 1|3|9 9 11 9 14 14 11 14 17 14 14 21 19 18 21 21 9	None-BC7
23401472	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-Aza-dC @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The transfection of an HNF1α expression plasmid into the HK-2 cells resulted in an increase of @GENETgt$ UGT1A1 @/GENETgt$ mRNA only in the presence of @CHEMICALSrc$ 5-Aza-dC. @/CHEMICALSrc$ In summary , we found that DNA hypermethylation along with histone hypoacetylation interferes with the binding of HNF1α , resulting in the defective expression of UGT1A1 in the human kidney .	2 12 7 7 7 7 2 11 11 11 2 12 15 15 12 19 16|19 19 16|19 15 23 23 23 12 25 23 23 23 28 23 31 31 12 39 34 39 38 38 38 34 31 42 42 39 44 42 39 39 50 50 50 46 52 50 56 56 56 50 12	INDIRECT-UPREGULATOR
23408116	CHEMICAL	GENE	T16	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] The UDP-Glucuronosyltransferase ( UGT ) 1A Polymorphism c.2042C > G ( rs8330 ) Is Associated with Increased Human Liver Acetaminophen Glucuronidation , Increased @GENETgt$ UGT1A @/GENETgt$ Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional @CHEMICALSrc$ Acetaminophen-Induced @/CHEMICALSrc$ Acute Liver Failure .	8 7 4 7 7 7 8 8 15 15 12 10 12 15 8 21 21 21 21 21 15 21 31 26|23 26 26|23 31 26 31 31 31 21 15 15 35 15 42 42 42|36 42 42|36 42 42 35 15	None-BC7
23408116	CHEMICAL	GENE	T16	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ UDP-Glucuronosyltransferase (UGT) 1A @/GENETgt$ ? [SEP] The @GENETgt$ UDP-Glucuronosyltransferase ( UGT ) 1A @/GENETgt$ Polymorphism c.2042C > G ( rs8330 ) Is Associated with Increased Human Liver Acetaminophen Glucuronidation , Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional @CHEMICALSrc$ Acetaminophen-Induced @/CHEMICALSrc$ Acute Liver Failure .	9 8|1|2 8|1|2 8|1|2 8|1|2 8|1|2 8|2 8|1|2 9 9 16 16 13 11 13 16 9 22 22 22 22 22 16 22 31 26 31 26 31 31 31 22 16 16 35 16 42 42 32|42 42 32|42 42 42 35 16	None-BC7
23408116	CHEMICAL	GENE	T15	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ UDP-Glucuronosyltransferase (UGT) 1A @/GENETgt$ ? [SEP] The @GENETgt$ UDP-Glucuronosyltransferase ( UGT ) 1A @/GENETgt$ Polymorphism c.2042C > G ( rs8330 ) Is Associated with Increased Human Liver @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ Glucuronidation , Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure .	9 8|1|2 8|1|2 8|1|2 8|1|2 8|1|2 8|2 8|1|2 9 9 16 16 13 11 13 16 9 23 23 23 23 23|15 23 23|15 16 23 32 27 32 27 32 32 32 23 16 16 36 16 42 42 42 42 42 36 16	None-BC7
23408116	CHEMICAL	GENE	T14	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after acetaminophen overdose .	15 3 1 3 13 8|5 8 8|5 13|6 13 13|6 11 13 13 4 15 15 17 15 20 20 17 20 23 20 26 26 23 29 29 23 15	None-BC7
23408116	CHEMICAL	GENE	T8	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the acetaminophen @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ overdose .	14 3 1 3 12 7 12|6 12 12|6 10 12 12 4 14 14 16 14 19 19 16 19 22 19 25 25 22 29 25|29 29 25|29 22 14	None-BC7
23408116	CHEMICAL	GENE	T15	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] The UDP-Glucuronosyltransferase ( UGT ) 1A Polymorphism c.2042C > G ( rs8330 ) Is Associated with Increased Human Liver @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ Glucuronidation , Increased @GENETgt$ UGT1A @/GENETgt$ Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure .	8 7 4 7 7 7 8 8 15 15 12 10 12 15 8 22 22 22 22 19|22 22 19|22 15 22 32 27|23 27 27|23 32 27 32 32 32 22 15 15 36 15 42 42 42 42 42 36 15	None-BC7
23408116	CHEMICAL	GENE	T11	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] Of these , only three linked single nucleotide polymorphisms ( SNPs ) located in the shared @GENETgt$ UGT1A-3'UTR @/GENETgt$ region ( rs10929303 , rs1042640 , rs8330 ) were associated with @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation activity , with rs8330 consistently showing higher acetaminophen glucuronidation at all the tested concentrations of acetaminophen .	2 6 6 5 6 6 9 9 6 11 9 11 9 19 19 19 16|19 19 16|19 13 21 19 21 21 23 21 21 28 6 33 33|28 33 33|28 33 28 28 36 38 38 28 41 41 38 46 46 46 46 41 48 46 6	None-BC7
23408116	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the acetaminophen UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) enzymes could explain interindividual variability in @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation and variable risk for liver injury after acetaminophen overdose .	14 3 1 3 12 7 12 9 8|12 12 8|12 12 4 14 14 16 14 20 16|20 20 16|20 16 20 23 20 26 26 23 29 29 23 14	None-BC7
23408116	CHEMICAL	GENE	T8	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the acetaminophen UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ overdose .	14 3 1 3 12 7 12 9 8|12 12 8|12 12 4 14 14 16 14 19 19 16 19 22 19 25 25 22 29 25|29 29 25|29 22 14	None-BC7
23408116	CHEMICAL	GENE	T3	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] Cotransfection studies demonstrated an inhibitory effect of exon 5b containing cDNAs on @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation by @GENETgt$ UGT1A1 @/GENETgt$ and UGT1A6 cDNAs containing exon 5a .	2 3 3 6 6 3 9 9 6 6 10 15 12|15 15 12|15 11 17 11|15 11 11|15 17 17 17 21 24 22 3	SUBSTRATE
23408116	CHEMICAL	GENE	T17	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ c.2042C>G @/GENETgt$ ? [SEP] The @CHEMICALSrc$ UDP-Glucuronosyltransferase @/CHEMICALSrc$ ( UGT ) 1A Polymorphism @GENETgt$ c.2042C > G @/GENETgt$ ( rs8330 ) Is Associated with Increased Human Liver Acetaminophen Glucuronidation , Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure .	9 8|1 8 8|1 5 8 8 8 9 17|9|7 17|9|7 17|9|7 17|9 17|9|7 14 9 14 17 9 23 23 23 23 23 17 23 32 27 32 27 32 32 32 23 17 17 36 17 42 42 42 42 42 36 17	None-BC7
23408116	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGTs 1A1, 1A6, 1A9, and 2B15 @/GENETgt$ ? [SEP] In this study , human liver bank samples were phenotyped for @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation activity and genotyped for the major acetaminophen-glucuronidating enzymes ( @GENETgt$ UGTs 1A1 , 1A6 , 1A9 , and 2B15 @/GENETgt$ ) .	3 3 10 10 8 7 8 10 10 10 15 11|15 15 11|15 15 10 10 10 22 22 22 22 17 24 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24 10	None-BC7
23408116	CHEMICAL	GENE	T12	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] Of these , only three linked single nucleotide polymorphisms ( SNPs ) located in the shared @GENETgt$ UGT1A-3'UTR @/GENETgt$ region ( rs10929303 , rs1042640 , rs8330 ) were associated with acetaminophen glucuronidation activity , with rs8330 consistently showing higher @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation at all the tested concentrations of acetaminophen .	2 6 6 5 6 6 9 9 6 11 9 11 9 19 19 19 16|19 19 16|19 13 21 19 21 21 23 21 21 28 6 32 32 32 28 28 35 37 37 28 41 41|37 41 41|37 37 46 46 46 46 41 48 46 6	SUBSTRATE
23408116	CHEMICAL	GENE	T13	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] Of these , only three linked single nucleotide polymorphisms ( SNPs ) located in the shared @GENETgt$ UGT1A-3'UTR @/GENETgt$ region ( rs10929303 , rs1042640 , rs8330 ) were associated with acetaminophen glucuronidation activity , with rs8330 consistently showing higher acetaminophen glucuronidation at all the tested concentrations of @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ .	2 6 6 5 6 6 9 9 6 11 9 11 9 19 19 19 16|19 19 16|19 13 21 19 21 21 23 21 21 28 6 32 32 32 28 28 35 37 37 28 40 40 37 45 45 45 45 40 47 45 45 45 6	None-BC7
23408116	CHEMICAL	GENE	T7	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the acetaminophen @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) enzymes could explain interindividual variability in @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation and variable risk for liver injury after acetaminophen overdose .	14 3 1 3 12 7 12|6 12 12|6 10 12 12 4 14 14 16 14 20 16|20 20 16|20 16 20 23 20 26 26 23 29 29 23 14	None-BC7
23408116	CHEMICAL	GENE	T15	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ c.2042C>G @/GENETgt$ ? [SEP] The UDP-Glucuronosyltransferase ( UGT ) 1A Polymorphism @GENETgt$ c.2042C > G @/GENETgt$ ( rs8330 ) Is Associated with Increased Human Liver @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ Glucuronidation , Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure .	8 7 4 7 7 7 8 16|8|7 16|8|7 16|8|7 16|8 16|8|7 13 8 13 16 8 23 23 23 23 17|23 23 17|23 16 23 32 27 32 27 32 32 32 23 16 16 36 16 42 42 42 42 42 36 16	None-BC7
23408116	CHEMICAL	GENE	T14	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after acetaminophen overdose .	15 3 1 3 13 8|5 8 8|5 13 10 8|13 13 8|13 13 4 15 15 17 15 20 20 17 20 23 20 26 26 23 29 29 23 15	None-BC7
23408116	CHEMICAL	GENE	T10	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGTs 1A1, 1A6, 1A9, and 2B15 @/GENETgt$ ? [SEP] In this study , human liver bank samples were phenotyped for acetaminophen glucuronidation activity and genotyped for the major @CHEMICALSrc$ acetaminophen-glucuronidating @/CHEMICALSrc$ enzymes ( @GENETgt$ UGTs 1A1 , 1A6 , 1A9 , and 2B15 @/GENETgt$ ) .	3 3 10 10 8 7 8 10 10 10 14 14 14 10 10 10 22 22 22 19|22 22 19|22 16 24 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24|22 24 10	None-BC7
23408116	CHEMICAL	GENE	T3	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ and @GENETgt$ UGT1A6 @/GENETgt$ ? [SEP] Cotransfection studies demonstrated an inhibitory effect of exon 5b containing cDNAs on @CHEMICALSrc$ acetaminophen @/CHEMICALSrc$ glucuronidation by UGT1A1 and @GENETgt$ UGT1A6 @/GENETgt$ cDNAs containing exon 5a .	2 3 3 6 6 3 9 9 6 6 10 15 12|15 15 12|15 11 17 11 17 17 17 17 17 21 24 22 3	SUBSTRATE
23408116	CHEMICAL	GENE	T16	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Acetaminophen @/CHEMICALSrc$ and @GENETgt$ c.2042C>G @/GENETgt$ ? [SEP] The UDP-Glucuronosyltransferase ( UGT ) 1A Polymorphism @GENETgt$ c.2042C > G @/GENETgt$ ( rs8330 ) Is Associated with Increased Human Liver Acetaminophen Glucuronidation , Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional @CHEMICALSrc$ Acetaminophen-Induced @/CHEMICALSrc$ Acute Liver Failure .	8 7 4 7 7 7 8 16|8|7 16|8|7 16|8|7 16|8 16|8|7 13 8 13 16 8 22 22 22 22 22 16 22 31 26 31 26 31 31 31 22 16 16 35 16 42 42 34|42 42 34|42 42 42 35 16	None-BC7
23408116	CHEMICAL	GENE	T17	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT1A @/GENETgt$ ? [SEP] The @CHEMICALSrc$ UDP-Glucuronosyltransferase @/CHEMICALSrc$ ( UGT ) 1A Polymorphism c.2042C > G ( rs8330 ) Is Associated with Increased Human Liver Acetaminophen Glucuronidation , Increased @GENETgt$ UGT1A @/GENETgt$ Exon 5a/5b Splice Variant mRNA Ratio , and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure .	9 8|1 8 8|1 5 8 8 8 9 9 16 16 13 11 13 16 9 22 22 22 22 22 16 22 32 27|23 27 27|23 32 27 32 32 32 22 16 16 36 16 42 42 42 42 42 36 16	None-BC7
23408116	CHEMICAL	GENE	T2	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Polymorphisms in genes encoding the acetaminophen @CHEMICALSrc$ UDP-glucuronosyltransferase @/CHEMICALSrc$ ( @GENETgt$ UGT @/GENETgt$ ) enzymes could explain interindividual variability in acetaminophen glucuronidation and variable risk for liver injury after acetaminophen overdose .	15 3 1 3 13 7 13|6 13 13|6 10 8|13 13 8|13 13 4 15 15 17 15 20 20 17 20 23 20 26 26 23 29 29 23 15	None-BC7
17603759	CHEMICAL	GENE	T8	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ ? [SEP] As a result of this , the weak activity of mMDH on @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ is sufficient to account for the amount of L-2-hydroxyglutarate that is excreted by patients deficient in FAD-linked @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ .	3 3 16 5 3 16 9 9 16 11 9 13 9|12 9 9|12 16 16 18 16 21 21 18 23 21 26 26 21 28 26 28 32 32 32|29|30 32|29|30 32|29 32|29|30 16	None-BC7
17603759	CHEMICAL	GENE	T7	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ oxaloacetate @/CHEMICALSrc$ and @GENETgt$ cMDH @/GENETgt$ ? [SEP] Both @GENETgt$ cMDH @/GENETgt$ and mMDH are highly active in tissues and alpha-ketoglutarate is much more abundant than @CHEMICALSrc$ oxaloacetate @/CHEMICALSrc$ and more concentrated in mitochondria than in the cytosol .	2 8|1 8 8|1 2 2 8 8 8 10 8 10 10 16 15 16 8 18 16 16 16 18 22 18 24 22 28 28 28 16 8	SUBSTRATE
17603759	CHEMICAL	GENE	T16	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ and @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ ? [SEP] The oxidation-reduction potential of the 2-hydroxyglutarate/alpha-ketoglutarate couple is such that @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ could potentially be produced through the reduction of alpha-ketoglutarate by a @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ .	3 3 9 7 7 7 3 9 9 16 16|10 16 16|10 16 16 16 9 19 19 16 21 19 24 24 24|19|22 24|19|22 24|19|22 24|19|22 24|19 24|19|22 9	PRODUCT-OF
17603759	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ ? [SEP] L-2-hydroxyglutaric aciduria is a metabolic disorder in which L-2-hydroxyglutarate accumulates as a result of a deficiency in FAD-linked @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ , a mitochondrial enzyme converting L-2-hydroxyglutarate to @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ .	2 6 6 6 6 6 8 10 10 6 13 13 10 16 16 13 19 19 16|18|19 16|18|19 16|19 16|18|19 19 25 25 19 25 26 29 26 26 26 6	PRODUCT-OF
17603759	CHEMICAL	GENE	T6	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] Both cMDH and @GENETgt$ mMDH @/GENETgt$ are highly active in tissues and @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ is much more abundant than oxaloacetate and more concentrated in mitochondria than in the cytosol .	2 8 2 2|3 2 2|3 8 8 8 10 8 10 10 10 10 17 16 17 8 19 17 19 22 19 24 22 28 28 28 17 8	None-BC7
17603759	CHEMICAL	GENE	T10	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] As a result of this , the weak activity of @GENETgt$ mMDH @/GENETgt$ on alpha-ketoglutarate is sufficient to account for the amount of L-2-hydroxyglutarate that is excreted by patients deficient in FAD-linked @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ dehydrogenase .	3 3 16 5 3 16 9 9 16 11 9|10 9 9|10 14 9 16 16 18 16 21 21 18 23 21 26 26 21 28 26 28 34 34 34|30 34 34|30 29 16	None-BC7
17603759	CHEMICAL	GENE	T24	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ Blue Sepharose @/CHEMICALSrc$ and @GENETgt$ cytosolic L-malate dehydrogenase @/GENETgt$ ? [SEP] This enzyme co-purified with @GENETgt$ cytosolic L-malate dehydrogenase @/GENETgt$ ( cMDH ) upon further chromatography on @CHEMICALSrc$ Blue Sepharose @/CHEMICALSrc$ .	2 3 3 5 3|4|5 3|4|5 3|4|5 3|5 3|4|5 10 5 10 14 14 3 16 16|12|14 16|12|14 16|14 16|12|14 3	None-BC7
17603759	CHEMICAL	GENE	T26	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] Mitochondrial fractions also contained an NADH-linked , ' @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ reductase ' , which similarly co-purified with mitochondrial L-malate dehydrogenase ( @GENETgt$ mMDH @/GENETgt$ ) .	2 4 4 4 11 11 6 6 8|11 11 8|11 4 11 11 16 16 11 20 20 20 16 22 20 20 20 22 4	None-BC7
17603759	CHEMICAL	GENE	T9	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ and @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ ? [SEP] As a result of this , the weak activity of mMDH on alpha-ketoglutarate is sufficient to account for the amount of @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ that is excreted by patients deficient in FAD-linked @GENETgt$ L-2-hydroxyglutarate dehydrogenase @/GENETgt$ .	3 3 15 5 3 15 9 9 15 11 9 13 9 15 15 17 15 20 20 17 22 20|21 20 20|21 26 26 20 28 26 28 32 32 32|29|30 32|29|30 32|29 32|29|30 15	SUBSTRATE
17603759	CHEMICAL	GENE	T25	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ alpha-ketoglutarate reductase @/GENETgt$ ? [SEP] Mitochondrial fractions also contained an @CHEMICALSrc$ NADH-linked @/CHEMICALSrc$ , ' @GENETgt$ alpha-ketoglutarate reductase @/GENETgt$ ' , which similarly co-purified with mitochondrial L-malate dehydrogenase ( mMDH ) .	2 4 4 4 10 10|5 10 10|5 6 6 8|10|4 8|10|4 10|4 8|10|4 10 10 17 17 10 21 21 21 17 23 21 23 4	None-BC7
17603759	CHEMICAL	GENE	T14	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ 2-hydroxyglutarate @/CHEMICALSrc$ and @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ ? [SEP] The oxidation-reduction potential of the @CHEMICALSrc$ 2-hydroxyglutarate/alpha-ketoglutarate @/CHEMICALSrc$ couple is such that L-2-hydroxyglutarate could potentially be produced through the reduction of alpha-ketoglutarate by a @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ .	3 3 10 8 8 8|5 8 8|5 3 10 10 16 16 16 16 16 10 19 19 16 21 19 24 24 24|19|22 24|19|22 24|19|22 24|19|22 24|19 24|19|22 10	None-BC7
17603759	CHEMICAL	GENE	T8	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] As a result of this , the weak activity of @GENETgt$ mMDH @/GENETgt$ on @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ is sufficient to account for the amount of L-2-hydroxyglutarate that is excreted by patients deficient in FAD-linked L-2-hydroxyglutarate dehydrogenase .	3 3 17 5 3 17 9 9 17 11 9|10 9 9|10 14 9|12 9 9|12 17 17 19 17 22 22 19 24 22 27 27 22 29 27 29 34 34 34 30 17	SUBSTRATE
17603759	CHEMICAL	GENE	T2	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] Purified @GENETgt$ mMDH @/GENETgt$ catalysed the reduction of @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ to L-2-hydroxyglutarate with a catalytic efficiency that was about 10(7)-fold lower than that observed with oxaloacetate .	2 1|4 4 1|4 4 6 4 8 6 6 6 11 6 15 15 15 6 20 20 19 20 15 22 20 22 25 23 4	SUBSTRATE
17603759	CHEMICAL	GENE	T25	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ mitochondrial L-malate dehydrogenase @/GENETgt$ ? [SEP] Mitochondrial fractions also contained an @CHEMICALSrc$ NADH-linked @/CHEMICALSrc$ , ' alpha-ketoglutarate reductase ' , which similarly co-purified with @GENETgt$ mitochondrial L-malate dehydrogenase @/GENETgt$ ( mMDH ) .	2 4 4 4 11 11|5 11 11|5 6 6 11 4 11 11 16 16 11 18 16|18 16|18 16|18 16|18 16|18 23 18 23 4	None-BC7
17603759	CHEMICAL	GENE	T23	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ L-malate @/CHEMICALSrc$ and @GENETgt$ cytosolic L-malate dehydrogenase @/GENETgt$ ? [SEP] This enzyme co-purified with @GENETgt$ cytosolic @/GENETgt$ @CHEMICALSrc$ L-malate dehydrogenase @/CHEMICALSrc$ ( cMDH ) upon further chromatography on Blue Sepharose .	2 3 3 7 4|7 7 4|7 3|5|7 3|5|7 3|7 3|5|7 11 7 11 15 15 3 18 18 15 3	None-BC7
17603759	CHEMICAL	GENE	T25	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ NADH @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] Mitochondrial fractions also contained an @CHEMICALSrc$ NADH-linked @/CHEMICALSrc$ , ' alpha-ketoglutarate reductase ' , which similarly co-purified with mitochondrial L-malate dehydrogenase ( @GENETgt$ mMDH @/GENETgt$ ) .	2 4 4 4 11 11|5 11 11|5 6 6 11 4 11 11 16 16 11 20 20 20 16 22 20 20 20 22 4	None-BC7
17603759	CHEMICAL	GENE	T15	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ alpha-ketoglutarate @/CHEMICALSrc$ and @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ ? [SEP] The oxidation-reduction potential of the @CHEMICALSrc$ 2-hydroxyglutarate/alpha-ketoglutarate @/CHEMICALSrc$ couple is such that L-2-hydroxyglutarate could potentially be produced through the reduction of alpha-ketoglutarate by a @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ .	3 3 10 8 8 8|5 8 8|5 3 10 10 16 16 16 16 16 10 19 19 16 21 19 24 24 24|19|22 24|19|22 24|19|22 24|19|22 24|19 24|19|22 10	None-BC7
17603759	CHEMICAL	GENE	T24	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Blue Sepharose @/CHEMICALSrc$ and @GENETgt$ cMDH @/GENETgt$ ? [SEP] This enzyme co-purified with cytosolic L-malate dehydrogenase ( @GENETgt$ cMDH @/GENETgt$ ) upon further chromatography on @CHEMICALSrc$ Blue Sepharose @/CHEMICALSrc$ .	2 3 3 7 7 7 3 9 8|7 7 8|7 9 14 14 3 16 16|14 16|14 16|14 16|14 3	None-BC7
17603759	CHEMICAL	GENE	T1	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ L-malate @/CHEMICALSrc$ and @GENETgt$ mitochondrial L-malate dehydrogenase @/GENETgt$ ? [SEP] Mitochondrial fractions also contained an NADH-linked , ' alpha-ketoglutarate reductase ' , which similarly co-purified with @GENETgt$ mitochondrial @/GENETgt$ @CHEMICALSrc$ L-malate dehydrogenase @/CHEMICALSrc$ ( mMDH ) .	2 4 4 4 10 10 6 6 10 4 10 10 15 15 10 19 16|19 19 16|19 17|19|15 17|19|15 19|15 17|19|15 23 19 23 4	None-BC7
17603759	CHEMICAL	GENE	T19	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ NADP @/CHEMICALSrc$ and @GENETgt$ NAD- or NADP-linked oxidoreductase @/GENETgt$ ? [SEP] The oxidation-reduction potential of the 2-hydroxyglutarate/alpha-ketoglutarate couple is such that L-2-hydroxyglutarate could potentially be produced through the reduction of alpha-ketoglutarate by a @GENETgt$ NAD- or @/GENETgt$ @CHEMICALSrc$ NADP-linked oxidoreductase @/CHEMICALSrc$ .	3 3 9 7 7 7 3 9 9 15 15 15 15 15 9 18 18 15 20 18 26 26 26|22|23 26|22|23 26|23 26|22|23 18|23 18|23 18|23 18|23 9	None-BC7
17603759	CHEMICAL	GENE	T9	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ and @GENETgt$ mMDH @/GENETgt$ ? [SEP] As a result of this , the weak activity of @GENETgt$ mMDH @/GENETgt$ on alpha-ketoglutarate is sufficient to account for the amount of @CHEMICALSrc$ L-2-hydroxyglutarate @/CHEMICALSrc$ that is excreted by patients deficient in FAD-linked L-2-hydroxyglutarate dehydrogenase .	3 3 16 5 3 16 9 9 16 11 9|10 9 9|10 14 9 16 16 18 16 21 21 18 23 21 21 21 27 27 21 29 27 29 34 34 34 30 16	None-BC7
